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Summary 
Gene therapeutic applications have gained substantial significance in modern medicine, 
especially for the treatment of cancer diseases. Genetically engineered T cells that 
express a chimeric antigen receptor (CAR) have been shown to mediate impressive 
anti-tumoral efficacy in patients suffering from B cell malignancies. In 2017, the first 
CAR T cell product was approved in the United States (U.S.). However, cell selective 
gene delivery still represents a big hurdle, making ex vivo gene delivery indispensable 
that is accompanied by complex efforts and high costs due to the personalized treatment. 
Receptor-targeted lentiviral vectors mediate selective gene delivery into a certain cell type 
and represent a powerful tool for the in vivo gene transfer. This thesis investigates the 
in vivo generation of CAR T cells in small animal models using a CD8-targeted lentiviral 
vector (CD8-LV). 
CD8-LV has been generated before by pseudotyping lentiviral vectors with modified Nipah 
virus glycoproteins displaying an anti-human CD8-targeting domain. In this thesis, 
selective in vivo reporter gene delivery into CD8+ lymphocytes was demonstrated upon 
systemic administration of CD8-LV into mice engrafted with human peripheral blood 
mononuclear cells (PBMC). Thereby, reporter gene expression exclusively within the 
CD8+ cells proved the highly selective targeting of CD8-LV. In vitro generation of 
CAR T cells upon transduction of PBMC with CD8-LV transferring a CD19-specific 
chimeric antigen receptor was shown, and functionality of these generated CAR T cells 
was demonstrated. They selectively expanded upon antigen stimulus and specifically 
killed CD19+ target tumor cells in vitro. CD8-LV(CAR) administration into mice resulted in 
the in vivo generation of CAR T cells with remarkably high frequencies of CAR-positive 
cells. Higher frequencies of transgene-positive and CD8-positive cells compared to 
reporter gene transfer indicated selective CAR T cell expansion in vivo. Importantly, 
functionality of in vivo generated CAR T cells was demonstrated when CD19+ target cells 
had been eliminated. Moreover, CD19+ cells were identified as antigen stimulus triggering 
antigen-specific CAR T cell proliferation. Phenotype analysis of CAR T cells by surface 
marker analysis revealed the presence of diversely differentiated CAR T cells, which is 
highly preferable in terms of generating a pool of CAR T cells with various effector 
functions and proliferative capabilities. Furthermore, anti-tumoral efficacy was evaluated 
in xenograft mice engrafted with human tumor cells. Although tumor outgrowth was not 
prevented, these CAR T cells demonstrated killing activities against CD19+ B cells and 
emigrated to various organs. Showing organ-specific subset distribution of diversely 
differentiated CAR T cells, highest levels of effector CAR T cells were observed at the 
tumor site. 
This thesis highlights the potential of CD8-LV to genetically engineer CD8 T cells in vivo. 
Selective gene transfer and functionality of in vivo generated human CAR T cells 
represent encouraging data to build on for further investigations in translational research. 
Pursuing receptor-targeted LVs for clinical application as an alternative approach of 
CAR T cell generation opens up an attractive possibility to tremendously simplifying CAR 
T cell therapy. In conclusion, CD8-LV represents a promising tool for the in vivo CAR T cell 
generation with the potential to transform personalized CAR T cell therapy into a broad 
applicable treatment option.  
 
 
 Zusammenfassung  
Gentherapeutische Anwendungen gewinnen zunehmend an Bedeutung in der modernen 
Medizin, im Besonderen auch in der Krebstherapie. Genetisch veränderte T-Zellen, die 
einen chimären Antigen-Rezeptor (CAR) exprimieren, haben beeindruckende 
anti-tumorale Wirksamkeit in Patienten gezeigt, die an B-Zell Erkrankungen litten. Dies 
führte 2017 zur Marktzulassung der ersten CAR-T-Zell-Therapie in den Vereinigten 
Staaten von Amerika. Eine der größten Herausforderungen der Gentherapie bleibt jedoch 
der zielgerichtete Gentransfer, sodass eine ex vivo Manipulation der Zellen noch immer 
unerlässlich ist. Diese personalisierte Behandlung ist mit hohem Aufwand und Kosten 
verbunden. Rezeptor-targetierte Vektoren vermitteln selektiven Gentransfer in einen 
bestimmten Zelltyp und könnten einen alternativen Ansatz zur derzeitigen Behandlung 
eröffnen. Diese Arbeit zeigt die in vivo Generierung von CAR-T-Zellen in Kleintiermodellen 
mittels eines CD8-targetierten lentiviralen Vektors (CD8-LV). 
Der CD8-LV wurde bereits zuvor generiert, wobei der lentivirale Vektor mit modifizierten 
Glykoproteinen des Nipah Virus pseudotypisert und eine Targeting-Domäne gegen den 
humanen CD8 Rezeptor präsentiert wird. In der vorliegenden Arbeit wurde zuerst der 
selektive Reportergentransfer in CD8+ Zellen in vivo nachgewiesen. Dazu wurden 
humane Immunzellen in Mäuse transplantiert und der Vektor systemisch injiziert. Die 
Expression des Reportergens, ausschließlich in den Zielzellen, wies einen hoch 
selektiven Gentransfer nach. In vitro Studien zeigten die Generierung von CAR-T-Zellen 
mittels CD8-LV, der einen CD19-spezifischen CAR in CD8 T-Zellen transferierte. Des 
Weiteren wurden die Funktionalität der CAR-T-Zellen gezeigt, wie zum Beispiel die 
selektive Expansion nach Antigen-Stimulus und die spezifische Eliminierung von 
CD19+ Tumorzellen. Nach Injektion von CD8-LV(CAR) konnte die in vivo Generierung von 
CAR-T-Zellen nachgewiesen werden, wobei ein bemerkenswert hoher Anteil der 
CD8 T-Zellen CAR-positive Zellen waren. Dabei war der prozentuale Anteil von 
transgen-exprimierenden Zellen sowie von CD8-positiven Zellen im Vergleich zum 
Reportergentransfer erhöht, was darauf hindeutete, dass eine selektive Expansion der 
CAR-T-Zellen stattgefunden hatte. Diese CAR-T-Zellen eliminierten CD19+ Zellen, was 
darauf hindeutete, dass in vivo generierte CAR-T-Zellen funktional waren. Die 
Phänotypisierung anhand von Oberflächenmarkern zeigte die Generierung von 
CAR-T-Zellen mit unterschiedlichem Differenzierungsgrad. Dies ist gerade in Bezug auf 
die klinische Wirksamkeit von CAR-T-Zellen erwünscht, da unterschiedlich 
ausdifferenzierte CAR-T-Zellen einerseits wichtige Effektor Funktionen erfüllen als auch 
proliferatives Potential besitzen. Die anti-tumorale Wirksamkeit wurde in Mäusen 
überprüft, die humane Tumorzellen transplantiert bekamen. Obwohl das Tumorwachstum 
nicht verhindert wurde, eliminierten die CAR-T-Zellen die CD19+ B-Zellen und wanderten 
in verschiedene Organe aus. Dabei wurde eine Organ-spezifische Verteilung von 
Subtypen beobachtet, wobei der größte Anteil der Effektor CAR-T-Zellen beim Tumor 
gefunden wurde. 
Diese Arbeit zeigt das Potential von CD8-LV CD8 T-Zellen in vivo genetisch zu verändern. 
Selektiver Gentransfer und funktionale in vivo modifizierte Zellen stellen 
vielversprechende Daten dar, auf denen in der translationalen Forschung weiter 
aufgebaut werden kann. Der Ansatz Rezeptor-targetierte lentivirale Vektoren in der 
klinischen Anwendung zu nutzen, bietet einen neuen Weg CAR-T-Zellen herzustellen und 
würde eine attraktive Möglichkeit eröffnen die CAR-T-Zell-Therapie wesentlich zu 
vereinfachen. Der CD8-LV stellt ein sehr vielversprechendes Instrument für die in vivo 
Herstellung von CAR-T-Zellen dar und birgt das Potential die personalisierte 
CAR-T-Zell-Therapie zu revolutionieren und eine breit anwendbare Therapiemöglichkeit 
zu schaffen.   
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1  Introduction 
The immune system is the host’s defense to protect from harmful pathogens. 
Distinguishing between foreign and self is a critical task to prevent diseases. Especially 
when it comes to cancer progression, the immune system fails to discriminate between 
healthy and malignant cells. Current state-of-the art cancer therapies aim in empowering 
the patient’s immune system to fight cancer. So called cancer immunotherapies, using 
several different strategies, have led to dramatic clinical success in cancer patients whose 
conditions were considered untreatable. Among others, a promising therapy involves 
engineering the patient’s own T cells to express a chimeric antigen receptor (CAR) 
sensitizing the immune system to recognize and eliminate cancer cells. Clinical success 
was so remarkable that the U.S. Food and Drug Administration (FDA) approved the first 
CAR T cell therapy in 2017, making this therapy available for patients in need.  
1.1 T lymphocytes 
T cells represent, besides B cells, major key players in the adaptive immune system 
mediating specific and long-lasting immune response against harmful pathogens, foreign 
agents as well as malignant, tumorigenic cells. Once selected for being unresponsive to 
self-antigens, naïve T cells circulate through secondary lymphoid organs and get activated 
upon antigen encounter which mediates an antigen-specific immune response (Chaplin, 
2010; Murphy et al., 2012). Effector T cells are generated in large numbers to clear 
pathogens distributed anywhere in the periphery. Upon clearance, T cell numbers are 
reduced and long-lasting immunity is implemented by the surviving memory T cells (Kaech 
et al., 2002; Sallusto et al., 2004; Farber et al., 2014). 
1.1.1 T cell receptor-mediated activation  
To induce T cell activation, naïve T cells need to encounter their cognate antigen via 
T cell receptor (TCR)-mediated binding of the antigen that is presented by a major 
histocompatibility complex (MHC) on professional antigen-presenting cells (APCs) such 
as dendritic cells (DCs). The TCR consists of two chains, the alpha and beta chain, which 
are linked via disulfide bridges (Meuer et al., 1983; Wang and Reinherz, 2012; Reinherz, 
2014). Each chain consists of one constant and one variable immunoglobulin (Ig) domain, 
which in turn contains three hypervariable complementarity determining regions dedicated 
to bind the antigen (Davis and Bjorkman, 1988; Katayama et al., 1995). The TCR is 
associated with the CD3 receptor consisting of three heterodimers CD3 γε, CD3 δε and 
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CD3 ζζ. Building a complex structure, the TCR-CD3 complex consists of in total four 
heterodimers. Since the cytosolic domains of the TCR are too short, those of CD3 mediate 
intracellular signaling via their immunoreceptor-tyrosin-based activation motifs (ITAM) 
(Weiss and Stobo, 1984; Irving and Weiss, 1991). Upon receptor-ligand interaction, 
clustering of intracellular signaling domains results in phosphorylation of ITAMs activating 
a kinase cascade with several mediators involved, such as src and syk kinases, activating 
various downstream signaling pathways (Irving and Weiss, 1991; Letourneur and 
Klausner, 1991; Chan et al., 1992; Iwashima et al., 1994; Minguet et al., 2007). For 
productive T cell activation, three signals are required, the first signal being provided by 
antigen recognition. For full activation, co-stimulatory receptor binding (signal 2) and 
interleukin-2 (IL-2) (signal 3) are just as much required (Smith-Garvin et al., 2009). T cell 
activation is characterized by several intrinsic changes mediated by the activation of 
transcription factors which regulate gene expression of T cell activating genes such as 
IL-2 (Serfling et al., 2000). Furthermore, differential surface receptor expression, 
increased metabolic activity, production of various cytokines and subsequent clonal 
expansion or differentiation comes along with T cell activation (Savignac et al., 2007; 
Smith-Garvin et al., 2009; Almeida et al., 2016). 
1.1.2 Subsets of T cells 
Dependent on the expression of CD4 or CD8 co-receptors, two types of T cells are 
distinguished – CD4+ T helper cells and CD8+ cytotoxic T cells conducting different 
effector functions. While CD4 T cells are mainly professional cytokine producing cells 
helping other immune cells to actively participate in the immune response, CD8 T cells 
directly execute killing activities against infected cells. Upon antigen binding, calcium 
dependent release of lytic granules triggers apoptosis-induced cell death of target cells in 
which both perforin and granzymes are crucial for effective cell killing. Immediate action 
and elimination of infected cells make CD8 T cells highly critical to prevent disease 
outbreak and to limit infections. 
CD4 and CD8 T cells can be further distinguished. Dependent on their status of 
differentiation, subset phenotypes are categorized into naïve T cells (TN), effector T cells 
(TEff) and memory T cells. Thereby, additional subtypes exist for memory T cells, namely 
the central memory T cells (TCM) and the effector memory T cells (TEM). In 2011, Gattinoni 
et al. discovered an intermediate phenotype, the stem cell-like memory T cell (TSCM) 
(Gattinoni et al., 2011). The degree of differentiation not only affects the capacity of 
self-renewal, proliferation and effector function but also correlates with the differential 
expression of surface molecules. The combinatorial expression of surface markers is 
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typically used to identify the phenotype of a T cell. Common markers for the identification 
of CD8 subtypes are depicted in Figure 1. TN cells represent the least differentiated 
phenotype which have not yet encountered their antigen and are characterized by a high 
self-renewal capacity. High expression levels of lymph node homing receptors CD62L, 
CD45RA and C-C chemokine receptor 7 (CCR7) dedicates them to recirculate between 
blood and secondary lymphoid organs to enhance the chance of antigen encounter. Upon 
binding to their cognate antigen, TN cells produce high levels of IL-2 and differentiate into 
TEff cells (Butcher et al., 1999; van Stipdonk et al., 2001; Berard and Tough, 2002; van 
den Broek et al., 2018). TEff cells own the capability of invading into peripheral tissue and 
producing various cytokines such as IL-2, interferon gamma (IFN-ɤ) and tumor necrosis 
factor alpha (TNF-α). This allows immediate cytotoxicity towards infected cells. However, 
being highly differentiated, they have a low proliferative capability and die off rapidly upon 
antigen clearance (Podack and Kupfer, 1991; Haring et al., 2006). 
 
Figure 1: The different CD8+ subsets  
T cell subtypes are distinguished according to their differentiation status. Degree of differentiation from lowest 
to highest (left to right), with least differentiated TN (highest proliferative capability) and highest differentiated 
TEff (lowest proliferative capability). Effector functions inversely correlate with proliferative capability. Each 
subtype is characterized by a differential expression of the surface markers CD62L, CD45RA, CD45RO and 
CCR7. TN, naïve T cell; TSCM, stem cell memory T cell; TCM, central memory T cell; TEM, effector memory 
T cell; TEff, effector T cell. Modified from (Golubovskaya and Wu, 2016). 
In contrast, memory T cells provide long lasting immunity. With a certain capability of 
self-renewal and high expression of anti-apoptotic proteins they survive the absence of 
antigen in a quiescent state, even for years (Lau et al., 1994; Hammarlund et al., 2003). 
While TCM represent early differentiated progenitors with higher self-renewal capacity and 
expression of lymph node homing receptors, TEM confer more rapid effector functions and, 
due to the lack of CD62L expression, are able to invade into peripheral tissue (Sallusto et 
al., 2004). TSCM are antigen-experienced and acquire rapid effector functions following 
TCR stimulation. However, they also possess a strong naïve-like phenotype being unique 
in combining the most characteristic properties of TN and TEff (Gattinoni et al., 2011; Lugli 
et al., 2013). To ensure a sufficient pool of memory and naïve T cells, cytokines such as 
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IL-7 and IL-15 provide homeostatic proliferation stimuli conferring T cell proliferation 
without differentiation (Schluns et al., 2000; Boyman et al., 2009). 
1.2 Cancer Immunotherapy 
Strengthening the immune system to fight cancer has become an indispensable pillar of 
current cancer therapies. Traditional cancer treatments such as surgery, radio- and 
chemotherapy, which unspecifically eliminate rapidly growing cells, paved the way for 
clinically relevant success in anti-cancer therapies. However, recurrences of aggressive 
tumors, metastases and complex tumor entities require more effective therapies. The 
combination of conventional therapies accompanied by immunotherapies resulted in 
impressive clinical success of end-stage-cancer patients, some of which became 
tumor-free upon treatment. Several different strategies have been developed, including 
cancer vaccines, oncolytic viruses, immune checkpoint inhibitors and cell therapies such 
as allogeneic and autologous T cell transfer (Farkona et al., 2016; Oiseth and Aziz, 2017). 
1.2.1 Cell therapies 
Adoptive T cell transfer is meant to enhance the number of functional tumor-specific 
T cells in the cancer patient. In tumor-infiltrating lymphocyte (TIL) therapy, tumor-specific 
T cells are obtained from resected tumor fragments and expanded ex vivo under 
reactivating cytokine conditions before they are infused back into the patient (Dudley et 
al., 2010). TIL therapy has demonstrated clinical success in end-stage melanoma 
patients, however, failed to induce anti-tumoral effects in other cancer types (Dudley et 
al., 2002; Rosenberg et al., 2008; Yee, 2013; Hinrichs and Rosenberg, 2014). The lack of 
tumor-specific T cells due to tumor tolerance was of major hindrance and resulted in the 
development of new therapeutic approaches using genetically engineered T cells. 
Introducing TCR genes provides flexibility in targeting cancer associated antigens. For 
this purpose, tumor-specific T cells are screened ex vivo from patients with natural 
anti-tumor activities and TCR genes are isolated. These can be engineered further to 
increase affinity before they are transferred into the lymphocytes via retro- or lentiviral 
gene delivery (Hughes et al., 2005; Presotto et al., 2017). Mediating newly established 
tumor-specific immune response, TCR-engineered T cells induced cancer regression in 
melanoma patients (Morgan et al., 2006; Robbins et al., 2011). However, TCR-mediated 
tumor antigen recognition relies on MHC-dependent tumor antigen presentation, which is 
often downregulated in cancer cells, a common evasion mechanism of tumor cells limiting 
TCR T cell therapy (Garrido et al., 2016). 
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CAR-engineered T cells circumvent this obstacle by recognizing antigens in a 
MHC-independent manner. CAR T cell therapy is highly effective in B cell malignancies, 
as demonstrated by high response rates, e.g. up to 88% in acute lymphoblastic leukemia 
(ALL) patients treated with CD19 CAR T cells (Davila et al., 2014; Maude et al., 2014). 
Given this tremendous clinical success, the FDA approved two CAR T cell therapies by 
the end of 2017. Novartis’ Kymriah™ was the first approved CAR T cell therapy for 
relapsed/refractory (r/r) B-cell ALL for young adults and for r/r diffuse large B-cell 
lymphoma (DLBL) for adult patients. Kite Pharma got Yescarta™ approved by the FDA 
for the treatment of end-stage patients suffering from large B-cell lymphoma. CAR T cell 
therapy represents a breakthrough therapy and was recently celebrated as Advance of 
the Year in the annual report 2018 of the American Society of Clinical Oncology (ASCO), 
highlighting its clinical relevance for future cancer therapies.  
1.3 CAR T cell therapy 
1.3.1 Structure of CARs 
CARs are artificial receptors that combine the specificity of an antibody and the 
intracellular signaling machinery of a T cell receptor (Figure 2). The extracellular domain 
confers antigen specificity via the incorporation of a single chain variable fragment (scFv) 
that is derived from an antibody and mediates MHC-independent antigen recognition 
(Kuwana et al., 1987; Gross et al., 1989; Eshhar et al., 2001). As scFvs are exchangeable, 
any desired antigen can be targeted, simply limited by the availability of scFvs. Recently, 
also designed ankyrin repeat proteins (DARPins), which are poorly immunogenic and can 
be generated by a selection process to any kind of antigen, were used as targeting 
domains for CARs (Stumpp and Amstutz, 2007; Hammill et al., 2015; Siegler et al., 2017). 
The hinge domain links the targeting domain and the transmembrane domain (TM), 
providing scFv flexibility. Parts of several different Ig-like domains such as IgG1, IgG4 and 
the extracellular CD8 domain have been successfully used (Moritz and Groner, 1995; 
Zhao et al., 2009; Hombach et al., 2010; Jonnalagadda et al., 2015). Dependent on the 
size of the targeted antigen, the distance between tumor and CAR T cell can vary. 
Thereby, the length of the hinge domain can affect proper tumor antigen recognition and 
CAR T cell effector functions (Hombach et al., 2007; Hudecek et al., 2015). The TM 
domain is typically derived from membrane-spanning domains of CD4, CD8 or CD28 
(Kahlon et al., 2004; Pulè et al., 2005; Milone et al., 2009). The intracellular domain 
provides crucial signaling domains, ensuring CAR T cell activation upon antigen 
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encounter. Over the years, CAR design evolved and meanwhile different generations of 
CAR structures can be distinguished (Figure 2).  
 
Figure 2: Scheme of the structure and design of CARs  
CARs are artificial proteins that combine the intracellular signaling domain of the T cell receptor (TCR) with 
an extracellular binding domain that is usually an antibody-derived scFv. The hinge domain links the targeting 
domain to the transmembrane domain, which is fused to the intracellular signaling domain. First generation 
CARs contain CD3ζ, second generation and third generation CARs additionally contain one or two 
co-stimulatory domains, such as CD28 or 4-1BB. mAB, monoclonal antibody; scFv, single chain variable 
fragment; VH, variable heavy chain; VL, variable light chain. 
While first generation CARs incorporate a single CD3ζ activation domain, second 
generation CARs harbor an additional co-stimulatory domain such as CD28, 4-1BB, OX40 
and others (Finney et al., 2004; Imai et al., 2004; Kowolik et al., 2006). The usage of 
different co-stimulatory domains confers individual properties to the CAR T cells. While 
the CD28 co-stimulatory domain confers rather immediate effector functions, but also 
augments exhaustion in CAR T cells, the 4-1BB domain has been shown to mediate 
longer persistence of CAR T cells (Maude et al., 2014; Lee et al., 2015). Third-generation 
CARs consist of one activation and two co-stimulatory domains. Although preclinical 
studies demonstrated superior CAR T cell expansion, these CARs did not outperform 
second-generation CARs in clinical trials so far, but rather were associated with toxicities 
(Morgan et al., 2010; Till et al., 2012).  
1.3.2 CD19-specific CAR T cells against B cell malignancies 
Several clinical trials have been performed to investigate the clinical potential of 
CAR-engineered T cells against various cancer types (Hartmann et al., 2017). However, 
the most remarkable success in CAR T cell therapy was achieved with second generation 
CARs targeting the CD19 antigen in B cell malignancies. End-stage patients suffering 
from chronic lymphocytic leukemia (CLL) or ALL with no further treatment options were 
enrolled in CD19 CAR clinical trials. Meanwhile, one can look back at several clinical trials 
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providing comprehensive data sets for the treatment of B cell malignancies with 
CD19 CAR T cells. 
The first trial was performed using T cells engineered with first generation CARs (Jensen 
et al., 2010). Although anti-tumoral effects were only temporary, lessons were learned 
about beneficial structures of CARs and lymphodepletion. As already seen in 
TIL therapies, pre-conditioning prior to T cell transfer depletes cytokine sinks and 
regulatory T cells resulting in beneficial engraftment and enhanced efficiency of the 
transferred cells (Dudley et al., 2005; Brentjens et al., 2011). 
Clinical trial investigations implicated major advantages of the usage of second generation 
over first generation CARs. Long-term anti-tumoral effects were observed with second 
generation CARs and clearly correlated with efficient proliferation and persistence of the 
CAR T cells (Kalos et al., 2011; Porter et al., 2011). However, first signs of toxicities 
appeared. Some patients developed symptoms of systemic inflammatory reactions 
indicated by high fever, nausea, tachycardia, hypotension and dyspnea (Brentjens et al., 
2011; Porter et al., 2011; Kochenderfer et al., 2015). Although never observed in 
pre-clinical models, several patients enrolled in different studies showed symptoms of 
cytokine release syndrome (CRS), which is categorized into grade 1-4, ranging from mild 
to severe CRS. Being a direct effect of T cell proliferation and large numbers of activated 
T cells, high amounts of IFN-γ, IL-6 and TNF-α can cause severe, life-threatening CRS 
with the need for intensive care (Kochenderfer et al., 2012; Grupp et al., 2013; Davila et 
al., 2014; Lee et al., 2015). Treatment with corticosteroids and the IL-6 receptor-blocking 
monoclonal antibody tocilizumab usually used for the treatment of rheumatoid arthritis 
have been shown to be effective in reversing severe CRS (Grupp et al., 2013; Davila et 
al., 2014; Lee et al., 2014; Maude et al., 2014). Meanwhile, inpatient treatment and 
improved guidelines for early treatment suggest these side effects to be manageable. 
Along with efficient tumor cell elimination, B cell depletion was observed in patients. 
B cells also express the CD19 antigen. Therefore, B cells are targeted as well by 
CD19 CAR T cells, known as on-target/off-tumor toxicity. Despite being a side effect of 
the treatment, B cell depletion upon CD19 CAR T cell treatment serves as useful 
pharmacodynamic marker of CAR T cell persistence. The absence of B cells, however, 
requires immunoglobulin replacement therapy, but represents a tolerable and 
manageable side effect (Kochenderfer et al., 2012; Maude et al., 2014). 
With market authorization of Kymriah™ and Yescarta™ in the U.S., CAR T cell therapy is 
available for patients. However, along with market access, the highly personalized 
manufacturing process faces hurdles never met with conventional commercially available 
off-the-shelf drugs.  
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1.3.3 Manufacturing of CAR T Cells  
Generating CAR T cells begins with the collection of PBMC from the patient, a process 
termed leukapheresis. Prior to activation of the T cells, T cells are isolated, and a T cell 
selection process such as magnetic separation of CD3+ cells or even the separation of 
CD4+ and CD8+ cells may be included. Different activation protocols are available and 
applied in clinical trials (Wang and Rivière, 2016). While cell-based T cell activation by 
DCs or artificial APCs require human leukocyte antigen (HLA)-matched cell lines and 
hinders broad applicability, usage of beads covalently coupled with αCD3 and αCD28 
antibodies together with IL-2 represents a standardized method of T cell activation. 
Engineering T cells with the CAR transgene often relies on retro- or lentiviral gene transfer. 
Following gene transfer, a process of T cell expansion generates high numbers of 
CAR T cells. According to different protocols, this procedure may take between ten days 
up to three weeks until CAR T cells are finally prepared for re-infusion into the patient (Dai 
et al., 2016). 
1.3.3.1 Drawbacks of an ex vivo manufactured personalized CAR T cell product 
Several protocols with varying expansion times and cytokine treatments to generate 
CAR T cell products are currently available among different centers. So far, it is still under 
discussion which procedure generates the most efficient CAR T cell product. It is known, 
however, that longer expansion times can favor T cell exhaustion impeding anti-tumoral 
functions of CAR T cells. Therefore, shorter manufacturing processes are desired to 
generate more efficient products (Gattinoni et al., 2012). Furthermore, the differentiation 
status, which is highly influenced by ex vivo culture conditions, is discussed to influence 
anti-tumoral potency. Often, ex vivo manipulation favors T cell differentiation and efforts 
are ongoing to prevent CAR T cell differentiation during ex vivo manufacturing. The 
addition of homeostatic cytokines (IL-15 and IL-7) during the expansion process is known 
to favor the maintenance of less differentiated CAR T cells (Klebanoff et al., 2004; Cieri 
et al., 2013). Meanwhile, CAR T cell products generated from TN, TSCM and TCM cells are 
under investigation to mediate more efficient anti-tumoral effects (Wang et al., 2012; 
Casati et al., 2013; Xu et al., 2014; Sabatino et al., 2016). 
The generation of an individualized medicinal product makes CAR T cell manufacturing a 
complex process that faces logistic challenges never met with commercially off-the-shelf 
drugs. CAR T cell generation currently represents a highly labor-intensive process with 
the need for well-equipped, good manufacturing practice (GMP)-certified facilities as well 
as highly skilled staff. During ex vivo cell manipulation, separate machines for cell 
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preparation, activation, transduction, expansion and final formulation are required. 
Transfer between the machines and the included washing steps require cell handling in 
open systems with the risk of contamination (Levine et al., 2017). Closed systems such 
as the CliniMACS Prodigy® combine processes of cell preparation until final formulation 
within a single device that minimizes the risk of contamination and ensures consistently 
high quality of the product by a standardized and fully automated procedure. Hospitals 
equipped with CliniMACS Prodigy® devices would enable CAR T cell manufacturing and 
patient treatment to be performed at a single location without the need for cell shipments 
(Kaiser et al., 2015). Current standard, however, are central manufacturing sites that allow 
upscaling and provide infrastructure to make this therapy available to larger patient 
populations. However, this process is underpinned by complex logistics (Levine et al., 
2017; Roberts et al., 2017) (Figure 3).  
  
Figure 3: Centralized manufacturing process of CAR T cells 
Generation of CAR T cells at central manufacturing sites requires cell shipment between the clinic and the 
manufacturing site. Top panel: Process of CAR T cell generation. (1) Blood cells are isolated from the patient 
(leukapheresis). (2) T cells are isolated and activated via αCD3 and αCD28 antibodies with the addition of 
cytokines (e.g. IL-2). (3) CAR gene transfer into the T cells is performed by retro- or lentiviral vector 
transduction (4) followed by CAR T cell expansion and cryopreservation. (5) The final CAR T cell product is 
re-infused into the patient. Lower panel: Facilities involved during CAR T cell therapy. Patient’s treatment 
involving leukapheresis and re-infusion of the CAR T cells are performed at the clinic (green). CAR T cell 
manufacturing is carried out at the manufacturing site (red). Cell shipments between both locations are 
required: from the clinic to the manufacturing center and backwards (blue). Modified from (Levine et al., 2017).  
Shipment of the isolated cells to the manufacturing site, preparation of cells and transfer 
of the cell product back to the clinic requires supply chain management with the need for 
precise cell product tracking from the beginning of T cell isolation until re-infusion of the 
product into the patient (Levine et al., 2017; Roberts et al., 2017). Furthermore, upon final 
formulation of the product, individualized medicinal products require single-lot-release 
testing to ensure high product quality and potency. This includes flow cytometry analysis 
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of CAR expression and phenotype analysis. Cytokine production, killing and viability 
assessments evaluate functional potency of the product. Sterility testing, including 
bacterial, fungal and endotoxin tests and absence of replication-competent viral particles 
ensure safety of the product (Gee, 2015; Wang and Rivière, 2015). With the approval of 
Kymriah™ and Yescarta™, however, this therapy will be made available for patients in 
need, which faces high financial efforts and technical challenges. It is desirable to 
translate the manufacturing process into a more automated and standardized production 
line-like system. 
1.4 Cell type-specific gene delivery 
Ex vivo modification of cells is the current gold standard in gene therapeutic approaches. 
However, in vivo modification would circumvent the highly personalized and complex 
procedure. To enable local or systemic vector administration, highly selective gene 
transfer is inevitable to prevent unwanted off-target effects. To ensure efficient and safe 
gene therapy, receptor-targeted lentiviral vectors have been developed to restrict gene 
transfer to a target cell population that is characterized by the expression of a distinct 
receptor.  
1.4.1 Lentiviral vectors 
Lentivirus-derived lentiviral vectors (LVs) ensure efficient gene delivery and integrate their 
genomic information stably into the host’s genome, which ensures therapeutic gene 
expression not only in the gene-modified cells but also in all daughter cells. Several years 
of clinical application resulted in improved and safety-optimized LVs, which are meanwhile 
considered as an attractive tool for the treatment of various diseases (Kaufmann et al., 
2013; Naldini et al., 2016). Derived from human immunodeficiency virus-1 (HIV-1) 
lentivirus of the retroviridae family, LVs carry a positive single-stranded diploid RNA 
genome (Knipe and Howley, 2007). However, to ensure safe gene delivery using LVs, 
these vector particles contain defective genomes, which allow for a single transduction 
but avoid replication and the release of further viral particles afterwards. To generate 
replication-incompetent LVs, viral vector production is performed using a trans-packaging 
system, splitting the viral genes onto several distinct plasmids (Zufferey et al., 1997; Pluta 
and Kacprzak, 2009). Using the second generation lentiviral vector system, three 
plasmids are co-transfected to a packaging cell line, typically human embryonic kidney 
293T (HEK-293T) cells (Figure 4). 
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Figure 4: Production of lentiviral vectors by triple transfection  
(1) Co-transfection of packaging-, envelope-, and transfer vector into a packaging cell, typically HEK-293T 
results in (2) transient viral gene expression. (3) Vector particles bud from the cell membrane and (4) are 
released into cell culture supernatant. 
The packaging plasmid encodes for the structural genes gag and pol, while the envelope 
coding sequence is located on a separate plasmid. The transfer vector plasmid encodes 
the therapeutic gene driven by an internal promotor such as spleen focus forming virus 
(SFFV) or elongation factor 1 alpha (EF1α). Flanked by long terminal repeats (LTRs), the 
expression cassette of the transfer vector is the only sequence that is integrated into the 
host’s genome. The third-generation lentiviral vector system was designed to further 
enhance the biosafety of LVs. The rev and tat genes had been removed from the 
packaging plasmids and are encoded separately (Dull et al., 1998). To further minimize 
the risk of insertional oncogenesis enhancer elements from the U3 region were deleted, 
resulting in the inactivation of internal promoter activity. These are the so-called 
self-inactivating LVs (SIN-LVs) (Miyoshi et al., 1998). 
1.4.2 Pseudotyping of lentiviral vectors 
Binding of the viral glycoprotein to the cell surface receptor represents the first contact 
between the viral particle and the cell, and triggers cell entry upon conformational 
changes. Given the specific binding of the viral glycoprotein to its target receptor, viruses 
show a restricted tropism to a certain cell type. Incorporating heterologous glycoproteins 
derived from other enveloped viruses is called pseudotyping and is used to expand or 
restrict the tropism of lentiviral vectors (Cronin et al., 2005; Frecha et al., 2008). Since LVs 
bud from the cell surface and incorporate proteins presented at the cell surface, 
overexpression of the desired glycoprotein is sufficient for incorporation into the vector 
particle. Further modifications such as cytoplasmic tail truncations might be necessary to 
ensure efficient glycoprotein incorporation (Merten et al., 2005; Frecha et al., 2008; Funke 
et al., 2008; Bender et al., 2016).  
transfer vector
packaging vector
envelope vector
1
2
3
4
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To enable transduction of various cell types such as lymphocytes, hematopoietic stem 
cells (HSCs), muscle cells, cancer cells and others, ex vivo gene therapeutic applications 
rely on LVs with expanded tropism. Pseudotyping LVs with the glycoprotein G of vesicular 
stomatitis virus (VSV) has become the gold standard for targeting human cells, since the 
low density lipoprotein (LDL) target receptor is present on almost every human cell entity 
(Naldini et al., 1996; Blömer et al., 1997; Kafri et al., 1997; Miyoshi et al., 1997; 
Finkelshtein et al., 2013). However, to increase the efficiency and restrict gene transfer to 
a certain cell type, envelope proteins, which preferentially bind to certain cell entities, are 
used. With this approach, lentiviral vectors have been targeted to unstimulated 
CD34+ HSCs by incorporating baboon endogenous virus (BaEV) glycoproteins (Girard-
Gagnepain et al., 2014). Sendai virus and Ebola Zaire virus-derived glycoprotein 
demonstrated efficient transduction of airway epithelial cells (Kobinger et al., 2001; 
Mitomo et al., 2010).  
1.4.3 Receptor-targeted lentiviral vectors 
Cell-specific gene delivery is indispensable in order to prevent off-target effects, especially 
when on-site modification of cells is desired. Receptor-targeted LVs restrict gene delivery 
to a distinct cell type that is characterized by a cell surface marker.  
For this purpose, natural binding sites of the incorporated glycoproteins need to be 
abolished and a separate binding domain is displayed, mediating selective receptor 
binding to a distinct cell type. Using this approach, incorporation of measles virus (MV) 
glycoproteins results in successful re-targeting (Anliker et al., 2010; Buchholz et al., 2015). 
For this purpose, the fusion protein (F) and the hemagglutinin (H) are incorporated into 
vector particles. Cytoplasmic tail truncations of the H (18 amino acids) and F (30 amino 
acids) allows efficient glycoprotein incorporation. Point mutations within the H protein 
abolish binding to its natural receptors CD46 and SLAM. As targeting domain, either a 
scFv or a DARPin can be used providing flexibility in terms of receptor usage and 
subsequent re-targeting to any cell type of choice. To date, several receptor-targeted LVs 
have been generated and proven to selectively deliver genes into their target cell 
population while non-target cells remained untransduced. Successful re-targeting to 
various cell types such as CD105+ endothelial and CD133+ hematopoietic progenitor cells 
as well as CD4+, CD20+ and CD8+ lymphocytes has been achieved (Funke et al., 2008; 
Anliker et al., 2010; Zhou et al., 2012; Abel et al., 2013; Zhou et al., 2015). Recently, a 
new platform was established incorporating Nipah virus (NiV) glycoproteins into LVs. 
Truncations of 34 amino acids in the G protein and 22 amino acids in the F protein resulted 
in efficient incorporation of the glycoproteins. Incorporation rate of glycoproteins was three 
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to four times higher than for MV glycoproteins. Although less flexible in target receptor 
choice, several cell types were successfully targeted, including CD8 T cells (Bender et al., 
2016) (Figure 5). 
 
Figure 5: CD8-targeted LVs pseudotyped with NiV glycoproteins  
The HIV-1-derived LV displays truncated NiV glycoproteins at the surface, namely the F protein and the 
G protein that is blinded for its natural receptor. A scFv, derived from a monoclonal antibody, specific for 
human CD8 is fused to the G protein. CD8-LV mediates selective transduction into CD8+ cells (green) while 
CD8- cells remain untransduced (grey). F, fusion protein; G, glycoprotein; HIV-1, human immunodeficiency 
virus type 1; LV, lentiviral vector; NiV, Nipah virus; scFv, single chain variable fragment.  
1.4.3.1 Lymphocyte-targeted LVs 
Although LVs are able to transduce non-proliferating cells such as neuronal cells, 
transduction of quiescent lymphocytes using the VSV-G envelope is challenging due to 
the absence of the LDL receptor on the surface of unstimulated lymphocytes (Amirache 
et al., 2014). To ensure efficient gene transfer, lymphocytes need to be activated prior to 
transduction, which induces upregulation of the LDL receptor. However, activation of 
lymphocytes often results in unintentional differentiation. To overcome this hurdle, 
strategies involve the targeting of alternative receptors. Besides BaEV-pseudotyped LVs 
also receptor-targeted lentiviral vectors successful delivered genes into unstimulated 
lymphocytes. 
First attempts in targeting B cells were made by pseudotyping LVs with Sindbis Virus 
glycoproteins. A monoclonal antibody, specific for CD20 and a Sindbis-derived fusion 
protein deficient for binding to its natural receptor were incorporated (Lei et al., 2009). 
Although this approach demonstrated selective B cell targeting, pH-dependent entry via 
endocytosis and the incorporation of a complete antibody might limit transduction 
efficiency. In contrast, MV-pseudotyped LVs enter cells pH-independently directly at the 
cell membrane by membrane fusion. Displaying a CD20-specific scFv on the MV-H 
resulted in exclusive transduction of B cells, while sparing CD20- cells in co-culture 
transduction experiments (Funke et al., 2008). Even more, the CD20-targeted MV-LV 
efficiently transduced resting B cells, likely, due to a proliferative stimulus triggered upon 
binding to CD20 receptor (Kneissl et al., 2013). 
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By exchanging the targeting domains, a pool of lymphocyte-targeted LVs had been 
generated, among them MV-pseudotyped CD4MV- and CD8MV-targeted LVs (Zhou et al., 
2012; Zhou et al., 2015). The transfer of therapeutic transgenes in vitro has been shown 
for both vectors. The CD8MV-LV-modified T cells even demonstrated higher killing 
activities in vitro upon the transfer of a TCR gene compared to VSV-G-transduced cells. 
Most likely, this is a result of preferential transduction of T cells with high levels of CD8 
correlating with higher granzyme B and perforin expression. First in vivo transduction 
experiments had been performed with both vectors in PBMC-humanized mice. Besides 
successful reporter gene transfer exclusively into CD4+ T cells, even stable expression of 
the forkhead box P3 (FoxP3) gene for 2 months post CD4MV-LV administration was shown 
(Zhou et al., 2015). Upon intraperitoneal (i.p.) injection of CD8MV-LV into 
PBMC-humanized mice, reporter gene transfer was exclusively observed in CD8+ cells, 
resulting in 10% transduced CD8+ cells (Zhou et al., 2012). However, vector production 
only resulted in moderate titers, rendering the CD8MV-LV inappropriate for intravenous 
(i.v.) vector administration. In contrast, vector productions of the CD8-targeted LV 
pseudotyped with NiV glycoproteins (CD8-LV) yielded much higher titers (Bender et al., 
2016). Long-term transgene expression in CD8+ cells within human PBMC has been 
demonstrated already in vitro. Further, in contrast to MV, the absence of neutralizing 
antibodies in the majority of the human population against NiV is thought to increase 
efficiency of in vivo transduction, rendering CD8-LV a promising tool for the investigation 
of in vivo gene delivery upon systemic vector administration.    
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1.5 Objective 
Aim of this study was the in vivo modification of CD8 T cells to express a CD19-specific 
CAR and subsequent characterization of in vivo generated CAR T cells. CAR T cell 
therapy, despite its great success, is a highly personalized, complex and time-consuming 
therapy due to the ex vivo manufacturing of CAR T cells. The idea of generating 
CAR T cells in vivo by systemic administration of CAR gene-carrying vector particles 
represents an innovative approach, which is investigated in this thesis.  
For this purpose, receptor-targeted LVs, which have been shown to deliver genes highly 
selective into distinct cell populations of choice, are an absolute requirement. Targeting 
CD8 T cells delivers the CAR transgene into cytotoxic immune cells, which are able to 
eliminate tumor cells once the CAR is expressed on the cell surface. NiV-pseudotyped 
LVs targeted to CD8+ cells represent high-titer vectors, which already demonstrated stable 
reporter gene transfer into human PBMC and are a promising tool for the generation of 
CAR T cells. 
First, the capability of CD8-LV to mediate in vivo gene transfer was evaluated in mice 
engrafted with human PBMC. To evaluate transduction efficiency in vivo, CD8-LV carrying 
a reporter gene was systemically injected into NOD.Cg.PrkdcscidIL2rgtmWjl/SzJ (NSG) mice 
and transgene expression was analyzed in various organs. Second, CD8-LV was 
investigated to generate functional CAR T cells in vitro. CAR encoding CD8-LVs were 
used to generate CAR T cells by transduction of primary cells. Functional properties of 
those CAR T cells were analyzed, such as the selective proliferation upon antigen 
exposure and killing of tumor cells. Third, in vivo generation of CAR T cells was evaluated 
upon CD8-LV(CAR) administration to PBMC-humanized NSG mice and in vivo generated 
CAR T cells were further characterized. In detail, CAR T cell proliferation was studied in 
the presence and absence of CD19+ target cells. Elimination of target cells was analyzed 
as well as transgene integration on genomic level and the clonality of CAR T cells. Based 
on surface marker analysis, the phenotype of in vivo generated CAR T cells was 
characterized. Finally, anti-tumoral functions of in vivo generated CAR T cells were 
evaluated in a xenograft mouse model using CD19+ human tumor cells. 
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2 Materials & Methods 
2.1 Material 
Chemicals and reagents were purchased from Becton Dickinson, Biochrom, Biowest, 
Biozym, Carl Roth, CP-Pharma, Lonza, Miltenyi Biotec, New England Biolabs, Nippon 
Genetics, Perkin Elmer, Roche, Sigma-Aldrich, Thermo Fisher Scientific and VWR. 
Consumables used for cell culture, molecular biology and animal work were purchased 
from 4titude, B. Braun, Becton Dickinson, Bioline, Bio-Rad, Biotix, Biozym, Cell Signaling 
Technology, Corning, Eppendorf, GE Healthcare, Genomed, Greiner Bio-One, 
Machery-Nagel, Micronic, Miltenyi Biotec, Promega, Sartorius, Thermo Fisher Scientific, 
Qiagen and VWR. Detailed information are given below. 
2.1.1 Chemicals & Reagents 
Name Supplier 
2-log DNA ladder New England Biolabs 
Agarose Biozym 
Ampicillin Roche 
BD Pharm LyseTM Becton Dickinson 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
CD19+ microbeads,  human Miltenyi Biotec 
gentleMACS C tube Miltenyi Biotec 
D-Luciferin Perkin Elmer 
Dulbecco’s Modified Eagle Medium (DMEM) High Glucose Biowest 
Ethidium bromide (1%) Sigma-Aldrich 
FcR blocking reagent, murine Miltenyi Biotec 
Fetal bovine serum (FBS, other name: FCS) Biochrom 
G418, Geneticin® Sigma-Aldrich 
Gel loading dye, purple (6X) New England Biolabs 
HEPES solution Sigma-Aldrich 
Histopaque®-1077 Sigma-Aldrich 
Isoflurane CP CP-Pharma 
L-Glutamine Sigma-Aldrich 
Midori Green DNA, Direct loading dye Nippon Genetics 
PBS (w/o Mg2+/Ca2+) Lonza 
Materials & Methods 
20 
 
Name Supplier 
Penicillin/Streptomycin Paul-Ehrlich-Institut 
Polyethylenimine (PEI), branched Sigma-Aldrich 
RPMI 1640 medium Biowest 
Sucrose Sigma-Aldrich 
Trypan blue Sigma-Aldrich 
UltraComp eBeads™ Compensation Beads Thermo Fisher Scientific 
2.1.2 Consumables 
Name  Supplier 
1.4 ml Tubes Micronic 
500 ml Rapid-Flow Bottle Top Filter, 0.45 µm SFCE Thermo Fisher Scientific 
BD Falcon Round Bottom Tube, 5 ml Becton Dickinson 
BD Microtainer® Blood Collection Tubes, Lithium Heparin 
(LH) 
Becton Dickinson 
BD Vacutainer Safety-Lok Blood Collection Set Becton Dickinson 
BD Vacutainer® CPT™ Mononuclear Cell Preparation 
Tube 
Becton Dickinson 
Cell Culture Dish, Ø 150 mm VWR 
Cell Strainer, 70 µm Corning 
Centrifuge Tube, 225 ml VWR 
Cryovial (2 ml) Greiner Bio-One 
Falcon (15 ml, 50 ml) Greiner Bio-One 
Frame Star 96 Well Plate, Roche Style 4titude 
Insulin Syringes, U-100; 0.33 mm (29G) x 12.7 mm Becton Dickinson 
LD Column Miltenyi Biotec 
Pasteur Pipet, glass, 14.6 cm VWR 
PCR Tubes Eppendorf 
Petri Dish, Ø10 cm Greiner Bio-One 
Pipette Tips, filtered (10 µl, 100 µl, 300 µl, 1000 µl) Biozym 
Serological pipettes (5 ml, 10 ml, 25 ml) Greiner Bio-One 
Sterican Cannulas (G24, G30) B. Braun 
Syringe Filters, Minisart (0.45 µm, 0.2 µm) Sartorius 
Tissue Culture Flask (T25, T75, T125) Greiner Bio-One 
Tissue Culture Plates (96-, 48-, 24-, 12-, 6-well) Thermo Fisher Scientific 
Materials & Methods 
21 
 
2.1.3 Software 
Name  Supplier 
Citavi 6 Swiss Academic Software 
FSC Express V4, V6 De Novo Software 
GraphPad Prism 7 GraphPad Software 
LightCycler® Software 4.1 Roche 
Living Image Perkin Elmer 
SnapGene 4.1 SnapGene 
Vector NTI® Thermo Fisher Scientific 
2.1.4 Buffers & Media 
Name  Composition 
Blocking solution 2% BSA in PBS w/o Mg2+/Ca2+ 
FACS fix 1% Formaldehyde in PBS w/o Mg2+/Ca2+ 
FACS washing buffer 2% FCS, 0.1% NaN3 in PBS w/o Mg2+/Ca2+ 
Freezing medium 10% DMSO, 90% FCS 
LB-medium 
1% Tryptone, 0.5% Yeast extract, 1% NaCl, in H2O, 
pH 7.2 
PBS/EDTA 2 mM EDTA in PBS w/o Mg2+/Ca2+ 
PEI transfection reagent 18 mM 25 kDa branched PEI in H2O 
S.O.C. medium 
1% Tryptone, 0.5% Yeast extract, 1% NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM Glucose in 
H2O 
Sucrose  20% Sucrose in PBS w/o Mg2+/Ca2+ 
T cell medium 
RPMI 1640 supplemented with 10% FCS, 2 mM 
L-Glutamine, 25 mM HEPES, 0.4% 
Penicillin/Streptomycin 
TAE buffer 40 mM Tris, 20 mM Acetic acid, 1 mM EDTA in H2O 
Trypsin working solution 
2 mM EDTA, 0.25% Trypsin-Melnick in PBS w/o 
Mg2+/Ca2+ 
2.1.5 Antibodies 
Name clone 
Dilution for flow 
cytometry 
application 
Supplier 
mouse anti-human CD19 LT19 1:100 Miltenyi Biotec 
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Name clone 
Dilution for flow 
cytometry 
application 
Supplier 
mouse anti-human CD28 15E8 
used for T cell 
activation (2.3.4) 
Miltenyi Biotec 
mouse anti-human CD3 BW264/56 1:100 Miltenyi Biotec 
mouse anti-human CD3 OKT3 
used for T cell 
activation (2.3.4) 
Miltenyi Biotec 
mouse anti-human CD45 5B1 1:100 Miltenyi Biotec 
mouse anti-human CD45RA T6D11 1:100 Miltenyi Biotec 
mouse anti-human CD62L 145/15 1:100 Miltenyi Biotec 
mouse anti-human CD8 BW135/80 1:100 Miltenyi Biotec 
mouse anti-myc 9B11 1:100 
Cell Signaling 
Technology 
2.1.6 Plasmids 
Name  Description Supplier 
pCAGGS-NiV-
Fc∆22 
Encodes NiV-Fc∆22 (Bender et al., 2016) 
pCAGGS-NiV-
Gc∆34CD8mut4 
Encodes NiV-Gc∆34 with four 
mutations to abolish natural binding 
sites of the NiV-G, is fused to the anti-
human CD8-specific scFv OKT8 
humVh1  
(Bender et al., 2016) 
pCMV∆R8.9 HIV-1 packaging plasmid 
U. Blömer  
(Zufferey et al., 1997)  
pH-luc-IRES-
Neomycin 
Encodes firefly luciferase fused to 
neomycin resistance via an internal 
ribosomal entry site (IRES) 
I. Schneider 
pMD2.G Encodes the glycoprotein G of VSV D. Trono 
pS-Albumin-W 
HIV-1 transfer vector encoding parts of 
exon(13)-intron(14) junction sequence 
of human albumin gene  
This thesis 
pS-CD19CAR-W 
HIV-1 transfer vector encoding CD19 
CAR, generated by removing the IRES-
GFP cassette from plasmid pS-63.28.z-
IEW 
W. Wels 
(Oelsner et al., 2017)  
pSEW HIV-1 transfer vector encoding GFP 
M. Grez  
(Demaison et al., 2002) 
pS-luc-gfp-W 
HIV-1 transfer vector encoding firefly 
luciferase and GFP, linked by a T2A 
site  
(Abel et al., 2013) 
Materials & Methods 
23 
 
Name  Description Supplier 
pS-rfp-W 
HIV-1 transfer vector encoding RFP, 
generated by exchanging the luc-gfp 
cassette in pS-luc-gfp-W with the RFP 
reading frame 
T. Abel 
2.1.7 Enzymes 
Name  Supplier 
Antarctic Phosphatase New England Biolabs 
KOD Hot Start DNA Polymerase Merck Millipore 
Restriction Endonucleases New England Biolabs 
Trypsin 2.5%  Paul-Ehrlich-Institut 
2.1.8 Oligonucleotide 
Name  Sequence (5’ → 3’) 
albumin fwd CAC ACT TTC TGA GAA GGA GAG AC 
albumin rev GCT TGA ATT GAC AGT TCT TGC TAT 
lvLTR1 [biotin]-GAA CCC ACT GCT TAA GCC TCA 
lvLTR2 AGC TTG CCT TGA GTG CTT CA 
lvLTR3 AGT AGT GTG TGC CCG TCT GT 
OCI GAC CCG GGA GAT CTG AAT TCG 
OCII AGT GGC ACA GCA GTT AGG ACG 
Probe-albumin [6FAM]-ACG TGA GGA GTA TTT CAT TAC TGC ATG TGT-[BHQ1] 
Probe-WPRE [Cy5]-TGC ACT GTG TTT GCT GAC GCA AC-[BHQ3] 
WPRE fwd TCC TGG TTG CTG TCT CTT TAT G 
WPRE rev TGA CAG GTG GTG GCA ATG 
2.1.9 Kits 
Name  Supplier 
CellTrace™ CFSE Cell Proliferation Kit Thermo Fisher Scientific 
DNeasy® Blood and Tissue Kit Qiagen 
eBioscienceTM Fixable Viablity Dye eFluorTM 450 Thermo Fisher Scientific 
GeneJET Gel Extraction Kit Thermo Fisher Scientific 
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientific 
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Name  Supplier 
JETSTAR 2.0 Plasmid Midiprep Kit Genomed 
JETSTAR 2.0 Plasmid Midiprep Kit Genomed 
Liver Dissociation Kit, mouse Miltenyi Biotec 
Lung Dissociation Kit, mouse Miltenyi Biotec 
Nucleobond XtraMaxiET Machery-Nagel 
Nucleobond XtraMidi Machery-Nagel 
Luciferase Assay System Promega 
QIAamp DNA Mini Kit Qiagen 
Rapid DNA Ligation Kit Thermo Fisher Scientific 
SensiFASTTM Probe No-Rox Kit Bioline 
2.1.10 Cell lines and bacteria 
Name  Description Source 
E.coli, Top 10 
Highly transformable laboratory strain of 
Escherichia coli 
Life technologies 
HEK-293T 
Human fetal kidney epithelial cells, 
transformed to express the adenoviral 
SV40 T antigen 
ATCC CRL-11268 
Hut-78 Human T lymphoblast cell line ATCC TIB-161 
MOLT4.8 Human T lymphoblast cell line 
C. J. Buchholz, 
Paul-Ehrlich-Institut 
Raji Human B lymphoblast cell line ATCC CCL-86 
Raji-luc 
Human B lymphoblast cell line, stable cell 
line, genetically engineered to express 
firefly luciferase, neomycin resistant 
This thesis 
2.2 Methods of molecular biology 
2.2.1 Transformation of chemically competent bacteria 
Plasmid DNA was amplified by cellular replication of transformed chemically competent 
E.coli Top 10. Bacteria were thawed on ice and 50 ng DNA or 3 µl ligation mix was added. 
After 30 min incubation on ice, a heat shock was performed at 42°C for 45 s and bacteria 
were immediately cooled on ice afterwards. S.O.C medium (100 µl) was added to the 
bacteria. After 30 min incubation at 37°C, shaking at 600 rpm, bacteria were plated onto 
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LB agar plates (4% (w/v) LB-agar containing 100 mg/l ampicillin, provided by 
Medienküche, Paul-Ehrlich-Institut) and incubated over night at 37°C. 
2.2.2 Plasmid preparation 
Plasmid DNA preparation was performed from transformed E.coli using silica membrane 
or anion exchange column-based DNA purification technique. For purification of low, 
medium and high amount of plasmid DNA, 5 ml, 50 ml or 250 ml LB medium were 
inoculated with a single bacteria clone in the presence of corresponding antibiotics and 
grown over night at 37°C, shaking at 180 rpm. Bacteria were harvested by centrifugation 
at 4600 rpm for 10 min (Multifuge 3S-R, Heraeus) or at 6000 rpm for 15 min (Sorvall® RC 
26 plus, rotor: SLA-1500). DNA purification was performed using GeneJET Plasmid 
Miniprep Kit, JETSTAR 2.0 Plasmid Midiprep Kit or JETSTAR 2.0 Maxiprep Kit according 
to the manufacturer’s protocol. DNA concentration was photometrically analyzed 
(NanoDropTM 2000c, Thermo Fisher Scientific). DNA quality was analyzed by restriction 
enzyme digest (2.2.3) and subsequent agarose gel electrophoresis (2.2.4). 
2.2.3 Restriction of DNA 
Restriction enzyme digest was performed for analytical and preparative DNA digestions. 
Restriction endonucleases from New England Biolab (NEB) were used according to the 
manufacturer’s protocol. Usually, 1 µg of DNA was mixed with 10 U of the corresponding 
enzyme and buffer conditions. Analytical digestions were performed with 1µg DNA and 
preparative digestions with 1-3 µg DNA. The reaction mix was incubated at the 
corresponding temperature optimum for 2-4 h (analytical) or 4-6 h (preparative). DNA 
fragments were separated using agarose gel electrophoresis (2.2.4) and, if required, 
purified form the gel using the GeneJET Extraction Kit (Thermo Fisher Scientific). 
2.2.4 Agarose gel electrophoresis 
Agarose gels electrophoresis separates DNA fragments according to their size and was 
used to analyze analytical and preparative DNA digests. Usually, 1-2% (w/v) agarose gels 
were used for analyses. For this purpose, agarose powder was dissolved in TAE buffer 
by heating and the solution was poured into a gel tray for polymerization. To visualize 
DNA, either ethidium bromide or Midori Green were used. 50 µg/ml ethidium bromide was 
added to the non-polymerized agarose gel solution and DNA samples were mixed with 
6x gel loading dye (NEB), prior loading them onto the polymerized gel. Midori Green was 
Materials & Methods 
26 
 
directly added to the DNA samples using Midori Green Direct (Nippon Genetics). Gel 
electrophoresis was performed at 70-120 V in a Wide Mini Sub-Cell® GT chamber 
(Bio-Rad). DNA fragment separation was analyzed by the use of ultraviolet or green/blue 
LED light, gel documentation imager (Intas) and a 2-log DNA ladder (NEB).  
2.2.5 Dephosphorylation and ligation of DNA 
Linearized DNA with compatible ends was dephosphorylated prior to ligation. 
Dephosphorylation of 5’-ends of DNA using Antarctic phosphatase (NEB) was performed 
according to the manufacturer’s protocol. In brief, 300 ng of linearized DNA were mixed 
with 5 U Antarctic phosphatase within appropriate buffer conditions and incubated at 37°C 
for 30 min. Prior to ligation, enzyme was inhibited by heat inactivation for 2 min at 80°C. 
For ligation, the Rapid DNA Ligation Kit (Thermo Fisher Scientific) was used according to 
the manufacturer’s protocol. Vector DNA was mixed with insert DNA at 3:1 molar excess 
over vector. Usually, 50 ng of vector DNA was used and mixed with insert DNA and 5 U/µl 
T4 DNA Ligase under appropriate buffer conditions. After 5 min incubation at 22°C, 3 µl 
of reaction mixture was used for transformation (2.2.1). 
2.2.6 Polymerase chain reaction 
Amplification of DNA fragments using sequence-specific primers was performed with the 
use of KOD Hot Start DNA Polymerase (Merck Millipore) according to the manufacturer’s 
protocol. For the introduction of restriction sites into DNA sequences, sequence-specific 
primers were designed with extended sequences of the desired restriction site. In general, 
a polymerase chain reaction (PCR) consists of several steps of different temperature 
cycles. Prior to the initial denaturation step, which melts double stranded DNA, an 
initialization step is required for activating the hot-start polymerase. After annealing of the 
primers at primer-specific temperature, the polymerase synthesizes a new DNA strand 
complementary to the template during the elongation step. Elongation time is dependent 
on the amplicon length and PCR reactions were prepared as shown in Table 1 with cycle 
conditions given in Table 2. 
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Table 1: PCR reaction 
component volume in µl 
plasmid template DNA (10 ng) 1 
10x Buffer for KOD Hot Start DNA polymerase 5 
MgSO4 (25 mM) 3 
dNTP (2 mM each) 5 
fwd primer (10 µM) 1,5 
rev primer (10 µM) 1,5 
KOD Pol (1 U/µl) 1 
PCR grade water 32 
 
PCR reaction was performed in a PCR thermal cycler (Bio-Rad) with following cycle 
reactions: 
Table 2: PCR cycle conditions 
 step temperature time 
1 Polymerase activation 95°C 2 min 
2 Denature 95°C 20 s 
3 Annealing 50-75°C * 10 sec 
4 Extension 70°C 10-25 s/kb ** 
 repeat step 2-4 25 cycles  
5 Final elongation 70°C 10 min 
6 Cool down  4°C hold 
* lowest primer melting temperature; ** extension time is dependent on the PCR product length: <500 bp: 
10 s/kb; 500-1000 bp: 15 s/kb; 1000-3000 bp: 20 s/kb; > 3000 bp: 25 s/kb 
PCR product was analyzed by agarose gel electrophoresis (2.2.4) and, if required, the 
DNA fragment was purified using GeneJet Gel extraction Kit (Thermo Fisher Scientific) 
according to manufacturer’s protocol.  
2.2.7 DNA sequencing 
Plasmid DNA sequencing was performed by GATC Biotech according to the company’s 
guideline. Sequencing results were analyzed using ContigExpress® software (Vector 
NTI®, Invitrogen). 
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2.2.8 Isolation of genomic DNA  
Genomic DNA (gDNA) was isolated from cell suspensions of organs from mice or from 
cell culture pellets using the DNeasy® Blood and Tissue Kit (Qiagen) or QiAamp DNA Mini 
Kit (Qiagen) according to the manufacturer’s protocol. When isolating gDNA from blood, 
maximum of 100 µl blood was used as starting material. A maximum of 5x106 cells was 
used to isolate gDNA from freshly prepared or -20°C frozen cell pellets. DNA 
concentration was photometrically analyzed (NanoDropTM 2000c, Thermo Fisher 
Scientific). 
2.2.9 Quantitative polymerase chain reaction  
Quantitative real-time PCR (qPCR) allows quantification of specific DNA sequences by 
monitoring the sequence amplification with fluorescent dyes during the PCR in real-time. 
Transgene integration of cells transduced by LVs was quantified by vector copy number 
(VCN) analysis. Vector copies were quantified by TaqMan-based qPCR in a multiplex 
approach using the SensiFAST Probe No Rox Kit (Bioline) and LightCycler® 480 
Instrument II (Roche) (Table 3) with cycle conditions given in Table 4. Transgene was 
detected using woodchuck hepatitis posttranscriptional element (WPRE)-specific probe 
and primers. A human albumin-specific probe and primers served as an internal 
reference.  
Table 3: qPCR reaction 
component volume in µl 
2x SensiFAST Probe No ROX 10 
Probe-albumin(2 µM) 2 
albumin fwd (10 µM) 0.4 
albumin rev (10 µM) 0.4 
Probe-WPRE (2 µM) 2 
WPRE fwd (10 µM) 0.4 
WPRE rev (10 µM) 0.4 
DNA template up to 4.4 
H2O, nuclease free ad 20 
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Table 4: qPCR cycle conditions 
 step temperature time 
1 Initial denaturation 95°C 5 min 
2 Denaturation 95°C 10 s 
3 Annealing + Extension 60°C 40 s 
 repeat step 2-3, 40 cycles   
4 Cool down 10°C hold 
 
Data were analyzed using LightCycler® Software. For quantification, a plasmid standard 
containing sequences of WPRE and human albumin (pS-Albumin-W) was used and VCN 
were calculated as the ratio of (copies WPRE)/(copies albumin).  
2.2.10 Ligation-mediated (LM)-PCR 
Lentiviral integration sites were analyzed by amplifying the 3‘ LTR as described in 
(Schmidt et al., 2001). These analyses were performed in close collaboration with Prof. 
Dr. Dr. Modlichs group (group “Gene modification in Stem Cells”, Paul-Ehrlich-Institut) 
with F. Schenk.  
Isolated gDNA (2.2.8) was digested with Tsp5091 (Thermo Fisher Scientific) (5 U per 
1 µg DNA) at 65°C for 3 h and precipitated with 100% ethanol, 20 µg glycogen and 0.1 M 
Na-acetate. Primer extension was performed by using the Pfu polymerase (Thermo Fisher 
Scientific) and 0.5 pmol of biotinylated lentiviral primer lvLTRI with cycle conditions given 
in Table 5. 
Table 5: Cycle conditions for primer extension 
 step temperature time 
1 Denaturation 94°C 5 min 
2 Annealing 64°C 30 min 
3 Extension 72°C 15 min 
 
The extension product was purified by QIA Quick PCR purification Kit (Qiagen), diluted in 
40 µl H2O and enriched using magnetic beads (Dynabeads, in 2x BW buffer (10 mM Tris 
[pH 7.5], 1 mM EDTA, 2 mM NaCl). The product was mixed with 40 µl magnetic beads 
and incubated at constant rotation for 5 h at RT. Captured DNA was washed twice using 
100 µl H2O, resuspended in ligation mix with 80 U of T4-Ligase and linker oligos, and 
incubated at 16°C overnight. For amplification, two PCR reactions followed. Hi-Fidelity 
PCR Master Mix (Thermo Fisher Scientific) was used and cycle conditions are given in 
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Table 6. For the first PCR, 1 µl of the product, lvLTR2 primer and the linker-specific primer 
OCI were used. The second PCR was performed with the PCR product (1:350 diluted in 
H2O) under same conditions using lvLTR3 and OCII primer. PCR products were analyzed 
by gel electrophoresis (2.2.4).  
Table 6: Cycle conditions for first and second PCR    
 step temperature time 
1 Initial denaturation 94°C 2 min 
2 Denaturation 94°C 15 s 
3 Annealing 60°C 30 s 
4 Extension 68°C 4 min 
 repeat step 2-4 for 30 cycles   
5 Final elongation 68°C 10 min 
2.3 Cell culture and virological methods 
2.3.1 Cultivation of eukaryotic cell lines 
Cells were cultivated at 37°C, 5% CO2 and 90% humidity in a cell culture incubator and 
handled under sterile conditions using a laminar flow cabinet. HEK-293T cells were 
cultivated in DMEM (10% FCS, 1% L-glutamine). Hut-78, MOLT4.8 and Raji cells were 
cultivated in RPMI (10% FCS, 1% L-glutamine). Raji-luc cells were cultivated in RPMI 
(10% FCS, 1% L-glutamine, 1mg/ml geneticin). Cells were passaged 2-3 times per week. 
For adherent cells, medium was removed. Cells were washed with phosphate buffered 
saline (PBS) and detached with trypsin working solution. Cells were resuspended in fresh 
medium and appropriate fraction of cells was transferred into a new cell culture flask with 
fresh medium. For passaging of suspension cells, cells were resuspended and an 
appropriate fraction of cells was seeded into a new cell culture flask with fresh medium. 
Cell lines were regularly checked for mycoplasma decontamination by PCR. 
2.3.2 Freezing and thawing of cells 
For freezing cells, cell suspensions were counted and centrifuged at 300xg for 3 min. Cell 
pellet was resuspended in appropriate volume of cold freezing medium and aliquoted. 
Cryovials were transferred to Mr. Frosty™ container (Thermo Fisher Scientific) and frozen 
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at -80°C. After 24 h, cryovials were transferred to the gas phase of liquid nitrogen for 
storage.   
Frozen cells were thawed in a 37°C water bath and resuspended in 10 ml prewarmed 
medium. Cells were pelleted at 300xg for 3 min, resuspended in appropriate medium, 
transferred to a cell culture flask and incubated at 37°C 
2.3.3 Isolation of PBMC 
Human PBMC were isolated from fresh blood of healthy anonymous donors that had given 
informed consent, or from buffy coats purchased from the German Red Cross blood 
donation center (DRK-Blutspendedienst Baden-Württemberg-Hessen, Frankfurt). Cell 
preparation tubes or Histopaque®-1077 gradient were used to separate PBMC from other 
blood components by density centrifugation. PBMC isolation with CPT tubes (Becton 
Dickinson) was performed according to manufacturer’s protocol and the mononuclear cell 
layer was transferred to a fresh tube. For isolation of PBMC using the Histopaque®-1077 
gradient, blood was diluted 1:1 in PBS/EDTA and 35 ml of the mixture was overlaid onto 
15 ml Histopaque®-1077 layer. After 30 min of centrifugation at 20°C, 1800 rpm in a 
swinging bucket rotor without break (Varifuge 3.0RS, Heraeus), mononuclear cell layer 
was aspirated and transferred to a fresh tube. PBMC were washed with 40 ml PBS/EDTA 
using a centrifugation step for 10 min at 300xg. To remove platelets, PBMC were 
resuspended in 40 ml PBS/EDTA and centrifuged for 15 min at 200xg. Erythrocytes were 
lysed using BD Pharm Lyse™ (Becton Dickinson) according to manufacturer’s protocol. 
PBMC were washed twice and were either activated (2.3.4), used for cell depletion (2.3.5) 
or were frozen (2.3.2). 
2.3.4 Activation and cultivation of T cells  
Prior to activation, 24 well plates were coated with 1 μg/ml anti-human CD3 mAb (clone 
OKT3, Miltenyi Biotec) (dissolved in PBS) for 2 h at 37°C or overnight at 4°C. Antibody 
solution was removed and blocking solution was added. After 30 min of incubation at 
37°C, the solution was removed and wells were washed twice with PBS.  
For activation, freshly isolated or thawed PBMC were used. 2x106 cells were seeded on 
24 well plates in 2 ml T cell medium supplemented with 100 U/ml IL-2 (Miltenyi Biotec) 
and 3 µg/ml anti-human CD28 mAb (clone: 15E8, Miltenyi Biotec). PBMC were incubated 
for 72 h at 37°C.  
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For cultivation of PBMC, depending on cell density, cells were passaged every 2-3 days 
or supplied with fresh medium by replacing the old medium with fresh T cell medium 
containing 100 U/ml IL-2 every 2-3 days.   
2.3.5 CD19+ cell depletion 
PBMC were depleted of CD19+ cells by MACS® Separation (Miltenyi Biotec) using 
MicroBeads (Miltenyi Biotec) specific for CD19. According to manufacturer’s protocol, 
cells were labelled with MicroBeads and loaded onto a LD Column (Miltenyi Biotec), which 
was placed in a magnetic field of the MACS Separator to retain magnetically labelled cells. 
Both fractions, unlabeled depleted cells as well as labelled enriched cells were analyzed 
for CD3 and CD19 expression by flow cytometry. Cells of the CD19-depleted fraction were 
either frozen (2.3.2) until further usage or activated (2.3.4).   
2.3.6 Generation of vector particles  
For vector particle generation, HEK-293T cells were transiently transfected using 
Polyethylenimine (PEI). One day prior transfection, 1x105 cells were seeded per T175 
flask. On the day of transfection, medium was replaced with 10 ml DMEM (15% FCS, 
2 mM L-glutamine) and the transfection mix was prepared. Per flask, 35 µg DNA was 
diluted in 2.3 ml DMEM without (w/o) additives. For CD8-LV production, 0.9 µg of plasmid 
pCAGGS-NiV-Gc∆34CD8mut4, 4.49 µg of plasmid pCAGGS-NiV-F∆22, 14.5 µg of the 
packaging plasmid pCMV∆R8.9 and 15.2 µg of the transfer vector encoding either 
Luc-GFP (pS-luc-gfp-W), CD19 CAR (pS-CD19CAR-W) or RFP (pS-rfp-W) were used. 
140 µl PEI was diluted in 2.2 ml DMEM and both solutions were mixed and vortexed, 
incubated at RT for 15-20 min and added to the cells. 24 h later, medium was exchanged 
with DMEM (10% FCS, 2 mM L-glutamine). Two days after transfection, vector particles 
released into the cell supernatant were harvested and filtrated through 0.45 µm filter. 
Concentration and purification of vector particles was performed by ultracentrifugation 
through 20% (w/v) sucrose cushion at 28.000 rpm, 4°C for 3 h (Beckmann Coulter, 
Beckman SW28) or at 4500 rpm for 24 h at 4°C (Multifuge XR3, Heraeus). The 
supernatant was discarded, the pellet was dissolved in 60 µl PBS and vector particles 
were stored at -80°C.       
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2.3.7 Transduction and titration of vectors 
For transduction, 2-4x104 MOLT 4.8 cells were seeded in 96-well plates. Vector was 
added to the cells (maximum total volume of 200 µl) which were incubated 96 h at 37°C 
prior to analysis. To determine vector titers, 2-4x104 MOLT 4.8 cells were seeded in 
96-well plates. Vector particles were added in serial dilution and cells were incubated for 
96 h at 37°C. Transgene expression was analyzed by flow cytometry. Based on dilutions 
showing a linear correlation between the dilution factor and the percentage of transduced 
cells, titer was determined as transducing units per ml (t.u./ml).  
2.3.8 Transduction of PBMC 
For transduction of primary human PBMC, 1x105 activated PBMC were seeded in T cell 
medium, supplied with 100 U/ml IL-2 per 48-well. Vector was added to the cells (maximum 
total volume of 300 µl) and spinfection was performed by centrifugation at 850xg for 
90 min at 32°C. Wells were filled up to 1 ml with T cell medium, supplied with 100 U/ml 
IL-2. Transgene expression was determined by flow cytometry (2.3.9) five days post 
transduction. 
2.3.9 Flow Cytometry 
Adherent and suspension cells 
Adherent cells were detached using trypsin working solution, resuspended in medium and 
transferred to micronic tubes. Suspension cells were resuspended prior to transferring 
them in micronic staining tubes. They were washed twice with FACS washing buffer by 
centrifugation at 300xg for 3 min. Cells were incubated with appropriate antibody dilution 
(in FACS washing buffer) for 30 min at 4°C before they were washed twice and fixed with 
100-200 µl FACS fix. Flow cytometric analysis was performed at the LSRII 
(BD Biosciences) or MACSQuant Analyzer10 (Miltenyi Biotec) and data were analyzed 
using FCS Express V4 and V6 (De Novo Software). 
 
Blood and organ-derived cell suspensions 
For flow cytometry analysis, maximum of 100 µl blood or 1-5x106 cells were used. Cells 
were washed twice with FACS washing buffer and incubated with murine FcRblock 
(Miltenyi Biotec) according to manufacturer’s protocol. After 15 min incubation at 4°C, 
antibody dilution (in FACS washing buffer) was added and cells were incubated for 30 min 
at 4°C. If required, erythrocytes were removed using BD Pharm Lyse (Becton Dickinson) 
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by resuspending the cells in 1 ml 1x lysis buffer. After 15 min incubation at room 
temperature (RT), cells were washed twice with PBS (1% FCS) and stained with 
LIVE/DEAD™ Fixable Dead Cell Stain (ThermoFisher Scientific) according to 
manufacturer’s protocol for 30 min at 4°C. Cells were washed twice and fixed with FACS 
fix prior flow cytometry analysis.  
For the analysis of cells derived from blood or organs from mice, in general, following 
gating strategy was applied, unless stated differently. Cells were excluded for cell debris 
and hierarchically gated as follows. Single cells were gated for living cells. Human cells 
were identified as CD45+ cells and further gated for T cells by CD3 expression. CD3+ cells 
were analyzed for CD8 expression and transgene expression was analyzed within 
CD3+CD8+ or CD3+CD8- cells. CD19+ cells were gated from CD45+ cells, whereby 
CD19+ Raji cells were distinguished from CD19+ B cells by the MFI of CD45. Thereby, 
CD45highCD19+ cells were identified as B cells and CD45lowCD19+ cells were identified as 
Raji cells. Flow cytometric analysis was performed at the LSRII (BD Biosciences) and 
data were analyzed using FCS Express V4 and V6 (De Novo Software). 
2.3.10 Killing assay 
The cytotoxicity of CAR T cells was determined by a flow cytometry-based assay. In 
general, CAR T cells (effector cells) were co-cultured with tumor cells (target cells) and 
killing efficacy was determined by analyzing dead cells after 4h of co-culture. Thereby, 
tumor cells were labelled with a fluorescent dye to distinguish between dead CAR T cells 
and killed tumor cells. Killing efficacy was evaluated in various effector to target ratios 
ranging from 5:1 to 0.15:1.  
One day prior to killing assay, CAR expression was analyzed by flow cytometry (2.3.9). 
Only CAR+ T cells were counted as effectors. Prior to target cell labelling, cells were 
washed twice with PBS by centrifugation at 300xg for 3 min. Cells were labelled with 
carboxyfluorescein succinimidyl ester (CFSE) according to the manufacturer’s protocol. 
In detail, 2.5 µM CFSE working solution (in PBS) was pre-warmed at 37°C in a water bath. 
1x106-4x107 target cells were resuspended in 1 ml CFSE working solution for 10 min at 
37°C. 1 ml FCS was added and cells were incubated on ice for additional 10 min before 
they were washed twice in PBS and resuspended in RPMI (10% FCS, 1% L-glutamine). 
Cells were stored temporarily at 37°C. CAR T cells were washed once and resuspended 
in RPMI (10% FCS, 1% L-glutamine). For the different effector to target ratios, CAR T cell 
dilutions were prepared. For co-incubation, 5x104 target cells in 100 µl were transferred 
to round-bottom 96-well plates. 100 µl of each CAR T cell dilution was added to the 
designated well and cells were co-cultivated for 4 h at 37°C. Cells were washed twice 
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prior to dead cell staining with the Fixable Viability Dye eFluor450™ according to 
manufacturer’s protocol. Cells were fixed using FACS fix and analyzed by flow cytometry. 
The percent killing of target cells was calculated by multiplying the ratio of the number of 
dead CFSE+ cells and the total cell number of CFSE+ cells with 100. 
2.3.11 Irradiation of cells 
Prior to irradiation, cells were expanded as needed. On the day of irradiation, cells were 
washed once, counted and resuspended in prewarmed RPMI medium (10% FCS, 1% 
L-glutamine). 2x108 cells were resuspended in 50 ml medium and mitotically inactivated 
by ɤ-irradiation. Raji cells were irradiated with 15 Gy, Hut-78 cells with 25 Gy. Cells were 
centrifuged at 300xg for 10 min, resuspended in freezing medium, aliquoted and stored in 
the gas phase of liquid nitrogen until usage.  
2.3.12 Proliferation assay 
The proliferation assay allows evaluation of the proliferative capability of CAR T cells. In 
the presence of antigen-positive cells, selective expansion of CAR T cells was evaluated 
by flow cytometry analyzing the percentage of CAR expressing cells within co-culture. 
Human PBMC were activated and transduced (2.3.4, 2.3.8). CAR expression was 
analyzed by flow cytometry five days post transduction. Dependent on the percentage of 
CAR+ cells, the amount of cells was calculated to have 1x104 CAR T cells present at start 
of the co-culture, or 1x104 green fluorescent protein (GFP)-positive cells as control. To 
compensate for varying transgene expression and thereby varying total cell number of 
plated cells, wells were filled up with untransduced cells to normalize total cell numbers 
between co-cultures of CAR- or GFP-positive cells. Same amount as transgene-positive 
cells or 10-fold excess of irradiated cells (2.3.11) were added to transgene-positive cells. 
Co-culture was performed in 48-well plate using T cell medium, supplemented with 
50 U/ml IL-2. Every 2-3 days, medium was exchanged and irradiated cells were added, 
or cells were passaged if required. At given time points, cells were analyzed for CD8 and 
CAR expression by flow cytometry. 
For the proliferation assay, starting with less than 1% CAR T cells (Figure 17), 2x105 cells, 
of which 0.5% were transgene-positive were used to start the co-culture. Due to the low 
amount of total CAR-positive T cells, the same amount (2x105) of irradiated target cells 
was added at the start of co-culture to enable cell-cell contact of CAR T cells with target 
cells. 
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2.3.13 Generation of stably transgenic cell lines  
Cells, stably expressing an introduced transgene were generated by transduction with a 
LV encoding for the transgene. Raji-luc cells were generated by transduction with 
VSV-G-pseudotyped LV, transferring the luciferase transgene and neomycin resistance 
gene. LVs were generated by transient transfection of HEK-293T cells (2.3.6). In 
particular, VSV-G-pseudotyped LV were generated in 6-well format by triple transfection 
of HEK-293T with 3.4 µg pMD2.G, 6.3 µg pCMV8.9 and 0.96 µg transfer vector 
(pH-Luc-IRES-Neomycin). Two days after transfection, supernatant was harvested and 
filtrated through 0.45 µm filter. Unconcentrated supernatant was used for transduction of 
Raji cells. For this, 1x105 cells were seeded in 48-well and transduced with different 
volumes of vector stock (0.1 µl-100 µl) with a maximum total volume of 300 µl. On the 
next day, wells were filled up with RPMI (10% FCS, 1% L-glutamine) to 1 ml. Three days 
after transduction, transgene expressing cells were selected by RPMI (10% FCS, 
1% L-glutamine) supplemented with geneticin (1 mg/ml). Raji-luc cells were selected for 
two weeks and were verified for luciferase expression using the luciferase assay system 
(Promega) according to the manufacturer’s protocol. Raji-luc cells were expanded and 
frozen (2.3.2).   
2.4 Experimental mouse work 
Animal experiments were performed in accordance to the German animal protection law 
and the respective European Union guidelines. NSG mice were purchased from Jackson 
Laboratory and from in-house breeding facility (Paul-Ehrlich-Institut). Mice were housed 
in the animal facility within individually ventilated cages (IVCs) and handled under a 
laminar flow hood. 
2.4.1 Administration of PBMC  
Freshly isolated or thawed PBMC were activated for three days (2.3.4) before 
administration into mice. On the day of administration, PBMC were washed twice with 
PBS by centrifugation at 300xg for 10 min, counted using MACSQuant Analyzer10 and 
resuspended in appropriate volume of PBS. For intravenous administration, mice were 
prewarmed using red light, in particular the tail to dilate blood vessels. Mice were 
restrained using a mouse restrainer and 1.5x107 cells resuspended in 200 µl PBS were 
injected into the tail vein using a 29 gauge needle. For intraperitoneal injection, mice were 
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restrained and 1x107 cells resuspended in 200 µl PBS were administered using a 
29 gauge needle. 
2.4.2 Administration of tumor cells 
Two weeks prior to administration, a fresh batch of Raji-luc cells was thawed and 
expanded as needed. On the day of administration, cells were washed twice with PBS by 
centrifugation at 300xg for 10 min. Cells were counted using MACSQuant Analyzer10 and 
resuspended in an appropriate volume of PBS. For intravenous and intraperitoneal 
administration, 5x105 cells resuspended in 200 µl PBS were injected using a 29 gauge 
needle.    
2.4.3 Administration of vector particles 
Prior to administration, vector aliquots were thawed on ice and pooled. For intravenous 
administration of CD8-LV(Luc-GFP), 200 µl of vector stock was administered. Titers of 
three independent vector productions were determined on MOLT4.8 cells with an average 
titer of 9.5x107 t.u./ml ± 7.1x106 t.u./ml. Hence, on average 1.9x107 t.u. were administered 
per mouse. For administration of CD8-LV(CAR), an average titer of 
1.1x107 t.u./ml ± 9.7x105 t.u./ml was determined on MOLT4.8 cells for five independent 
vector productions. 200 µl of vector stock was intraperitoneally administered to mice 
resulting in 2.2x106 t.u. per mouse. When comparing transgene delivery between 
CD8 LV(CAR) and CD8-LV(RFP) in mice, same amount of transducing units was 
administered. For this purpose, vectors were titrated on activated PBMC, which in general 
resulted in lower titers compared to titer determination on MOLT4.8 cell line. For example 
the same vector stock of CD8-LV(CAR) resulted in lower titers on PBMC than on 
MOLT4.8. When administering CD8-LV(CAR) and CD8-LV(RFP), on average 1.6x104 t.u. 
were injected per mouse.    
2.4.4 In vivo Imaging 
In vivo imaging allows visualization of luciferase expressing cells in living mice. With the 
use of the IVIS® Imaging System (Caliper Life Science) luciferase signals can be analyzed 
and quantified using the Living Image software (Caliper Life Science). For this purpose, 
150 mg D-luciferin (in PBS) per kg body weight was i.p. injected into mice. Mice were 
anesthetized with 2-3% isoflurane using a XGI-8 Gas Anesthesia system (Caliper Life 
Science) and imaged 10 min post luciferin administration.  
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2.4.5 Blood sampling 
Blood was taken retroorbital from mice. For this purpose, mice were anesthetized with 
2-3% isoflurane. Blood was taken using a thin sterilized glass capillaries and blood was 
transferred into BD microtainer® LH tubes (Becton Dickinson).  
2.4.6 Preparation of single cell suspensions from organs 
Mice were anesthetized with 2-3% isoflurane and sacrificed by cervical dislocation. Blood 
was taken, peritoneal cells were isolated by peritoneal lavage, specified organs (spleen, 
liver, lung, bone marrow) were removed and single cell suspensions prepared (2.4.6.1, 
2.4.6.2, 2.4.6.3). Cells were used for flow cytometry analysis (2.3.9) and 1-5x106 cells 
were pelleted and frozen for gDNA isolation (2.2.8). 
2.4.6.1 Isolation of peritoneal cells by peritoneal lavage 
Mice were sprayed with 70% ethanol, mounted on styrofoam on its back and the outer 
skin was pulled back. 5-10 ml PBS were slowly injected using a 24 gauge needle into the 
peritoneal cavity and gently massaged prior to collecting the fluid. Cell suspension was 
transferred in a tube, washed once and resuspended in PBS (2% FCS).  
2.4.6.2 Preparation of spleen, lung and liver cells  
Spleen, lung and liver were removed, transferred to PBS and stored on ice until further 
processing. Single cell suspensions from spleen were obtained by meshing the tissue 
through a 45 µm cell strainer. For lung and liver tissue dissociation, dissociation kits for 
murine lung or liver tissue (Miltenyi Biotec) were used together with the gentleMACS 
dissociator (Miltenyi Biotec) according to manufacturer’s protocol. In brief, enzyme mix 
was added to dissected lung or liver tissue within a gentleMACS C tube (Miltenyi Biotec). 
GentleMACS C tubes were placed into the gentleMACS and lung or liver program was 
started. Single cell suspensions were applied to a 70 µm cell strainer. Cells were washed 
once and resuspended in PBS (2% FCS).  
2.4.6.3 Preparation of bone marrow cells 
For bone marrow cell isolation, femur and tibia were removed. Residential tissue was 
removed and the bone was cut at both ends. Using a 30 gauge needle, cells from the 
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bone were flushed out with PBS until the flow through turned white. Cells were washed 
once and resuspended in PBS (2% FCS) 
2.5 Statistical analysis 
Statistical significance was determined as indicated in figure legends. In general, 
statistical significance between two groups was determined using unpaired student´s t 
and Mann-Whitney tests. P values are given in the figure legends. GraphPad Prism 7 
software was used for statistical analysis.  
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3 Results 
This thesis describes the usage of a CD8-targeted lentiviral vector to deliver transgenes 
selectively to CD8+ cytotoxic T cells in vivo. Successful in vivo gene transfer into 
CD8 T cells was first shown via reporter gene transfer into PBMC-humanized NSG mice 
upon CD8-LV administration. The transfer of a gene encoding a chimeric antigen receptor 
resulted in the in vitro generation of CAR T cells. Remarkably, upon administration of 
CD8-LV(CAR) into mice CAR T cells were generated in vivo. Furthermore, in vivo 
generated CAR T cells have proven to be functional, being able to proliferate upon antigen 
exposure and to eliminate CD19+ cells in vivo.  
3.1 In vivo reporter gene transfer into CD8+ lymphocytes 
For the purpose of targeting CD8 T cells, NiV-pseudotyped lentiviral vectors were 
previously generated and well characterized (Bender et al., 2016). Concentrated vector 
stocks reached titers of 1x108 t.u./ml for particles carrying the gfp transgene, 
CD8-LV(GFP). In vitro analysis demonstrated selective and stable reporter gene transfer 
into human CD8+ cytotoxic T cells. However, in vivo transgene delivery had not been 
evaluated with CD8-LV and is addressed in the following chapter.  
3.1.1 In vivo luminescence imaging reveals organ-wide distributed reporter gene 
expressing cells 
The ability of CD8-LV to deliver reporter genes in vivo into human CD8 T cells was 
evaluated in mice. Since the human CD8 receptor was targeted, the PBMC-humanized 
NSG mouse model was used. The administration of human PBMC into 
immunocompromised NSG mice results in engraftment of human immune cells mainly 
consisting of CD8+ and CD4+ T cells. Systemic administration of CD8-LV transferring both 
the gfp as well as the luciferase (luc) reporter genes (Luc-GFP) enabled the analysis of 
in vivo transduced cells. 
In detail, 1.5x107 activated human PBMC were injected i.v. into immunocompromised 
NSG mice, followed by i.v. injection of CD8-LV(Luc-GFP) seven days later. In vivo 
transduced cells were monitored by in vivo bioluminescence imaging 14 days after vector 
administration (Figure 6).  
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Figure 6: Experimental setting for the in vivo reporter gene transfer with CD8-LV into PBMC-
humanized NSG mice  
Human PBMC were activated for three days using IL-2, αCD3- and αCD28-antibodies. 1.5x107 activated 
PBMC were i.v. injected into NSG mice. Seven days later, CD8-LV(Luc-GFP) was i.v. administered. 14 days 
later, transduced cells were monitored via in vivo luminescence imaging. Mice were sacrificed and cell 
suspensions were analyzed by flow cytometry. 
For PBS-treated control mice, no luciferase signals were detected (Figure 7, bottom row). 
In contrast, CD8-LV(Luc-GFP)-treated mice showed luciferase signals distributed all over 
the body. Dorsal and ventral imaging revealed stronger signals in the lung (Figure 7, upper 
row, left) and in the spleen (Figure 7, upper row, middle). Mice were sacrificed and spleen, 
liver, heart, lymph node-like structures, lung and kidney were removed and imaged 
immediately. Imaging of the removed organs revealed luciferase signals in the lung and 
in the spleen (Figure 7, upper row, right).   
 
Figure 7: In vivo imaging of CD8-LV(Luc-GFP)-treated PBMC-humanized NSG mice 
PBMC-humanized NSG mice treated with CD8-LV(Luc-GFP) were monitored for transduced cells by in vivo 
bioluminescence imaging 14 days after vector administration. PBS-treated mice served as control. Ventral 
and dorsal sites of the mice were imaged. Mice were sacrificed and organs were explanted and analyzed. 
One representative mouse from three independent experiments is shown. s, spleen; li, liver; lu, lung; k, kidney; 
h, heart; ly, lymph node-like structures. 
The detection of luciferase signals indicated successful in vivo transduction of cells with 
CD8-LV(Luc-GFP). luc transgene-modified cells were distributed throughout the body with 
higher presence in the lung and in spleen.  
imaging & 
flow cytometry
1.5x107 PBMC 
i.v. injection
CD8-LV(Luc-GFP)
i.v. injection
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3.1.2 Exclusive transduction of CD8+ cells 
To further assess the selectivity of CD8-LV in vivo, the transduced cells were 
characterized. Blood cells as well as cell suspensions from spleen and lung were analyzed 
by flow cytometry. Cell debris was excluded and single cells were gated from the main 
population. Dead cells were excluded and human cells were identified as CD45+ cells. 
T cells were identified as CD3+ cells further separated in CD8+ and CD8- cells. Both 
populations were analyzed for GFP expression and fluorescence background levels were 
determined on CD8+ and CD8- cells of identically treated cells of PBS-injected mice.  
Humanization level of mice ranged between 20-80% for the different organs. More than 
98% of the CD45+ cells were CD3+ (data not shown). PBS-treated mice showed minor 
background levels in CD8+ and CD8- cells ranging between 0-0.02% GFP+ cells for all 
organs (Figure 8A-C, bottom panels) with highest levels in the lung (0.02% ± 0.01%). 
However, these events were characterized by a low mean fluorescence intensity (MFI) 
being close to the left gate border.  
 
Figure 8: Flow cytometry analysis of blood, spleen and lung cells of CD8-LV(Luc-GFP)-treated 
PBMC-humanized NSG mice 
Single cell suspensions from spleen, blood and lung of CD8-LV(Luc-GFP)- and PBS-treated mice were 
analyzed by flow cytometry. Dead cells were excluded and human cells were identified as CD45+ cells. From 
all human cells, T cells were identified as CD3+ cells, further distinguished for CD3+CD8+ and CD3+CD8- cells 
and analyzed for GFP expression. GFP expression was determined on CD3+CD8+ and CD3+CD8- cells in 
(A) blood, (B) spleen and (C) lung cells. One representative of three individual mice is shown. (D) Percentage 
of GFP+ cells in CD8+ (+) and CD8- (-) cells. N=3, mean ± standard deviation (SD) are shown. Statistical 
significance was determined by two-tailed unpaired t-test; *, p<0.05; **, p<0.01, ns, not significant.  
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Remarkably, in the blood of CD8-LV(Luc-GFP)-treated mice GFP+ cells were detected 
exclusively within the CD8+ population (Figure 8A, top panel). No GFP expression was 
observed in CD8- cells. Similarly, GFP+ cells were detected in spleen (Figure 8B, top 
panel) and lung (Figure 8C, top panel) with varying frequencies of CD8+GFP+ cells. These 
events were characterized by higher MFI, compared to above mentioned events in 
PBS-treated mice. On average 0.2% (± 0.07%) CD8+GFP+ cells were detected in blood, 
0.25% (± 0.21%) in spleen and 0.22% (± 0.10%) in the lung (Figure 8D).  
Previous analysis was performed on CD8+ and CD8- cells, pre-gated for human markers 
CD45 and CD3. To evaluate off-target transduction, GFP expression was analyzed on all 
cells, independently of murine or human origin. Hence, GFP expression was analyzed 
within CD8+ and CD8- cells of side- and forward scatter-gated cells. This analysis, using 
the different gating strategy, is exemplarily shown for lung cells. As expected, the highest 
frequency of GFP+ cells was observed in CD8+ cells of CD8-LV(Luc-GFP) treated mice. 
Few GFP events were detected in CD8- cells, but their numbers were similar to events 
observed in PBS-treated control mice (Figure 9). 
 
Figure 9: Analysis of off-target GFP expression in lung cells of CD8-LV(Luc-GFP)-treated 
PBMC-humanized NSG mice 
Single cell suspensions of the lung from CD8-LV(Luc-GFP)-treated and PBS-treated mice were analyzed by 
flow cytometry. Side- and forward scatter gated cells including murine and human cells were analyzed for 
CD8 expression. GFP expression was analyzed in CD8+ and CD8- cells. One representative of three individual 
mice is shown.  
Luciferase signals and GFP+ cells demonstrated successful in vivo reporter gene delivery 
upon systemic administration of CD8-LV(Luc-GFP) into PBMC-humanized NSG mice. 
Remarkably, CD8-LV(Luc-GFP) mediated selective gene transfer into human CD8+ 
lymphocytes. Although some minor GFP events within CD8- cells were detected, GFP 
events with similar frequency were detected in PBS-treated control mice, rather indicating 
false-positive events than real off-target transduction. GFP expression was largely present 
in CD8+ cells demonstrating the highly selective targeting capability of CD8-LV in vivo.  
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3.2 CD8-LV-mediated generation of CAR T cells and functional 
characterization in vitro 
Having shown that CD8-LV selectively mediated reporter gene delivery in 
PBMC-humanized NSG mice in vivo, the next step was to deliver a CAR gene. To set up 
the system, CAR gene transfer was first evaluated in vitro. For this purpose, CD8-LVs 
encoding a CD19-specific CAR were generated and characterized on cell lines as well as 
on primary cells to generate functional CAR T cells in vitro. 
3.2.1 Vector particle generation and titration  
A CD19-specific CAR was used throughout this work. The scFv was derived from the 
CD19-specific clone FMC63 (Nicholson et al., 1997). The CAR construct was encoded on 
the transfer plasmid pS-CD19CAR-W (Figure 10). As second generation CAR, the SFFV 
promotor-driven construct consists of the intracellular signalling domain CD3ζ and the 
co-stimulatory domain of CD28, which are fused to the CD28 transmembrane domain. 
A CD8 hinge as well as a myc-tag, which can be used for detection of CAR expression, 
link the TM domain to the αCD19-scFv.  
 
Figure 10: Scheme of the CAR construct  
Schematic drawing of the CD19-specific CAR within the lentiviral transfer vector pS-CD19CAR-W. The CAR 
construct is driven by an internal SFFV promoter. The αCD19-scFv (FMC63-derived) is linked to a CD8 hinge 
via a myc-tag, followed by the CD28 transmembrane domain and the intracellular signaling domains of CD28 
and CD3ζ. scFv, single chain variable fragment; SFFV, spleen focus forming virus; TM, transmembrane 
domain.  
To generate functional CAR T cells, it is critical that the CAR is efficiently expressed on 
the cell surface. Hence, CAR expression and detection via the myc-tag was evaluated on 
HEK-293T cells transfected with pS-CD19CAR-W. CAR surface expression was 
determined 48 h post transfection by flow cytometry using a phycoerythrin (PE)-labelled 
anti-myc-tag antibody. Untransfected cells incubated with the anti-myc-tag antibody 
served as control.  
99.2% of transfected cells showed CAR surface expression. The population was 
characterized by a high MFI (Figure 11). In conclusion, pS-CD19CAR-W mediated 
efficient CAR surface expression in transfected HEK-293T cells. 
pS-CD19CAR-W
SFFV mycαCD19-scFv
CD8 
hinge
CD28 CD3ζTM
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Figure 11: CAR surface expression of transfected HEK-293T cells  
HEK-293T cells were transfected with pS-CD19CAR-W (blue). CAR expression was determined 48 h later by 
flow cytometry using PE-labelled myc-tag antibody. Untransfected cells (grey) stained with the same antibody 
served as control.  
Next, CD8-LV(CAR) vector particles were generated via transient transfection of producer 
cells. HEK-293T cells were co-transfected with pCMV∆R8.9, pCAGGS-NiV-Fc∆22, 
pCAGGS-NiV-Gc∆34CD8mut4 and pS-CD19CAR-W. Vector particles were harvested 48 h 
later and purified via centrifugation through sucrose cushion. CAR gene transfer with 
CD8-LV(CAR) into CD8+ cells was evaluated on the T cell line MOLT4.8. Cells were 
incubated with 5 µl of vector stock at 37°C and CAR surface expression was determined 
four days later. Untransduced cells incubated with PE-labelled anti-myc-tag antibody 
served as negative control. 
Low background signals were detected for untransduced cells whereas 52.81% of the 
CD8-LV(CAR)-treated cells showed CAR expression (Figure 12), demonstrating 
successful in vitro generation of CAR T cells using CD8-LV(CAR).  
 
Figure 12: CAR surface expression of CD8-LV(CAR)-transduced MOLT4.8 cells  
Cells were transduced with 5 µl vector stock of CD8-LV(CAR) and analyzed by flow cytometry four days later. 
CAR surface expression was determined by staining using PE-labelled myc-tag antibody. Untransduced cells 
stained with the same antibody served as a control. 
For further analysis, the amount of functional vector particles was determined for each 
vector production by titration on MOLT4.8 cells. Cells were incubated with serial dilutions 
of vector particles. Four days later, the percentage of CAR expressing cells was analyzed 
by flow cytometry and the titer was calculated within linear correlation of the dilution factor 
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and the percentage of CAR+ cells. Five independent productions of CD8-LV(CAR) vector 
stocks showed an average titer of 1.1x107 t.u./ml (± 9.7x105 t.u./ml). 
These data demonstrated successful production of CD8-LV(CAR) particles which 
mediated CAR gene transfer into CD8+ T cell lines. An average titer of above 107 t.u./ml 
of concentrated vector stocks proofs that CD8-LV(CAR) allows high titer vector 
productions, suitable for in vivo gene delivery applications. 
3.2.2 CD8-LV(CAR) transduction of primary human T cells results in the 
generation of CAR T cells in vitro 
Successful transfer of CAR transgene into an immortalized CD8+ T cell line was shown. 
In a next step, the capability of CD8-LV(CAR) to transduce human primary cells was 
evaluated. The selectivity of CD8-LV was demonstrated on primary cell cultures with 
mixed cell populations. Human PBMC were used, which include CD8+ and CD4+ T cells. 
The CD8-LV was evaluated to mediate CAR gene transfer into primary cells and to 
discriminate between CD8+ and CD8- cells.  
PBMC were isolated from blood and activated with αCD3- and αCD28-antibody in 
combination with IL-2 for three days. PBMC were transduced using a multiplicity of 
infection (MOI) of 2 and transgene expression was determined by flow cytometry five days 
later using a PE labelled anti-myc antibody.  
For untransduced cells, low background signals were detected. Upon CD8-LV(CAR) 
transduction, PBMC showed a distinct cell population of CAR+ cells. Remarkably, 
CAR expression was restricted to CD8+ cells only (Figure 13A).  
 
Figure 13: CD8-LV(CAR) selectively transduces CD8+ primary human PBMC 
PBMC were activated for three days using IL-2, αCD3- and αCD28-antibody and subsequently transduced 
with CD8-LV(CAR) with a MOI of 2. (A) On day five, PBMC were analyzed for CD8 and CAR expression by 
flow cytometry. (B) Percentage of CAR expression of CD8+ cells. Data are shown from three independent 
experiments. N=3 with mean ± SD are shown. Statistical significance was determined by two-tailed unpaired 
t-test; **, p<0.01. 
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CD8- cells mainly remained untransduced, although some few events were detected in 
the CD8-CAR+ gate. PBMC from three different donors were transduced, resulting in 9.9% 
(± 3.1%) CAR expression within the CD8+ population (Figure 13B). 
The transduction of primary human PBMC with CD8-LV(CAR) resulted in the generation 
of CD8+CAR+ T cells demonstrating the selective CAR expression in CD8+ cells mediated 
by CD8-LV(CAR).  
3.2.3 CAR T cells efficiently kill CD19+ B cells 
In PBMC, other lymphocytes besides T cells are present but become overgrown in in vitro 
culture by the proliferating T cells by time. However, it was observed that remaining B cells 
are present for at least eight days post PBMC activation. Since B cells express the CD19 
antigen on the surface, they can be regarded as target cells of CD19 CAR T  cells. Thus, 
the ability of the generated CAR T cells to selectively target and subsequently kill 
CD19+ B cells was evaluated.  
For this purpose, CD8-LV(CAR) transduced PBMC were analyzed for CAR expression 
(as shown in 3.2.2) and additionally for the presence of CD19+ cells five days post 
transduction. PBMC from three different donors were transduced and analyzed. 
In untransduced PBMC, 0.65% B cells were detected (Figure 14A). Remarkably, in 
CD8-LV(CAR) transduced PBMC almost no B cells could be detected. Upon the 
generation of CAR T cells, the percentage of CD19+ cells was significantly reduced 
(0.04%) compared to untransduced cells (0.7%)(Figure 14B) for all three donors. 
 
Figure 14: CD8-LV(CAR)-generated CAR T cells eliminate CD19+ B cells 
PBMC were activated for three days and transduced with CD8-LV(CAR) at a MOI of 2. (A) Five days post 
transduction, CD3 and CD19 expression were analyzed by flow cytometry. Representative density plots of 
one of three different donors are shown. (B) Percentage of CD19+ cells. N=3 with mean ± SD are shown. 
Statistical significance was determined by two-tailed unpaired t-test; ****, p<0.0001. 
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This observation strongly indicated that the generated CAR T cells were functional in 
recognizing and killing CD19+ B cells in vitro. Remaining B cells were efficiently eliminated 
by the CAR T cells only five days post transduction with CD8-LV(CAR).  
3.2.4 CAR T cells efficiently kill CD19+ tumor cells 
Having shown that CAR T cells can be generated in vitro in primary human PBMC using 
CD8-LV(CAR) and that these cells were able to eliminate CD19+ B cells, the functional 
activity of CAR T cells to eliminate CD19+ tumor cells had to be further assessed. 
Killing was evaluated in a flow cytometry-based assay. CAR T cells were co-cultured with 
CD19+ tumor cells in different effector to target ratios. To distinguish tumor cells from 
CAR T cells, tumor cells were labelled with CFSE prior to co-culturing. After 4 h of 
co-culture, all cells were stained with Fixable Viability Dye eFluor™ and double positive 
cells were identified as dead tumor cells. Additionally, unspecific killing of tumor cells, 
which were co-cultured with untransduced PBMC, was assessed for each tumor cell line.  
Unspecific killing increased with higher effector to target ratios and was in the range of 
1-18% (Figure 15, dark and light grey). When CAR T cells were co-cultured in a 5:1 ratio 
with CD19+ tumor cells (Raji), CAR T cells selectively killed these target cells, showing up 
to 60% killed cells in the highest effector to target ratio (Figure 15, blue). Reduction of 
effector cells resulted in a decreased killing demonstrating a concentration-dependent 
killing effect of the CAR T cells. No specific killing was observed in the co-culture of 
non-target CD19- Hut-78 cells and CAR T cells (black).  
 
Figure 15: CD8-LV(CAR)-generated CAR T cells selectively kill CD19+ target tumor cells 
In a flow cytometry-based killing assay CAR T cells (effector cells) were co-cultured with CFSE-stained tumor 
cells (target cells) in different ratios for 4 h at 37°C. To assess selective killing of target cells, all cells were 
stained with a Fixable Viablity Dye eFluorTM and double positive cells were referred as killed target cells. 
Percentage of killed target cells is shown. CAR T cells were co-cultured together with CD19+ tumor cells (Raji) 
(blue). To assess non-selective killing, CAR T cells were co-cultured together with CD19- non-target cells 
(Hut-78) (black). For determination of background killing, untransduced PBMC (UT) were co-cultured with 
CD19+ Raji (dark grey) and CD19- Hut-78 cells (light grey). N=3 with mean ± SD are shown from three 
independent experiments. 
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These data demonstrated that CD8-LV(CAR)-generated CAR T cells selectively target 
and kill CD19+ tumor cells in vitro but do not harm CD19- cells.  
3.2.5 Selective proliferation of CAR T cells upon antigen stimulation 
Besides killing activity towards target cells, the ability to proliferate upon antigen stimulus 
is an important feature of CAR T cells. After demonstrating their killing activity, the 
proliferation capacity of CD8-LV(CAR)-generated CAR T cells upon antigen stimulation 
was analyzed. For in vivo generation of CAR T cells using CD8-LV(CAR) it was expected 
that only few CAR T cells would be generated. However, CAR T cells are expected to 
expand upon antigen stimulation. Hence, the capability of the generated CAR T cells to 
expand in vitro upon antigen stimulation was assessed.   
For this purpose, a proliferation assay was established in which CAR T cells were 
cultivated over long periods. Irradiated CD19+ Raji cells were added to the CAR T cells 
every two to three days to provide a repeated antigen stimulus. The enrichment of 
CAR T cells was monitored over 32 days by flow cytometry analyzing CD8+CAR+ cells. 
The co-culture was started with a CAR T cell to tumor cell ratio of either 1:1 or 1:10. 
Co-cultures of irradiated cells and CD8+GFP+ cells, which were generated by transduction 
with CD8-LV(GFP), served as control.  
CD8+GFP+ cells did not show enrichment within the observed time period but rather 
decreased from 2% to 0.5% (Figure 16, light and dark grey). In contrast, a strong increase 
in percentage of CD8+CAR+ cells was observed for both ratios (Figure 16, blue). Starting 
with 4% of CAR T cells in the beginning, on day 32 as much as 14% (1:1 ratio, blue circle) 
and 16% (for 1:10 ratio, blue square) CD8+CAR+ T cells were observed.   
 
Figure 16: CD8-LV(CAR)-generated CAR T cells selectively proliferate upon antigen stimulation 
CD8-LV(CAR)- or CD8-LV(GFP)-transduced cells were co-cultured with irradiated CD19+ Raji cells in either 
1:1 or 1:10 effector to target ratio. Every two to three days irradiated Raji cells were added to the co-culture. 
Cells were analyzed for CD8, CAR and GFP expression by flow cytometry. Percentage of transgene+ cells of 
CD8+ cells is shown. Selective proliferation of CAR T cells (blue) and GFP cells (grey) was followed over time.  
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The proliferative capability of CAR T cells generated by CD8-LV(CAR) was further 
confirmed when only very few CAR T cells were present in the initial co-culture. This 
proliferation assay had been started with as few as 0.5% CAR T cells (Figure 17A). After 
14 days of co-culture, CAR T cells were enriched 3-fold (Figure 17B).  
Altogether, these data demonstrated that CD8-LV(CAR)-generated CAR T cells reacted 
to their cognate antigen and were able to selectively proliferate upon antigen stimulation. 
For in vivo gene delivery, raising the detection level through expansion of CAR T cells by 
antigen stimulation seems possible.  
 
Figure 17: Enrichment of low amounts of CAR T cells upon antigen stimulation  
CD8-LV(CAR)- or CD8-LV(GFP)-transduced cells were co-cultured together with irradiated CD19+ Raji cells 
in an 1:1 effector to target ratio. Every two to three days irradiated Raji cells were added to the co-culture. 
Cells were analyzed for CD8, CAR and GFP expression by flow cytometry. Selective proliferation of 
CAR T cells (blue) and GFP+ cells (grey) was analyzed on day 14. (A) Percentage of transgene+ cells of 
CD8+ cells at day 0 and day 14. (B) Enrichment of transgene expressing cells after 14 days of co-culture. The 
percentage of transgene expressing CD8+ cells was normalized to one for day 0. Fold change enrichment of 
transgene expressing CD8+ cells is shown for day 14. N=3 with mean ± SD are shown from three technical 
replicates. 
3.3 In vivo CAR delivery and characterization of in vivo generated  
CAR T cells  
The previous data demonstrated successful in vitro CAR T cell generation upon 
transduction of PBMC with CD8-LV(CAR). It was also shown that CAR T cells efficiently 
and selectively killed target tumor cells and specifically proliferated upon antigen 
exposure.  
The following chapter addresses the feasibility of generating CAR T cells in vivo upon 
administration of CD8-LV(CAR) into PBMC-humanized NSG mice. In vivo generated 
CAR T cells are then further characterized in detail for their proliferative potential, killing 
efficacy and phenotype.  
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3.3.1 Detection of in vivo generated CAR T cells 
Upon CD8-LV(CAR) administration to PBMC-humanized NSG mice, it was evaluated 
whether CAR T cells were generated in vivo. Having shown that the in vivo transduction 
rate was below 1% when transferring the reporter gene luc-gfp (see chapter 3.1.2), the 
expectation regarding the transduction rate using CD8-LV(CAR) was at most the same, 
rather below. This might lead to detection hurdles due to reaching the detection limit of 
the flow cytometry-based detection method. However, the advantage of transferring a 
CAR transgene is the generation of potentially functional CAR T cells that should be able 
to proliferate upon antigen exposure. In order to proof this hypothesis, the in vivo 
generation and detection of CAR T cells was evaluated.  
In a first attempt, CD8-LV(CAR) was injected to PBMC-humanized NSG mice engrafted 
with CD19+ Raji-luc tumor cells. In this setting, Raji-luc cells provided an antigen stimulus 
to potentially generated CAR T cells. In detail, 5x105 Raji-luc cells were i.p. administered 
into NSG mice. Six days later, 1x107 activated PBMC were administered via the same 
route, followed by i.p. injection of CD8-LV(CAR) one day later (Figure 18).  
 
Figure 18: Experimental setting for the in vivo CAR gene delivery with CD8-LV(CAR) in 
PBMC-humanized NSG mice engrafted with tumor cells 
Tumor cells (Raji-luc) were i.p. injected into NSG mice followed by an i.p. injection of activated PBMC six days 
later. One day later, CD8-LV(CAR) was i.p. injected. Mice were sacrificed seven days post vector injection 
and cells from peritoneum, spleen and blood were analyzed for CD45, CD3, CD8, CD19 and CAR expression 
by flow cytometry. 
To evaluate the in vivo generation of CAR T cells, mice were sacrificed seven days after 
CD8-LV(CAR) administration and cells from various organs were analyzed for 
CAR expression by flow cytometry analysis. Blood and spleen cells as well as isolated 
cells from the peritoneal cavity were included in the analysis. Background signals for 
CAR events were determined on cell suspensions of organs of PBS-treated mice.  
Humanization levels (determined by the percentage of CD45+ cells) of mice ranged 
between 20-70% for the different organs. Thereby, more than 98% of the CD45+ cells 
were CD3+ (data not shown). CAR background signals were below 0.5% for all analyzed 
organs. Strikingly, in CD8-LV(CAR)-treated mice, a distinct CAR expression was 
observed in peritoneal cells. Hereby, CAR expression was exclusively present within the 
CD8+ population (Figure 19A). Remarkably, on average 47% of the CD8+ cells were 
CAR-positive (Figure 19B). CAR expression was also observed in other organs. In spleen, 
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9.74% of the CD8+ cells were CAR-positive, whereas in blood 9.16% CD8+CAR+ cells 
were detected (Figure 19B).  
 
Figure 19: CAR expression of CD8+ cells of CD8-LV(CAR)-treated PBMC-humanized NSG mice  
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Seven days post 
vector administration, mice were sacrificed and cell suspensions from indicated organs were analyzed by flow 
cytometry. CD45+CD3+ cells were analyzed for CAR and CD8 expression. (A) Density plots are shown 
exemplarily for peritoneal cells. (B) Percentage of CAR+ cells of CD8+ cells is shown for peritoneal, spleen 
and blood cells. N=3, mean ± SD are shown. Statistical significance was determined by two-tailed unpaired 
t-test; **, p<0.01; ****, p<0,0001; ns, not significant.  
These data show in vivo CAR transfer upon i.p. administration of CD8-LV(CAR) into 
PBMC-humanized NSG mice. High frequency of CAR T cells were detected in the 
peritoneum, but also in spleen and blood. Compared to in vivo reporter gene delivery 
(3.1.2), which resulted in less than 1% transgene expressing CD8+ cells, transferring the 
CAR transgene resulted in up to 56% of the CD8+ cells expressing the CAR. 
3.3.2 Selective CAR transfer into CD8+ lymphocytes 
Cell type-specific CAR transfer is critical to restrict CAR expression to target cells and 
minimize off-target effects. Thus, the selectivity of CD8-LV(CAR) was evaluated in vivo.  
To analyze off-target transfer, CAR expression was analyzed in CD8- cells by flow 
cytometry. Cells from peritoneum, spleen and blood were included in the analysis. 
PBS-treated mice served as a control to determine background signals. 
Background levels, hence percentages of CAR+ cells in PBS-treated mice, were below 
0.2% for all organs (Figure 20, black). Highest background signals were detected in 
spleen (0.13%), some signals in peritoneal cells (0.03%) and no background signals were 
detected in blood cells (0%). CAR signals within the CD8- cell population in 
CD8-LV(CAR)-treated PBMC-humanized mice were below 0.3% for all analyzed organs 
(Figure 20, blue). Looking at the individual organs, higher levels of CAR+ cells within the 
CD8- population of CD8-LV(CAR)-treated mice were only observed in the peritoneum. 
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0.12% CD8-CAR+ events in CD8-LV(CAR)-treated mice compared to 0.03% events in 
PBS-treated mice. A minor difference was observed in the blood and no difference in the 
spleen. 
 
Figure 20: CAR expression in CD8- cells of CD8-LV(CAR)-treated PBMC-humanized NSG mice  
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Seven days post 
vector administration, mice were sacrificed and cell suspensions from indicated organs were analyzed by flow 
cytometry. CAR expression was analyzed in CD3+CD8- cells. Percentage of CAR+ cells of CD3+CD8- cells is 
shown for peritoneal, spleen and blood cells. N=3, mean ± SD are shown.  
Taken together, no major off-target events were observed upon CD8-LV(CAR) injection 
to PBMC-humanized NSG mice. Some signals were observed, but were below 0.3% and 
close to background. Altogether, these data indicate selective CAR transfer in vivo upon 
systemic administration of CD8-LV(CAR) into PBMC-humanized NSG mice. 
3.3.3 Elimination of CD19+ cells 
CAR T cells were generated in vivo and were present in high frequencies already seven 
days post vector administration. Next, it was evaluated whether in vivo generated 
CAR T cells were able to recognize and kill CD19+ target cells. 
The presence of CD19+ cells was analyzed in flow cytometry in various organs. For this 
purpose, single living cells were pre-gated and CD19+ cells were gated from CD45+ cells. 
Cell suspensions from the peritoneal cavity, spleen and blood were included in the 
analysis. 
In PBS-treated mice, on average 0.8% CD19+ cells were detected in the peritoneum 
(Figure 21A and B). Further CD19+ cells were detected in spleen (0.3%) and blood 
(0.09%) (Figure 21B, black). Remarkably, all CD19+ cells were eliminated from the 
peritoneal cavity of CD8-LV(CAR)-treated mice (Figure 21B, blue). Even in cell 
suspensions from spleen and blood, no CD19+ cells were detected.  
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Figure 21: CD19 expression of CD45+ cells of CD8-LV(CAR)-treated PBMC-humanized NSG mice  
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Seven days post 
vector administration, mice were sacrificed and cell suspensions from indicated organs were analyzed by flow 
cytometry. CD45+ cells were analyzed for CD19 expression. (A) Exemplary density plots are shown for 
peritoneal cells. (B) Percentage of CD19+ cells of CD45+ cells is shown for peritoneal, spleen and blood cells. 
N=3, mean ± SD are shown. Statistical significance was determined by two-tailed unpaired t-test; *, p<0.05; 
****, p<0,0001. 
The complete elimination of CD19+ cells in all analyzed organs of CD8-LV(CAR)-treated 
mice indicated that in vivo generated CAR T cells were functional in recognizing and killing 
CD19+ target cells.  
3.3.4 Proliferative advantage of CAR T cells  
The interaction between CD19+ cells and CAR T cells in vivo resulted in complete 
elimination of CD19+ cells. A second process that is induced upon antigen recognition is 
the proliferation of CAR T cells. In chapter 3.3.1, high frequencies of in vivo generated 
CAR T cells were detected. Frequency of transgene expressing cells was about 100-fold 
higher compared to those observed for luc-gfp reporter gene delivery shown in chapter 
3.1.2. The high frequency of detected CAR T cells might already indicate CAR T cell 
proliferation upon target cell stimulation. Since CAR transfer was, as shown above, almost 
exclusively restricted to CD8+ cells, it was assumed that antigen-stimulated CAR T cell 
proliferation only affected CD8+ cells. Hence it was expected, that CAR transfer resulted 
in an enriched CD8 population.   
Thus, the frequency of CD8+ cells in CD8-LV(CAR)-treated mice was analyzed by flow 
cytometry and compared to the frequency of CD8+ cells in PBS-treated mice. 
The CD8+ cells in CD8-LV(CAR)-treated mice were significantly enriched in the 
peritoneum (33.48%) compared to PBS-treated mice (17.13%) (Figure 22A, B). Only a 
slight increase of CD8+ cells was observed in the spleen and no difference was observed 
in the blood (Figure 22B).  
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Figure 22: CD8 expression of CD3+ cells of CD8-LV(CAR)-treated PBMC-humanized NSG mice  
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Seven days post 
vector administration, mice were sacrificed and cell suspensions from indicated organs were analyzed by flow 
cytometry. CD45+CD3+ cells were analyzed for CD8 expression. (A) Density plots are shown exemplarily for 
peritoneal cells. (B) Percentage of CD8+ cells of CD3+ cells is shown for peritoneal, spleen and blood cells. 
N=3, mean ± SD are shown. Statistical significance was determined by two-tailed unpaired t-test; **, p<0.01; 
ns, not significant. 
These data demonstrated that the treatment with CD8-LV(CAR) resulted in an elevated 
level of CD8+ cells in the peritoneum. Together with the high frequency of CAR T cells, 
these data indicated CAR T cell proliferation due to antigen stimulus already after a short 
period of only seven days. However, this assumption of antigen-driven proliferation of 
in vivo generated CAR T cells needed to be evaluated further. 
3.3.4.1 Proliferative advantage of CAR T cells in the presence and absence of 
CD19+ tumor cells 
Antigen-induced proliferation can lead to significant enrichment of CAR T cells. However, 
upon removal of the antigen, CAR T cells lack specific proliferation stimulus. To evaluate 
whether the high frequency of CAR+ cells as seen in chapter 3.3.1 was a result of 
antigen-driven proliferation, the next experiment was designed to abolish the interaction 
between CAR T cell and antigen.  
To disturb antigen-specific CAR T cell proliferation, removing the antigen or exchanging 
the CAR for a reporter gene are possible options. The following experiment consisted of 
four groups either missing the antigen or the CAR transgene. Mice were engrafted with or 
without tumor cells and PBMC and were treated with CD8-LV(CAR). Two further groups, 
either engrafted with tumor cells or without were treated with CD8-LV carrying the reporter 
gene rfp (CD8-LV(RFP)). For all groups, CAR expression as well as CD8 and CD19 
expression were analyzed by flow cytometry of cell suspensions from peritoneum, spleen 
and blood.  
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First, CAR expression was analyzed in CD8-LV(CAR)-treated mice, injected with or 
without CD19+ tumor cells. Surprisingly, no difference in CAR expression was observed 
between tumor cell-injected (Figure 23, blue, filled square) and tumor- negative mice 
(blue, empty square). In both groups, 15-55% CD8+CAR+ cells were detected in the 
peritoneum. CAR T cells were detected in spleen and blood cells. As seen for the 
peritoneum, independently from having tumor cells or not, the same range of CAR 
expression was observed for both groups in the different organs. On average 27% 
CD8+CAR+ cells were detected in the spleen and 22% CD8+CAR+ cells in the blood. 
Strikingly, when transferring the rfp transgene much less cells were transgene-positive 
(Figure 23, red). In the peritoneum, the frequency of CD8+RFP+ cells ranged from 0.5-5%. 
In spleen and in blood, on average 2% CD8+RFP+ cells were detected.  
 
Figure 23: Transgene expression of CD8+ cells of CD8-LV(CAR)- and CD8-LV(RFP)-treated 
PBMC-humanized NSG mice  
NSG mice were injected with Raji-luc tumor cells (+) or with PBS (-) and engrafted with PBMC. Mice were 
treated with CD8-LV(CAR) or CD8-LV(RFP). Seven days post vector administration, mice were sacrificed and 
cells from indicated organs were analyzed for transgene and CD8 expression. Percentages of transgene-
positive cells within the CD8+ population are shown for CD8-LV(CAR)- (blue) and CD8-LV(RFP)- (red) treated 
PBMC-humanized NSG mice. N=3-4, mean ± SD are shown. Statistical significance was determined by 
two-tailed unpaired t-test; **, p<0.01; ***, p< 0,001; ****, p<0,0001.  
These data revealed similar CAR transfer efficiency as seen in chapter 3.3.1 with 20-60% 
CD8+CAR+ cells in the peritoneum. However, no difference in the frequency of CAR T cells 
was observed regardless of the presence or absence of tumor cells. Obviously, the 
presence of CD19+ tumor cells did not influence the frequency of CAR T cells. However, 
rfp gene transfer in general resulted in much less transgene positive cells. Higher 
transgene expression in CAR mice indicated specific CAR T cell proliferation for 
CD8+CAR+ cells but no specific proliferation of CD8+RFP+ cells.   
 
In chapter 3.3.4, enrichment of CD8+ cells was shown for CD8-LV(CAR)-treated mice 
when compared to a control group. To assess whether CAR T cell proliferation was 
reflected in an increased level of CD8+ cells, CD8 frequencies were analyzed. Comparing 
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the CD8 levels of both CD8-LV(CAR)-treated groups, the influence of CD19+ tumor cells 
on CAR T cell proliferation, hence, the enrichment of the CD8+ cells was evaluated. 
Additionally, ratios of CD8+ cells were compared between CD8-LV(CAR)-treated and 
CD8-LV(RFP)-treated mice in order to evaluate the influence of the transgene on the 
CD8 frequency. 
By comparing both CD8-LV(CAR)-treated groups, no difference in CD8 frequency was 
observed. On average 43% CD8+ cells were detected in the peritoneum (Figure 24, blue). 
In spleen and blood, comparison of both groups also revealed no difference within the 
same organ. Similar CD8+ frequencies of 41% (spleen) and 35% (blood) were observed. 
However, when transferring the rfp transgene, CD8 levels were significantly lower in the 
peritoneum (Figure 24, red). In spleen, CD8 frequencies were reduced in 
CD8-LV(RFP)-treated mice (41%) compared to CD8-LV(CAR)-treated mice (46%). The 
same was true for CD8 frequencies in blood, which were also slightly reduced in 
CD8-LV(RFP)-treated mice (35%) compared to CD8-LV(CAR)-treated mice (40%).   
 
Figure 24: CD8 expression of CD3+ cells of CD8-LV(CAR)- and CD8-LV(RFP)-treated PBMC-humanized 
NSG mice 
NSG mice were injected with Raji-luc tumor cells (+) or with PBS (-) and engrafted with PBMC. Mice were 
treated with CD8-LV(CAR) or CD8-LV(RFP). Seven days post vector administration, mice were sacrificed and 
cells from indicated organs were analyzed for CD3 and CD8 expression. Percentage of CD8+ cells of CD3+ 
cells are shown for CD8-LV(CAR)- (blue) and CD8-LV(RFP)- (red) treated PBMC-humanized NSG mice. 
N=3-4, mean ± SD are shown. Statistical significance was determined by two-tailed unpaired t-test; *, p<0.05; 
**, p<0.01; ****, p<0,0001; ns, not significant. 
Taken together, the frequency of CAR+ and CD8+ cells was not influenced by the presence 
of CD19+ tumor cells in CD8-LV(CAR)-treated mice. However, when transferring the 
reporter gene rfp, transgene levels and CD8 levels were lower. These data indicated 
proliferation of CAR T cells for both CD8-LV(CAR)-treated groups but no selective 
proliferation of RFP+ cells in the CD8-LV(RFP)-treated groups.   
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As already shown in chapter 3.2.3 and 3.2.4 in in vitro experiments, CAR T cells were 
able to selectively kill CD19+ cells. Elimination of CD19+ cells was assessed for each 
group. As expected, CD19+ cells were eliminated from all organs of CD8-LV(CAR)-treated 
mice (Figure 25, blue). In CD8-LV(RFP)-treated mice, which were pretreated with tumor 
cells, CD19+ cells were mainly detectable in peritoneum and spleen with frequencies 
ranging between 0.025-2.5% (Figure 25, red). Surprisingly, CD19+ cells were also 
detected in CD8-LV(RFP)-treated mice not pretreated with tumor cells. On average, 
similar frequencies as in tumor-pretreated mice were observed in spleen (0.27%) and 
blood (0.08%). Up to 0.92% CD19+ cells were observed in the peritoneal cavity. 
 
Figure 25: CD19+ cells of CD45+ cells in CD8-LV(CAR)- and CD8-LV(RFP)-treated PBMC-humanized 
NSG mice 
NSG mice were injected with Raji-luc tumor cells (+) or with PBS (-) and engrafted with PBMC. Mice were 
treated with CD8-LV(CAR) or CD8-LV(RFP). Seven days post vector administration, mice were sacrificed and 
cells from indicated organs were analyzed for CD45 and CD19 expression. Percentage of CD19+ cells of 
CD45+ cells are shown for CD8-LV(CAR)- (blue) and CD8-LV(RFP)- (red) treated PBMC-humanized NSG 
mice. N=3-4, mean ± SD are shown. Statistical significance was determined by two-tailed unpaired t-test; 
**, p<0.01; ns, not significant. 
To conclude, in CD8-LV(CAR)-treated mice all CD19+ cells were completely eliminated. 
In CD8-LV(RFP)-treated mice, as expected, CD19+ cells were still present. However, even 
when tumor cells were not administered, CD19+ cells were detectable. 
3.3.4.2 Proliferative advantage of CAR T cells in the absence of CD19+ B cells 
Initially, it was assumed that CD19+ tumor cells induce CAR T cell proliferation. However, 
the absence of CD19+ tumor cells unexpectedly did not affect the frequency of 
CAR T cells. Having seen that CD19+ cells were detected in mice although they were not 
injected with tumor cells was unexpected (chapter 3.3.4.1). It was assumed that these 
CD19+ cells were B cells that were transferred together with the PBMC transplant into 
mice. Thus, as antigen-CAR T cell interaction was assumed to trigger CAR T cell 
proliferation, remaining B cells might have triggered proliferation. Therefore, B cells were 
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further investigated for their potential to act as proliferation stimulus for in vivo generated 
CAR T cells.  
To investigate B cells as the proliferation stimulus for CAR T cells, B cells were depleted 
from PBMC prior to injection into NSG mice. PBMC were isolated from three healthy 
donors and B cells were depleted by magnetic cell isolation using microbeads against 
CD19+ cells. To determine successful depletion of CD19+ cells, cells were analyzed for 
CD3 and CD19 expression by flow cytometry prior and post CD19+ depletion.  
Prior to CD19+ depletion, the main population consisted of CD3+ T cells (55%) and 
CD3-CD19- cells (37%) (Figure 26). Less than 10% of the cells were CD19+. B cell 
frequencies from three different donors ranged from 2-8%. After CD19 depletion, 99.99% 
of the cells were CD19-, demonstrating the successful depletion of CD19+ cells.  
 
Figure 26: In vitro CD19+ B cell depletion of PBMC  
PBMC were isolated from blood and CD19+ cells were depleted from PBMC via MACS® technology using 
microbeads against CD19+ cells. Cells were separated using magnetic separation. PBMC were analyzed by 
flow cytometry for CD3 and CD19 expression before and after CD19+ cell depletion. Representative density 
plots from three individual experiments are shown. 
To evaluate if B cells are the proliferation stimulus for in vivo generated CAR T cells, 
CD8-LV(CAR) was administered into PBMC-humanized NSG mice, either engrafted with 
PBMC or PBMC that were depleted for CD19+ B cells.  
In detail, NSG mice were i.p. injected with 1x107 activated PBMC or PBMCCD19-depleted. One 
day later, CD8-LV(CAR) or PBS, as control, was injected. Seven days later, mice were 
sacrificed and CAR expression as well as CD8 and CD19 expression were analyzed in 
peritoneal, spleen and blood cells. Control groups (PBMC- or PBMCCD19-depleted-humanized 
mice treated with PBS) served as control for background signals in all organs. 
CAR background levels for blood and peritoneal cells were below 0.5% (Figure 27, black 
and grey). Cells from spleen showed a slightly higher background of up to 2%. In 
CD8-LV(CAR)-treated PBMC-humanized mice, CAR expression within CD8+ peritoneal 
cells was in the range of 20-37% (Figure 27, blue). Remarkably, CD8-LV(CAR)-treated 
PBMCCD19-depleted-humanized mice showed much less CAR T cells ranging between 2-8% 
CD8+CAR+ cells (Figure 27, orange). In CD8-LV(CAR)-treated PBMC-humanized mice, 
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CAR T cells were detected in spleen (5%) and in blood (7%) (Figure 27, blue). Contrarily, 
in CD8-LV(CAR)-treated PBMCCD19-depleted-humanized mice, CAR T cells detected in the 
spleen were not above background (Figure 27, orange). In blood, CAR T cells were slightly 
above background detection (1%), being in the range of 2% (Figure 27, orange).  
 
Figure 27: CAR expression of CD8+ cells of CD8-LV(CAR)-treated PBMC- or PBMCCD19-depleted-
humanized NSG mice  
NSG mice were injected with PBMC or CD19-depleted PBMC. Seven days post vector administration, mice 
were sacrificed and cells from indicated organs were analyzed for CD8 and CAR expression by flow cytometry. 
Percentage of CAR+ cells of CD8+ cells are shown for CD8-LV(CAR) (blue) or PBS (black) treated 
PBMC-humanized NSG mice and for PBMCCD19-depleted-humanized NSG mice treated with CD8-LV(CAR) 
(orange) or PBS (grey). N=3-4, mean ± SD are shown. Statistical significance was determined by two-tailed 
unpaired t-test; *, p<0.05; **, p<0.01; ****, p< 0,0001. 
In conclusion, significantly less CAR T cells had been detected in CD8-LV(CAR)-treated 
PBMCCD19-depleted mice compared to CD8-LV(CAR)-treated PBMC mice. Being much less, 
but still detectable in the peritoneal cavity and in blood, CAR T cells in the spleen were in 
the range of background detection. This strongly indicated antigen-specific CAR T cell 
proliferation in the presence of CD19+ B cells. 
 
As shown in the previous chapters 3.3.4 and 3.3.4.1, an enrichment of CD8+ cells in 
CD8-LV(CAR)-treated mice indicated a selective proliferation advantage of CAR-modified 
CD8+ cells Thus, CD8 levels were evaluated in peritoneal, spleen and blood cells from 
CD8-LV(CAR)-treated PBMC- or PBMCCD19-depleted-humanized mice.  
However, no significant differences were observed between CD8-LV(CAR)-treated 
PBMC- or PBMCCD19-depleted-humanized mice (Figure 28, blue and orange). In the 
peritoneum and spleen, CD8+ cells were in the range of 30-40% and less frequent in the 
blood ranging between 20-30%. However, in PBS-treated mice differences were observed 
for peritoneal cells. The frequency of CD8+ cells was enriched in PBMCCD19-depleted-
humanized mice (38%), compared to PBMC-humanized mice (25%). Also in spleen and 
blood, a tendency towards enrichment of CD8+ cells in PBMCCD19-depleted-humanized mice 
was observed compared to PBMC-humanized mice. 
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Figure 28: CD8 expression of CD3+ cells of CD8-LV(CAR)-treated PBMC- or PBMCCD19-depleted-
humanized NSG mice  
NSG mice were injected with PBMC or CD19-depleted PBMC. Seven days post vector administration, mice 
were sacrificed and cells from indicated organs were analyzed for CD3 and CD8 expression by flow cytometry. 
Percentage of CD8+ cells of CD3+ cells is shown for CD8-LV(CAR) (blue) or PBS (black) treated 
PBMC-humanized NSG mice and for PBMCCD19-depleted-humanized NSG mice treated with CD8-LV(CAR) 
(orange) or PBS (grey). N=3-4, mean ± SD are shown. Statistical significance was determined by two-tailed 
unpaired t-test; ns, not significant. 
The in vivo generation of CAR T cells was shown to be accompanied by the elimination 
of CD19+ cells (3.3.3). Hence, the presence of CD19+ cells in PBMC- or 
PBMCCD19-depleted-humanized mice was evaluated by flow cytometry of peritoneal, spleen 
and blood cells. 
As expected, in all organs, no CD19+ cells were detected in CD8-LV(CAR)-treated PBMC- 
or PBMCCD19-depleted-humanized mice (Figure 29, blue and orange). Also in PBS-treated 
PBMCCD19-depleted mice (grey) CD19+ cells were absent in all organs. Only in PBS-treated 
PBMC-humanized mice (black) up to 2% of CD19+ cells were detected in all organs. 
 
Figure 29: CD19 expression of CD45+ cells CD8-LV(CAR)-treated PBMC- or PBMCCD19-depleted-
humanized NSG mice  
NSG mice were injected with PBMC or CD19-depleted PBMC. Seven days post vector administration, mice 
were sacrificed and cells from indicated organs were analyzed for CD45 and CD19 expression by flow 
cytometry. Percentage of CD19+ cells of CD45+ cells is shown for CD8-LV(CAR) (blue) or PBS (black) treated 
PBMC-humanized NSG mice and for PBMCCD19-depleted-humanized NSG mice treated with CD8-LV(CAR) 
(orange) or PBS (grey). N=3-4, mean ± SD are shown. Statistical significance was determined by two-tailed 
unpaired t-test; ns, not significant. 
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The absence of CD19+ cells in PBS-treated PBMCCD19-depleted-humanized mice confirmed 
the successful B cell depletion. Taken together, the comparison of CD8-LV(CAR)-treated 
PBMC and PBMCCD19-depleted-humanized mice showed a significant enrichment of 
CAR T cells in mice engrafted with CD19+ B cells. Although CD8 levels were not enriched 
in CD8-LV(CAR)-treated PBMC-humanized mice, the significantly higher frequency of 
CAR T cells strongly argues for the CD19+ B cells to be the antigen stimulus that induced 
the proliferation of in vivo generated CAR T cells.  
3.3.5 Phenotypic characterization of CAR T cells 
CAR T cells behave differently in presence or absence of antigen. In the presence of 
CD19+ B cells they proliferate and expand. Furthermore, the interaction with antigen can 
induce the differentiation into a different T cell subtype. To evaluate potential differences 
in their differentiation status, antigen-experienced and antigen-unexperienced 
CAR T cells were characterized for their phenotype.  
In vivo generated CAR T cells from the peritoneal cavity (chapter 3.3.4.2) were 
phenotypically analyzed based on the surface expression of CD62L and CD45RA by flow 
cytometry. Subsequently, they were classified into stem cell memory/naïve T cells 
(TSCM/Naϊve: CD62L+/CD45RA+), central memory T cells (TCM: CD62L+/CD45RA-), effector 
memory T cells (TEM: CD62L-/CD45RA-) and effector T cells (TEff: CD62L-/CD45RA-) 
(Figure 30). CAR- cells (CD8+CAR- cells and CD8- cells) were analyzed as controls, 
representing cells being unaffected by the CD19 antigen.  
 
Figure 30: Scheme of subset-phenotyping of T cells by flow cytometry analysis  
T cells were analyzed for CD45RA and CD62L surface expression. According to their combinatorial 
expression, T cells were classified into stem cell memory/naïve T cells (TSCM/Naïve: CD45RA+CD62L+), effector 
memory T cells (TEM: CD45RA-CD62L-), central memory T cells (TCM: CD45RA-CD62L+) and effector T cells 
(TEff: CD45RA+/CD62L-).  
For PBMC-humanized mice and PBMCCD19-depleted-humanized mice, the average subset 
distribution in CD8- cells was very similar independently of CD8-LV(CAR)- or 
PBS-treatment (Figure 31A and B, right panel). The majority were TEM (54.84% ± 3.23%) 
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followed by TCM (30.36% ± 2.64%) a small fraction of TSCM/Naϊve (6.45% ± 0.82%) and few 
TEff (0.77% ± 0.11%). When comparing CD8+CAR- cells, again, a similar distribution 
pattern was observed (Figure 31A and B, middle panel). They were characterized by a 
majority of TEM (41.0% ± 4.47%) followed by two equally large populations, TCM 
(16.25% ± 2.17%) and TSCM/Naϊve (17.23% ± 3.2%). The smallest fraction was TEff 
(5.52% ± 1.28%).  
 
Figure 31: Subset-phenotype analysis of in vivo generated CAR T cells 
NSG mice were injected with PBMC or CD19-depleted PBMC. Seven days post vector administration, mice 
were sacrificed and cells from indicated organs were analyzed for CD45, CD3, CD8, CAR, CD62L and 
CD45RA expression by flow cytometry. Human T cells were identified by CD45 and CD3 expression. 
CD8+CAR+, CD8+CAR- and CD8- cells were analyzed for CD62L and CD45RA expression and classified into 
subset-phenotypes. Subsets are defined as pink: central memory T cells (TCM: CD45RA-CD62L+); yellow: 
stem cell memory/naïve T cells (TSCM/Naϊve: CD45RA+CD62L+); green: effector memory T cells 
(TEM: CD45RA-CD62L-); and turquoise: effector T cells (TEff: CD45RA+CD62L-). Pie chart representations of 
mean subset-phenotype percentages for CD8+CAR+, CD8+CAR- and CD8- cells are shown for CD8-LV(CAR)-  
or PBS-treated PBMC-humanized NSG mice and for PBMCCD19-depleted-humanized NSG mice, treated with 
CD8-LV(CAR) or PBS. N=3-4. 
To evaluate differences in the phenotype of CD8+CAR+ cells, CD8-LV(CAR)-treated 
PBMC-humanized and PBMCCD19-depleted-humanized mice were analyzed. CD8+CAR+ cells 
from PBMCCD19-depleted-humanized mice showed a similar average distribution as observed 
for CD8+CAR- cells (Figure 31B, left panel). The largest fraction was TEM 
(37.48% ± 4.99%) followed by two equally large TCM (28.54% ± 1.32%) and 
TSCM/Naϊve (20.92% ± 2.65%) fractions and the smallest fraction, TEff (13.06% ± 4.43%). 
Remarkably, CD8+CAR+ cells from PBMC-humanized mice showed a different subset 
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distribution (Figure 31A, left panel). They were characterized by a majority of 
TCM (53.64% ± 5.31) followed by two equally large TSCM/Naϊve (21.41% ± 2.61%) and TEM 
(20.96% ± 3.58%) populations. The smallest fraction was the TEff population 
(4.0% ± 1.91%). 
Taken together, the average subset-phenotype distributions for CD8- and CD8+CAR- 
populations were similar for all four groups. Remarkably, differences were observed when 
comparing antigen-experienced CAR T cells (CD8+CAR+ cells of PBMC-humanized mice) 
and antigen-unexperienced CAR T cells (CD8+CAR+ cells of PBMCCD19-depleted-humanized 
mice). Antigen-experienced CAR T cells showed an increased TCM fraction and lower 
frequencies of TEM and TEff.  
These data demonstrated that the interaction of CAR T cells and CD19+ cells influenced 
the phenotype of CAR T cells. Cells unaffected by this interaction (CD8+CAR- and CD8- 
cells) did not show a changed phenotype in absence of CD19+ cells.  
3.3.6 Characterization of transgene integration of in vivo generated  
CAR T cells 
In vivo gene transfer using CD8-LV was shown for CAR and rfp transgenes. Additionally, 
CAR transfer was performed in the presence or absence of CD19+ B cells. In the following 
chapter, transgene integration and clonality of the in vivo transduced cells were analyzed. 
3.3.6.1 Determination of vector copy number 
So far, successful in vivo gene transfer was determined as transgene expressing cells 
analyzed by flow cytometry. To calculate VCN, transgene integration was analyzed on 
genomic DNA by qPCR. 
Cells from peritoneum, spleen and blood were analyzed for lentiviral transgene integration 
in a probe-based qPCR assay. Genomic DNA was isolated and transgene integration was 
evaluated using woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE)-specific primers. The qPCR assay was a multicolour assay detecting the 
transgene and the human reference gene albumin. To determine the vector copy number, 
the ratio of transgene and albumin amounts was calculated. Cells from two individuals of 
PBS-, CD8-LV(CAR)-, CD8-LV(RFP)-treated PBMC-humanized NSG mice and cells from 
CD8-LV(CAR)-treated PBMCCD19-depleted-humanized mice were analyzed.  
In PBS-treated mice, VCN of 0 were determined for cells isolated from peritoneum, spleen 
and blood (Figure 32A, ctrl, black). For peritoneal cells from CD8-LV(CAR)-treated 
PBMC-humanized mice, a VCN of 0.41 was determined (CAR, blue). Cells from 
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CD8-LV(CAR)-treated PBMCCD19-depleted-humanized mice showed a lower VCN of 0.1 
(CARu, grey). Even lower was the VCN in CD8-LV(RFP)-treated mice with 0.05 
(RFP, red). Overall, reduced VCN were observed in spleen and blood for 
CD8-LV(CAR)-treated PBMC-humanized mice (0.27) and for CD8-LV(CAR)-treated 
PBMCCD19-depleted-humanized mice (0.07). An average VCN of 0.15 was detected for 
CD8-LV(RFP)-treated mice.  
To correlate transgene integration with transgene expression, vector copy numbers were 
compared to transgene expression analyzed by flow cytometry. CAR expression was 
analyzed on all human cells. For this purpose, human CD45+ cells were identified and the 
percentage of CAR expression was determined.  
CD8-LV(CAR)-treated PBMC-humanized mice showed the highest VCN in all organs 
(Figure 32A, blue) and the highest transgene expression (Figure 32B, blue). In spleen and 
blood, the second highest VCN were observed for CD8-LV(RFP)-treated PBMC mice, 
which also showed second highest transgene expression by flow cytometry. Lowest VCN 
were observed in CD8-LV(CAR)-treated PBMCCD19-depleted-humanized mice, which was in 
accordance to lowest transgene expression levels. In the peritoneum, unexperienced 
CAR T cells showed a higher VCN and higher transgene expression level compared to 
RFP cells. 
 
Figure 32: Transgene integration analysis by VCN determination and flow cytometry 
Transgene integration and expression of peritoneal, spleen and blood cells from PBS-treated 
PBMC-humanized NSG mice (ctrl), CD8-LV(CAR)-treated PBMC-humanized NSG mice (CAR), 
CD8-LV(RFP)-treated PBMC-humanized NSG mice (RFP) and CD8-LV(CAR)-treated PBMCCD19-depleted-
humanized NSG mice (CARu). Single cell suspensions were analyzed by flow cytometry and transgene 
integration was analyzed on genomic DNA. Two representative mice of each group were analyzed and 
individual values are shown for each mouse as black dots. (A) Transgene integration analysis. Transgene 
integration was determined by qPCR with WPRE-specific primers on genomic DNA. Albumin-specific primers 
were used for reference gene detection and vector copy numbers were calcuated as the ratio of 
WPRE-copies/ albumin-copies. (B) Flow cytometry analysis. CAR and CD45 expression were analyzed on 
single cell suspensions. Percentage of CAR+ cells of CD45+ cells are shown. N=2 with mean ± SD are shown. 
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Successful in vivo gene delivery of CD8-LV in PBMC-humanized mice was confirmed by 
transgene integration and transgene expression analysis. Furthermore, VCN ratios were 
well in accordance with the percentage of CAR+ cells. The highest VCN was observed for 
CD8-LV(CAR)-treated PBMC-humanized mice, correlating to the highest CAR+ levels. 
CD8-LV(RFP) and CD8-LV(CAR)-treated PBMCCD19-depleted-humanized mice showed 
three- to fourfold lower VCNs and less CAR+ cells. 
3.3.6.2 Clonality analysis 
As transgene integration was confirmed by qPCR, lentiviral integration sites were 
analyzed to evaluate clonality of in vivo transduced cells, revealing information about a 
potential in vivo selection of affected clones.   
Transgene integration sites were analyzed in LM-PCR assay using HIV-1 specific primers 
on genomic DNA that was isolated from peritoneal and spleen cells (LM-PCR analysis 
was performed in close collaboration with Prof. Dr. Dr. Modlich and F. Schenk (group 
“Gene modification in Stem Cells”, Paul-Ehrlich-Institut)). 
As expected, the internal band was absent in the water control and in genomic DNA from 
control mice due to the absence of the transgene (Figure 33). For CD8-LV(CAR)-treated 
PBMC (CAR) and PBMCCD19-depletedhumanzed mice (CARu) as well as for 
CD8-LV(RFP)-treated PBMC mice (RFP), internal bands were detected. A strong internal 
band surrounded by a faint smear characterized the amplified LV integration site pattern 
from transduced cells isolated from the peritoneal cavity. This indicated a rather polyclonal 
integration site pattern. In spleen cells, amplified LV integration sites were characterized 
by a strong internal band and several faint bands of various sizes, which indicated a more 
oligoclonal transgene integration site pattern.  
 
Figure 33: Detection of LV integration sites 
LV integration sites were analyzed on genomic DNA by LM-PCR. Isolated gDNA of peritoneal and spleen 
cells from PBS-treated PBMC-humanized NSG mice (ctrl), CD8-LV(CAR)-treated PBMC-humanized NSG 
mice (CAR), CD8-LV(RFP)-treated PBMC-humanized NSG mice (RFP) and CD8-LV(CAR)-treated 
PBMCCD19-depletd-humanized NSG mice (CARu) were analyzed. Two representative mice of each group are 
shown. Internal control band (at 245 bp), primer band and the water control (H2O) are shown. 
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In conclusion, specific transgene integration was observed for all mice treated with 
CD8-LV independently from the type of transgene. While a polyclonal integration pattern 
was observed for isolated cells from the peritoneal cavity, cells from the spleen showed a 
rather oligoclonal transgene integration site pattern. These data suggest polyclonal 
proliferation of in vivo transduced cells without any signs of monoclonal outgrowth. 
3.4 Evaluating anti-tumoral functions of in vivo generated CAR T cells 
Anti-tumoral functions of ex vivo generated CD19-specific CAR T cells had been 
demonstrated by others. NSG mice were i.v. injected with Raji-luc cells and successfully 
treated with CAR T cells (Xu et al., 2014; Hudecek et al., 2015; Sommermeyer et al., 
2015). In vivo generated CAR T cells, however, remain to be evaluated for their 
anti-tumoral functions.  
It was shown that systemic administration of CD8-LV(CAR) to PBMC-humanized NSG 
mice mediated in vivo generation of CAR T cells (chapter 3.3.1). In short-time 
experiments, in vivo generated CAR T cells completely eliminated CD19+ cells and 
proliferated upon antigen stimulation. However, it remains to be seen whether the in vivo 
generated CAR T cells have anti-tumoral functions and are able to prevent tumor 
outgrowth.  
For this purpose, 5x105 Raji-luc cells were i.v. injected into NSG mice. Five days later, 
1x107 PBMC were injected followed by i.p. administration of CD8-LV(CAR) or PBS one 
day later (Figure 34).  
 
Figure 34: Experimental setting to evaluate anti-tumoral functions of in vivo generated CAR T cells in 
Raji-luc xenograft PBMC-humanized NSG mice  
NSG mice were i.v. injected with 5x105 Raji-luc cells. Five days later 1x107 activated PBMC were i.p. injected, 
followed by i.p. administration of CD8-LV(CAR). On day ten, blood was taken to evaluate in vivo generation 
of CAR T cells. Tumor growth was monitored by in vivo bioluminescence imaging at indicated time points.  
Tumor growth was monitored by in vivo bioluminescence imaging. Mice were regularly 
checked for their health status and sacrificed when termination criteria were reached. As 
seen in chapter 3.3.1, upon administration of CD8-LV(CAR) into PBMC-humanized mice, 
in vivo generated CAR T cells had been detected seven days after CD8-LV(CAR) 
administration. To evaluate in vivo generation of CAR T cells for CD8-LV(CAR)-treated 
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mice during the ongoing experiment, blood was taken on day ten and analyzed by flow 
cytometry for CD45, CD8 and CAR expression. PBS-treated mice served as control.  
For PBS- and CD8-LV(CAR)-treated mice, on average 30% CD45+ cells were detected in 
the blood (data not shown). On average 50% of the cells were CD8+ cells. Seven out of 
eight CD8-LV(CAR)-treated mice showed CAR expression. On average 16.5% of the 
CD8+ cells were CAR-positive (Figure 35A). To calculate the frequency of CAR T cells in 
the blood, the percentage of CD45+CAR+ cells was determined ranging between 
5.8-12.7% (Figure 35B). 
 
Figure 35: CAR expression of CD8+ and CD45+ cells in the blood of CD8-LV(CAR)-treated Raji-luc 
xenograft PBMC-humanized NSG mice 
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Ten days after vector 
administration, blood was taken from mice and analyzed by flow cytometry for CD45, CD8 and CAR 
expression. Percentage of (A) CAR+ cells of CD8+ cells and (B) CAR+ cells of CD45+ cells is shown for 
PBS-treated (black) and CD8-LV(CAR)-treated (blue) mice. N=8, mean ± SD are shown. Statistical 
significance was determined by two-tailed unpaired t-test; ****, p<0,0001. 
These data demonstrated successful in vivo generation of CAR T cells in seven out of 
eight mice. Whether these CAR T cells mediated anti-tumoral effects was evaluated by 
tumor growth monitoring via in vivo bioluminescence imaging. 
3.4.1 Monitoring tumor growth via in vivo imaging 
Mice were imaged five days post Raji-luc administration (referred as day -1) and 12 and 
20 days post CD8-LV(CAR) administration.  
On day -1, luciferase signals were comparable between both groups. Until day 12, the 
luciferase signals further increased (Figure 36), indicating tumor growth for both, PBS and 
CD8-LV(CAR)-treated mice. For all mice, luciferase signals were distributed over the 
whole body. The highest signals were observed in the lower region of the body 
co-localizing with the knees of the mice, suggesting that these signals indicated tumor 
growth within the bone marrow. For some mice in both groups, signals coming from the 
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abdominal region were observed. In control mice, three out of eight mice had higher 
signals coming from the head region. However, on day 20, luciferase signals strongly 
decreased in PBS-treated mice. Luciferase signals were not covering the whole body, but 
were only present in distinct regions. Two out of four mice showed only two to three 
remaining regions of luciferase signals. All CD8-LV(CAR)-treated mice showed stronger 
luciferase signals compared to PBS-treated mice. However, compared to day 12, two of 
four CD8-LV(CAR)-treated mice also showed decreased luciferase signals. But the 
decrease of luciferase signals was not as pronounced as for PBS-treated mice.  
 
Figure 36: Tumor cell growth monitoring by in vivo bioluminescence imaging of CD8-LV(CAR)-treated 
Raji-luc xenograft PBMC-humanized NSG mice  
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Control mice were 
treated with PBS. Tumor cell growth was monitored by in vivo bioluminescence imaging one day prior vector 
administration (day -1) and on day 12 and 20 post CD8-LV(CAR) administration. Sacrificed mice are marked 
with X.  
In vivo bioluminescence imaging data revealed a completely unexpected outcome 
concerning anti-tumoral effects. Luciferase signals on day 20 post PBMC administration 
indicated that PBS-treated mice had a lower tumor burden than CD8-LV(CAR)-treated 
mice.  
3.4.2 Presence of in vivo generated CAR T cells in various organs 
The in vivo bioluminescence imaging data from day 20 were completely unexpected. 
Having seen that PBS-treated mice had a lower tumor burden than CD8-LV(CAR)-treated 
mice was against all expectations. Until day 17, four mice of each group had to be 
sacrificed at earlier time points reaching termination criteria. Symptoms were 
characterized by partial or complete hind-limb-paralysis, hunching, weight loss and 
reduced mobility. From day 18 on, however, none of the mice had to be sacrificed because 
of hind-limb-paralysis. Stagnating or even decreasing luciferase signals on day 20 was in 
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line with missing tumor burden symptoms. For endpoint analysis, mice were sacrificed 
and analyzed in detail.  
For all mice, independently of being sacrificed at early time points or later for endpoint 
analysis, single cell suspensions from spleen, peritoneum, blood and bone marrow were 
prepared and analyzed by flow cytometry for the presence of CAR T cells. To evaluate 
CAR T cell distribution among different organs, CAR expression of CD45+ cells was 
analyzed. To distinguish between mice sacrificed at early time points and mice sacrificed 
for endpoint analysis, mice were marked differently in the scatter plots shown below. Mice 
sacrificed until day 17 were marked by empty circles/squares. Mice sacrificed later were 
marked with filled circles/squares. 
PBS-treated mice served as control (Figure 37, black). Seven out of eight mice 
CD8-LV(CAR)-treated mice showed CAR expression. One mouse did not show 
CAR expression in the blood at day ten and had to be sacrificed at an early time point 
(Figure 35) (Figure 36, mouse at the far right). Flow cytometry of cells from various organs 
confirmed the absence of CAR T cells. Therefore, this mouse was excluded in further 
analyses. In peritoneal cells from CD8-LV(CAR)-treated mice, on average 18% 
CD45+CAR+ cells were detected. In spleen, CAR expression was on average 8% and 
further CAR T cells had also been detected in blood and bone marrow. On average, 6% 
CD45+CAR+ T cells were detected in the blood and 10% in the bone marrow (Figure 
37, blue). Surprisingly, mice, which had been sacrificed at early time points, showed the 
higher frequencies of CAR T cells (Figure 37, blue, empty square). 
  
Figure 37: CAR expression of CD45+ cells in various organs of CD8-LV(CAR)-treated Raji-luc xenograft 
PBMC-humanized NSG mice 
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Mice were sacrificed 
at early time points due to termination criteria (empty circles/squares) or for endpoint analysis (filled 
circles/squares). Single cell suspensions of indicated organs were prepared and analyzed for CD45 and CAR 
expression by flow cytometry. Percentage of CAR+ cells of CD45+ cells of peritoneal, spleen, blood and bone 
marrow is shown for PBS-treated (black) and CD8-LV(CAR)-treated mice (blue). N=7-8, mean ± SD are 
shown.  
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These data demonstrated that CAR T cells were generated in mice treated with 
CD8-LV(CAR). CAR T cells were distributed throughout the whole body being present in 
the peritoneal cavity, in the spleen, blood and in the bone marrow. Highest frequencies of 
CAR T cells were present in the peritoneal cavity followed by bone marrow. Strikingly, 
mice, which had to be sacrificed at early time points showed higher frequencies of 
CAR T cells within all organs compared to mice, which had been sacrificed for of endpoint 
analysis. 
3.4.3 Analysis of the presence of CD19+ B cells and CD19+ tumor cells in various 
organs 
CAR expression for CD8-LV(CAR)-treated mice was observed in various organs. 
However, luciferase signals indicated continuous tumor growth suggesting that the in vivo 
generated CAR T cells were not able to prevent outgrowth of CD19+ Raji-luc tumor cells. 
Therefore, CD19+ tumor cells were analyzed in detail in single cell suspensions of 
peritoneum, spleen, blood and bone marrow by flow cytometry. With the engraftment of 
Raji-luc cells and PBMC into NSG mice, the assumption was that CD19+ tumor cells and 
CD19+ B cells were present in the mice. Both populations had to be analyzed separately 
to evaluate effects of the in vivo generated CAR T cells on tumor cells and B cells, 
respectively. The different CD19+ populations were distinguished by their CD45 
expression, in particular by their different MFI for CD45. While CD19+ B cells were 
characterized by a higher MFI for CD45, CD19+ tumor cells showed a lower MFI for CD45. 
Thereby CD45highCD19+ cells were identified as B cells and CD45lowCD19+ cells as tumor 
cells. To evaluate the effect of in vivo generated CAR T cells on B cells and tumor cells, 
single cell suspensions of peritoneal, spleen, blood and bone marrow were assessed for 
the percentages of CD45highCD19+ B cells and CD45lowCD19+ tumor cells by flow 
cytometry.  
In PBS-treated mice, CD45highCD19+ B cells were detected in the peritoneal cavity and in 
the spleen (Figure 38, top panel). The highest frequency (0.14%) was detected in the 
peritoneal cavity of mice sacrificed at early time points (black). In spleen, a minor 
frequency of B cells close to background was detected. For CD8-LV(CAR)-treated mice 
sacrificed at early time points (dark blue) almost no B cells were detected. Some 
remaining B cells in CD8-LV(CAR)-treated mice sacrificed for endpoint analysis were 
detected and were comparable to PBS-treated mice. However, these events were in a 
very low range between 0-0.5%. For both groups, CD45lowCD19+ tumor cells were mainly 
detected in the bone marrow (Figure 38, lower panel). In all other organs, tumor cell 
frequencies were below 0.1% for all groups. Strikingly, a difference between 
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CD8 LV(CAR)- and PBS-treated mice was observed in the subgroup of mice sacrificed at 
early time points. CD8-LV(CAR)-treated mice showed less tumor cells (4.6%) than 
PBS-treated mice (10.2%). However, comparing endpoint analyzed mice more tumor cells 
had been found in CD8-LV(CAR)-treated mice compared to PBS-treated mice.  
 
Figure 38: Analysis of CD19+ Raji-luc or B cells in various organs from CD8-LV(CAR)-treated Raji-luc 
xenograft PBMC-humanized NSG mice 
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Mice were sacrificed 
at early time points due to termination criteria (dark blue and black) or for endpoint analysis (light blue and 
grey). Single cell suspensions were prepared from indicated organs and analyzed for CD45 and CD19 
expression by flow cytometry. Percentage of B cells (CD19+ of CD45high) is shown in the upper panel and 
percentage of Raji-luc cells (CD19+ of CD45low) in the lower panel. N=7-8, mean ± SEM are shown.  
These data suggest that B cells were mainly present in peritoneum and spleen and absent 
in blood and bone marrow in PBS-treated mice. For CD8-LV(CAR)-treated mice, B cells 
had been almost completely eliminated. Tumor cells were primarily detected in the bone 
marrow. Strikingly, mice, which had to be sacrificed at early time points showed higher 
frequencies of tumor cells in PBS-treated mice compared to CD8-LV(CAR)-treated mice. 
This indicated anti-tumoral CAR T cell activity until day 17. However, at endpoint analysis, 
CD8-LV(CAR)-treated mice showed a higher tumor cell frequency in the bone marrow 
than PBS-treated mice.   
CD8-LV(CAR) - sacrificed at early time points
CD8-LV(CAR) - sacrificed for endpoint analysis
PBS - sacrificed at early time points
PBS - sacrificed for endpoint analysis
peritoneum spleen blood bone marrow
B cells
Raji-luc cells
0.0
0.1
0.2
0.3
0.4
10
20
30
%
 C
D
1
9
+
 o
f 
C
D
4
5
h
ig
h
0.0
0.1
0.2
0.3
0.4
10
20
30
%
 C
D
1
9
+
 o
f 
C
D
4
5
lo
w
peritoneum spleen blood bone marrow
Results 
73 
 
 
The luciferase signals and the presence of CD19+ tumor cells in CD8-LV(CAR)-treated 
mice indicated that in vivo generated CAR T cells were not able to prevent tumor 
outgrowth. Besides others, one reason might be CD19 antigen loss of tumor cells. Upon 
CAR T cell activation against CD19+ tumor cells, loss of the CD19 antigen can occur 
(Grupp et al., 2013). CAR T cells would not be able to recognize tumor cells anymore and 
therefore would not exert anti-tumoral functions. However, downregulation of the targeted 
antigen does not affect the surface expression of other antigens. Raji cells express, 
besides other surface markers, the CD20 antigen. 
To evaluate antigen loss of tumor cells single cell suspensions from bone marrow were 
analyzed for the co-expression of CD19 and CD20 by flow cytometry analysis. As control, 
in vitro cultivated Raji-luc cells were analyzed. 
Co-staining of CD20 and CD19 of in vitro cultured Raji-luc cells demonstrated 86.4% of 
the Raji-luc cells to be double positive for both markers (Figure 39). Co-staining of single 
cell suspensions from bone marrow cells of CD8-LV(CAR)-treated mice sacrificed for 
endpoint analysis revealed 85.8% of all CD20+ cells to express CD19. Some few 
CD19+ cells showed a lower MFI, indicating lower expression of CD19. Furthermore, 
some cells were detected to be CD19-. However, these were only very few cells (3%). 
These data demonstrated that the majority of tumor cells explanted from 
CD8-LV(CAR)-treated mice expressed the CD19 antigen on the cell surface although 
some few cells downregulated or did not express the CD19 antigen.  
 
Figure 39: CD19 and CD20 co-expression analysis of Raji-luc cells explanted from bone marrow from 
CD8-LV(CAR)-treated Raji-luc xenograft PBMC-humanized NSG mice 
NSG mice, engrafted with PBMC and Raji-luc cells were treated with CD8-LV(CAR). Mice were sacrificed for 
endpoint analysis and single cell suspensions from bone marrow were analyzed for CD19 and CD20 
expression by flow cytometry. One representative density plot is shown (far right, N=2). In vitro cultivated 
Raji-luc cells were analyzed for CD19 and CD20 co-expression as control (Raji-luc).  
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3.4.4 Phenotypic characterization of CAR T cells in various organs 
In vivo generated CAR T cells were distributed to various organs including peritoneum, 
spleen, blood and bone marrow. They were able to eliminate CD19+ B cells, but the 
outgrowth of tumor cells was not prevented. CAR T cells were further characterized for 
their subset phenotype to investigate functionality of the CAR T cells in detail. CAR T cells 
were analyzed by flow cytometry for CD62L and CD45RA surface expression, classifying 
them into TSCM/Naϊve, TCM, TEM and TEff. CAR- cells (CD8+CAR- cells and CD8- cells) were 
analyzed as controls representing cells being unaffected by the interaction of CAR T cells 
and antigen. The following analysis included four mice of each group, which had been 
sacrificed for endpoint analysis. Subset distribution was separately evaluated for the 
different organs: peritoneum, spleen, blood and bone marrow. 
For peritoneal cells, the average distribution in CD8- cells was similar in 
CD8-LV(CAR)- and PBS-treated mice. The majority were TCM (51.91% ± 3.99%) followed 
by TEM (47.94% ± 3.98%). Almost no TSCM/Naϊve (0.07% ± 0.08%) or TEff (0.09% ± 0.05%) 
were present (Figure 40A, right panel). Comparing CD8+CAR- cells, a similar distribution 
pattern was observed for both treatments with a majority of TCM (53.51% ± 5.96%) followed 
by TEM (45.44% ± 5.99%). Only very few TSCM/Naϊve (0.59% ± 0.22%) and 
TEff (0.09% ± 0.05%) were detected (Figure 40A, middle panel). The subset-phenotype 
distribution of CD8+CAR+ cells showed the same overall distribution pattern as in 
CD8+CAR- and as in CD8- cells having almost no TSCM/Naϊve (0.21% ± 0.25%) and 
TEff (0.42% ± 0.35%) present. However, the fraction of TCM was enriched 
(64.95% ± 9.52%) and less TEM (34.41% ± 9.87%) were detected (Figure 40A, left panel).   
In the spleen, cells were characterized by the same overall subset distribution with two 
major populations of TEM and TCM and two smaller population represented by TSCM/Naϊve and 
TEff. In detail, CD8- cells showed the same distribution in CD8-LV(CAR)- as in PBS-treated 
mice. TEM were of highest frequency (57.35% ± 9.94%) followed by 37.61% ± 7.75% TCM. 
Remaining cells were TSCM/Naϊve (2.94% ± 1.76%) and TEff (2.11% ± 1.08%) (Figure 40B, 
right panel). A similar distribution was observed in CD8+CAR- cells independently of being 
treated with PBS or CD8-LV(CAR). Most cells were TEM (52.51% ± 7.32%) followed by 
TCM (37.45% ± 8.22%). TSCM/Naϊve (6.15% ± 2.76%) and TEff (3.89% ± 2.58%) being the 
smallest fractions (Figure 40B, middle panel). CD8+CAR+ cells showed higher frequencies 
of TCM (49.32% ± 7.01%) and lower frequencies of TEM (44.62% ± 1.0%). TSCM/Naϊve 
(3.34% ± 3.72%) and TEff (2.72% ± 3.59%) cell fractions were comparable to CD8+CAR- 
and CD8- cells (Figure 40B, left panel). 
Blood cells were also characterized by two major populations of TEM and TCM. CD8- cells 
from PBS and CD8-LV(CAR)-treated mice showed a similar distribution pattern of subset 
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phenotypes. Almost equally large TCM (47.6% ± 7.25%) and TEM (45.11% ± 10.71%) 
fractions and few TSCM/Naϊve (5.58% ± 3.16%) and TEff (1.70% ± 0.63%) (Figure 40C, right 
panel) were observed. CD8+CAR- cells showed a slightly different pattern, having more 
TCM (59.35% ± 5.69%), TEM (26.07% ± 6.86%) and a larger portion of TSCM/Naϊve 
(11.56% ± 5.69%). Few TEff were present (3.03% ± 1.35%) (Figure 40C, middle panel). 
Against all previous data, for blood cells, the distribution of CD8+CAR+ cells was similar to 
the pattern of CD8+CAR- cells. The largest fraction was TCM (66.89% ± 1.20%), followed 
by TEM (22.21% ± 7.03%), TSCM/Naϊve (9.56% ± 6.22%) and a small fraction of 
TEff (1.34% ± 0.33%) (Figure 40C, left panel). 
In contrast to all previous organs, subset distribution in the bone marrow within CD8- and 
CD8+CAR- cells were different between CD8-LV(CAR)- and PBS-treated groups. 
CD8- cells of CD8-LV(CAR)-treated mice were characterized by higher frequencies of 
TEM (54.1% ± 17.34%) and TEff (15.78% ± 17.48%) (Figure 40D, right panel). In contrast, 
PBS-treated mice had less TEff (3.34% ± 1.13%) and more TEM (70.7% ± 13.85%). 
Frequencies of TSCM/Naϊve and TCM were similar with on average 3.23% ± 3.01% TSCM/Naϊve 
and 24.06% ± 10.4% TCM. A similar distribution was observed for CD8+CAR- cells with 
similar average frequencies of TSCM/Naϊve (1.35% ± 0.81%) and TCM (6.6% ± 3.87%) (Figure 
40D, middle panel). Similarly, as observed for CD8- cells, CD8-LV(CAR)-treated mice 
showed higher TEff (19.15% ± 19.84%) with 73.11% ± 18.48% TEM. PBS-treated mice 
showed lower frequencies of TEff (3.75% ± 1.43%) with 88.11% ± 6.81% TEM. Remarkably, 
the subset distribution of CD8+CAR+ cells was strikingly different. The fraction was 
characterized by a high frequency of TEff (43.02% ± 28.62%). TEM still made up the biggest 
portion (46.25% ± 25.62%) followed by a smaller TCM fraction (7.5% ± 5.08%) and a minor 
TSCM/Naϊve fraction (3.23% ± 3.93) (Figure 40D, left panel). 
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Figure 40: Subset-phenotype analysis of in vivo generated CAR T cells in various organs from 
CD8-LV(CAR)-treated Raji-luc xenograft PBMC-humanized NSG mice 
NSG mice were engrafted with Raji-luc cells and PBMC, and treated with CD8-LV(CAR). Mice were sacrificed 
for endpoint analysis. Single cell suspensions from peritoneum, spleen, blood and bone marrow were 
analyzed for CD45, CD3, CD8, CAR, CD62L and CD45RA expression by flow cytometry. Human T cells were 
identified as CD45+CD3+ cells. CD8+CAR+, CD8+CAR- and CD8- cells were analyzed for CD62L and CD45RA 
expression and classified into subset-phenotypes. Subsets are defined as pink: central memory T cells (TCM: 
CD45RA-CD62L+); yellow: stem cell memory/naϊve T cells (TSCM/Naϊve: CD45RA+CD62L+); green: effector 
memory T cells (TEM: CD45RA-CD62L-); and turquoise: effector T cells (TEff: CD45RA+CD62L-). Pie chart 
representations of mean subset-phenotype percentages for CD8+CAR+, CD8+CAR- and CD8- cells are shown 
for CD8-LV(CAR)- or PBS-treated PBMC-humanized NSG mice. N=4.  
Taken together, these data demonstrate, that CD8+CAR- and CD8- cells often show the 
same subset distribution pattern within individual organs, independently of the treatment, 
either treated with PBS or CD8-LV(CAR). Peritoneal, spleen and blood cells, were mostly 
characterized by two main populations of TEM and TCM. TSCM/Naϊve and TEff were 
underrepresented in the three organs. Being absent in the peritoneum, some TSCM/Naϊve 
and TEff were detected in spleen and blood. In these three organs, CAR T cells showed a 
different pattern compared to CD8+CAR- and CD8- cells with larger frequencies of TCM, 
but had the tendency for a similar overall subset distribution, and were characterized by 
high frequencies of TEM. Strikingly, in the bone marrow the overall subset distribution was 
changed, showing more TEff. Remarkably, highest frequency of TEff were observed in 
CAR T cells in CD8-LV(CAR)-treated mice.   
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4  Discussion 
Successful CAR T cell therapy currently relies on ex vivo modification of cells and thereby 
faces financial hurdles and logistic expenses due to its highly personalized and complex 
manufacturing process. In vivo generation of CAR T cells by vector administration would 
de-personalize the current process and facilitate CAR T cell therapy as an off-the-shelf 
product for cancer immunotherapy. 
This thesis demonstrates the first proof-of-principle study for the in vivo generation of 
human CAR T cells in a preclinical mouse model using CD8-receptor-targeted LVs. First 
conclusions can be made on transduction efficiency, functionality of the CAR T cells, such 
as proliferation, killing of CD19+ cells, and phenotypic characteristics. These data suggest 
CD8-LV as a highly promising candidate for further investigations to be a powerful tool for 
the in vivo generation of CAR T cells. 
4.1 CD8-targeted LV for in vivo gene delivery into T cells  
Current genetic modifications of lymphocytes require the isolation of blood cells from the 
patient to engineer them ex vivo using VSV-G-pseudotyped LVs. Two main reasons 
hinder direct in vivo modification of cells: (i) selective gene delivery without off-target 
transduction and (ii) a non-permissive status of resting cells for VSV-G LV transduction. 
Due to the lack of the LDL receptor, gene delivery by VSV-G LV to unstimulated 
lymphocytes, such as HSCs, monocytes and resting B and T lymphocytes is inefficient 
(Amirache et al., 2014). Receptor-targeted LVs address both issues. They have been 
shown to reliably and selectively deliver genes into the target cell population while 
non-target cells remain untransduced. So far, in vitro and in vivo studies demonstrated 
successful targeting to diverse cell entities, among them CD133+ hematopoietic cells, 
CD20+ B lymphocytes as well as CD4+ and CD8+ T lymphocytes (Funke et al., 2008; 
Anliker et al., 2010; Zhou et al., 2012; Zhou et al., 2015). Furthermore, for some of these 
vectors, the targeting domain induced mild activation of the target cells allowing gene 
transfer into resting cells. Gene delivery into resting B cells was achieved by the 
CD20- and CD19-targeted LVs inducing the transfer of cells into the G1b cell cycle phase 
(Kneissl et al., 2013). Also for CD4-LV, transduction of unstimulated T cells was 
demonstrated (Zhou et al., 2015). These studies had been performed using 
MV-pseudotyped LVs requiring further investigations for NiV-pseudotyped LVs. However, 
since the activating stimulus is mediated by the incorporated scFv displayed on the vector 
particle it is assumed to be independent from the type of incorporated glycoproteins. The 
scFv used either for NiV- or MV-pseudotyped CD8-targeted LV is derived from OKT8, 
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which has been shown to mediate activating functions and to trigger effector functions 
upon binding, whereas six other CD8-specific antibodies did not (Clement et al., 2011). 
Therefore, the type of incorporated scFv can be chosen in a way to equip the vector with 
activating modulation properties and thereby enhancing transduction efficiency into 
resting lymphocytes. Studies incorporating additional molecules such as IL-7 into the LVs 
demonstrated activation of lymphocytes and might provide a further tool for transduction 
of unstimulated T cells without the usage of broad activating modulating agents 
(Verhoeyen et al., 2003).  
 
To evaluate the capability of CD8-LV to deliver transgenes in vivo, studies shown in this 
thesis were performed in preclinical mouse models. Thereby, the PBMC-humanized NSG 
mouse model with a stable T cell engraftment was chosen, which enables a 
comprehensive analysis on transduction efficiency. While selective gene delivery into 
CD8 T cells had been shown in vitro for NiV- and MV-pseudotyped CD8-LV, in vivo gene 
delivery requires vector stocks to be producible in reasonable titers. Only with the 
establishment of NiV-pseudotyped LVs, sufficient titers of CD8-LV being 100-fold higher 
compared to CD8MV-LV allowed systemic administration of vector particles (Bender et al., 
2016). In the present study, successful in vivo gene delivery was demonstrated by 
luciferase and GFP expressing cells upon intravenous administration of 
CD8-LV(Luc-GFP) into mice (Figure 7, Figure 8). Although luciferase signals were 
distributed over the whole body and CD8+GFP+ cells were detected in lung, spleen and 
blood, on average only 0.2% of the CD8 T cells were GFP-positive. Compared to 
CD4MV-LV, showing on average 6% of CD4 transduced cells upon systemic administration 
(Zhou et al., 2015), transduction efficiency was unexpectedly low. While the reasons are 
not yet clear, individual properties of the vectors might have contributed to the different 
transduction efficiency. Whereas CD8-LV is pseudotyped with NiV glycoproteins 
displaying a scFv, CD4MV-LV is pseudotyped with MV glycoproteins displaying a DARPin 
as targeting domain (Zhou et al., 2015; Bender et al., 2016). DARPins usually show higher 
binding affinities than scFV, which might have contributed to the increased transduction 
efficiency (Plückthun, 2015). However, direct comparison was not performed so far and it 
remains to be evaluated whether CD8-specific DARPins mediate higher transduction 
efficiency in vivo.  
When vectors were intraperitoneally administered, transduction efficiency became more 
similar for both vectors with slightly higher levels of transduced cells (12%) for CD4MV-LV 
transferring blue fluorescent protein (bfp) gene compared to 3% transduced cells by 
CD8-LV transferring rfp (Figure 23) (Zhou et al., 2015). While the type of the reporter gene 
is not expected to influence transduction efficiency, the administration route of PBMC and 
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vector affects engraftment kinetics of human cells and distribution of the vector, thereby 
influencing the likelihood of vector-cell contact. Intravenously administered PBMC directly 
enter circulation resulting in faster distribution of human cells and various localizations. 
Diverse distribution of human cells and vector particles probably limits their contact 
frequencies resulting in lower transduction efficiency. In contrast, intraperitoneally injected 
PBMC require 7-14 days to drain from the peritoneal cavity to the circulation (King et al., 
2008). Therefore, i.p. injection of PBMC and vector brings these two components in close 
proximity, most likely increasing transduction efficiency. Although low transduction levels 
upon i.v. administration were disappointing in the first place, doubting the potential of 
CD8-LV, i.p. injection demonstrated that administration routes influence transduction 
efficiency. Furthermore, low amounts of initially transduced cells must not be 
disadvantageous, especially with CAR gene delivery, which was expected to confer 
proliferative advantage.   
 
Off-target transduction is a major concern of in vivo CAR gene delivery. Given the wide 
distribution of luciferase signals, CD8-LV appeared to be unspecific on the first view. 
However, this is rather the result of circulating transduced CD8 T cells present in the 
blood. Another reason for these signals also might be the infiltration of CD8 T cells into 
the skin as a result from graft-versus-host disease (GvHD), which is known as xenogeneic 
reaction occurring in NSG mice transplanted with PBMC. Stronger luciferase signals were 
observed in the lung and in the spleen – organs that have been shown by others to be 
homing sites of transferred T cells (van Rijn et al., 2003; King et al., 2009). To characterize 
off-target transduction in detail, the specificity of the vector was evaluated by analyzing 
non-target cells. A closer look at CD8- cells revealed some events in the GFP-positive 
gate (Figure 8). These events, however, had a low MFI compared to GFP events within 
the CD8+ cells, which were of higher MFI. Additionally, the percentage of GFP events 
within the CD8- cells of vector-treated mice was similar to those observed in the 
PBS-treated control mice indicating that these events can be considered as background 
signal. When including murine cells in the analysis, also no off-target GFP expression was 
observed (Figure 9). For in vitro transduction experiments, events within the gate of 
target-negative cells were observed, however, they were always below 1% (Figure 13). 
These observations were also seen with the CD4MV-LV, which were in this case explained 
by a temporary downregulation of the receptor upon vector particle binding and 
incorporation (Zhou et al., 2015). Whether these few events result from real off-target 
transduction requires detailed analysis of the potentially transduced cells. With the 
exception of these few events, the CD8-LV demonstrated high selectivity with transgene 
expression almost exclusively present in CD8-positive cells.  
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Taken together, CD8-LV represents a new receptor-targeted LV mediating in vivo gene 
delivery. Importantly, CD8-LV demonstrated in vivo gene delivery upon systemic 
administration, which was not achieved with CD8MV-LV. Although transduction efficiency 
is different from that observed with CD4MV-LVs it is unclear whether this is a result from 
targeting different cell populations or caused by individual vector properties. This requires 
further studies with direct comparisons. Transduction efficiency, however, was increased 
when administering PBMC and vector intraperitoneally. This indicated that a rather 
restricted area bringing vector and target cells in close proximity is beneficial for 
transduction efficiency. Furthermore, GFP expressing cells within CD8+ cells 
demonstrated selective gene delivery of CD8-LV, a critical prerequisite for a potential 
usage of CD8-LV for in vivo gene delivery.   
4.2 In vivo generation of CAR T cells and their functionality 
The capability of CAR T cells to mediate anti-tumoral activity is extensively studied in 
animal models, particularly in murine models before their clinical potential is studied in 
humans. Hereby, different mouse models can be distinguished: syngeneic and 
humanized, xenograft mouse models (Figure 41). Many preclinical studies are performed 
in xenograft models, in which human CAR T cells and human tumor cell lines are 
engrafted into immune-incompetent mice. This model was also used in the present study. 
 
Figure 41: Schematic overview of mouse models used for CAR T cell studies 
Depiction of immune components and tumor cells in syngeneic and humanized, xenograft mice. Advantages 
(+) and disadvantages (-) for CAR T cell studies are shown below each model. GvHD, graft-versus-host 
disease; HLA, human leukocyte antigen. 
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In this thesis, for the first time, the in vivo generation of human CAR T cells was 
demonstrated. Key for this achievement was the used CD8-LV and PBMC-humanized 
NSG mice allowing first insights into the functionality of in vivo generated CAR T cells. 
Remarkably, intraperitoneal administration of CD8-LV(CAR) resulted in on average 50% 
of the CD8+ cells being CAR-positive. Using the same administration route with 
CD8-LV(RFP), however, resulted in at least ten-fold less transgene-positive cells (Figure 
23). Additionally, higher percentages of CD8+ cells were observed in CD8-LV(CAR)-
treated mice, compared to PBS- or CD8-LV(RFP)-treated mice (Figure 24).  
Both observations suggest a selective enrichment of CD8+CAR+ T cells. Once the CAR 
was expressed and presented on the surface of the transduced cell a selective 
proliferation of CAR T cells must have been triggered by antigen stimulus – most likely by 
CD19+ cells. Although it was initially assumed that Raji cells provide this proliferation 
stimulus, this hypothesis turned out to be at least partially wrong. The frequency of 
CAR T cells was unaltered in mice engrafted with or without Raji-luc cells (Figure 23). In 
contrast, the engraftment of B cell-depleted PBMC resulted in lower transgene expression 
of CD8-LV(CAR)-treated mice demonstrating that the CD19+ B cells were the proliferation 
stimulus that triggered selective proliferation of the in vivo generated CAR T cells in this 
experiment. However, it cannot be excluded that Raji cells also triggered CAR T cell 
proliferation, but this requires further investigation. Even more, CAR T cells eliminated 
CD19+ cells not only in the peritoneum, but also in spleen and in blood, which besides 
circulating activities of the CAR T cells also proves their ability to recognize and to kill 
target cells providing strong evidence for their functionality. 
Although these short-term experiments were meant to provide first proof-of-principle of 
in vivo CAR T cell generation, additional conclusions about the functionality of in vivo 
generated CAR T cells already can be drawn. In fact, both observations: elimination of 
B cells and proliferation of CAR T cells are very promising observations for generating 
functional CAR T cells and are critical determinants in clinical studies. CAR T cell 
proliferation highly correlates with anti-tumoral activities, having sufficient CAR T cell 
numbers around to enable tumor destruction (Kalos et al., 2011; Grupp et al., 2013; Lee 
et al., 2015). B cell elimination correlates with successful clinical outcome in B cell 
malignancy patients treated with CD19 CAR T cells (Maude et al., 2014). Hence, these 
two observations can be regarded as promising indications that in vivo generated 
CAR T cells are functional.  
 
While the work of this thesis was ongoing, also other groups put efforts in the in situ 
modification of T cells to express a chimeric antigen receptor. Smith and colleagues used 
targeted nanoparticles to generate murine CAR T cells in vivo in immunocompetent mice 
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(Smith et al., 2017). Consisting of several layers of polymers, these nanoparticles 
incorporate DNA molecules and have an outer layer of polyglutamic acid coupled to an 
anti-CD3e f(ab’)2 fragment to enable targeting of murine CD3+ T cells. Selective targeting 
was demonstrated in syngeneic mouse models transferring a mouse CD19-specific CAR. 
Co-integration of a transposase encoding plasmid into nanoparticles ensured stable 
integration of the CAR transgene. They were able to show, that in vivo engineered 
CAR T cells are as effective as ex vivo manufactured CAR T cells regarding anti-tumoral 
activities. However, in vitro transduction efficiency of 3% upon administration of a 
nanoparticle to T cell ratio of 3000 indicate inefficient transduction. This was further 
underlined by the bolus applications of 3x1011 nanoparticles on five consecutive days to 
achieve in situ T cell modification. Off-target CAR expression was observed in 6% of 
non-target cells, including neutrophils, B cells, monocytes, natural killer (NK) cells and 
eosinophils, stating phagocytic uptake of the nanoparticles as the reason for off-target 
expression. Although off-target events and transduction efficiency need to be further 
investigated and improved, nanoparticles represent a further tool for in vivo engineering 
of T lymphocytes with anti-tumoral functions upon CAR transfer.  
 
Despite the fact that syngeneic models allow functional studies of CAR T cells within an 
immunocompetent environment, results obtained in this model cannot easily be 
transferred to the human system. The fully murine-derived components impede 
transferring the obtained results into human context, since the murine immune system 
does not always reflects the human biology (Siegler and Wang, 2018) (Figure 41). It is 
unknown, whether transduction with nanoparticles works equally well on human cells and 
whether nanoparticle-engineered human CAR T cells are functional. Thereby, murine 
CAR T cells only provide limited insights into human CAR T cell mechanism. In contrast 
to Smith et al., modification with the CD8-LV enables analysis and characterization of 
human CAR T cells within PBMC-engrafted NSG mice. Functional testing and detailed 
characterization of human CAR T cells including transgene integration analysis and 
phenotype characterization provide first insights into characteristics of in vivo generated 
human CAR T cells. 
Transgene integration and clonality analysis provided further insights into 
CD8-LV-modified human cells. The clonality analysis revealed a polyclonal integration 
pattern (Figure 33) demonstrating the absence of clonal dominance or monoclonal 
outgrowth after vector-mediated transgene insertion. Although this short-time experiment 
does not allow comprehensive conclusions about safety, it did not reveal any evidence for 
clonal expansion. 
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Ex vivo generated CAR T cells often have multiple integrations due to the transduction 
with multiple transducing particles per cell. Resultant overexpression of CAR molecules 
on the surface, however, has been shown to be of disadvantage. In fact, physiological 
CAR expression controlled by endogenous TCR promotor outperformed conventional 
CAR T cells in murine tumor models (Eyquem et al., 2017). Thus, as long as transgene 
expression is sufficient to mediate therapeutic effects single transgene integrations are 
preferred over multiple insertion sites in terms of safety and functional aspects. Upon 
CD8-LV administration, the highest VCN (0.4) was found on peritoneal cells, which was 
in line with the flow cytometry data showing the highest transgene expression in the 
peritoneum (Figure 32). Given this low VCN multiple integrations rather can be excluded 
for the in vivo approach, which might contribute to a lower risk of insertional mutagenesis 
and a potentially better CAR T cell product. 
Observations in this xenograft mouse model also provided insights into the differentiation 
status of in vivo generated CAR T cells. Phenotype analysis suggested a pool of diversely 
differentiated CAR T cells generated with CD8-LV. Not only effector CAR T cells but also 
less differentiated phenotypes such as TSCM/Naïve and both memory T cell phenotypes TCM 
and TEM showed CAR expression demonstrating that CD8-LV-mediated transduction of 
T cells generates all types of CAR T cells. Even more, clear differences between 
antigen-experienced and unexperienced CAR T cells were observed. Phenotype analysis 
was performed on cells isolated from the peritoneal cavity seven days post vector 
administration. At this time point, CD19+ cells were already eliminated in 
CD8-LV(CAR)-treated mice. In mice transplanted with CD19-depleted PBMC, however, 
they were absent from the beginning of this experiment. CAR T cells generated in these 
two settings revealed differences in the phenotypic patterns. Antigen-experienced 
CAR T cells showed higher frequencies of TCM subtypes, whereas antigen-unexperienced 
CAR T cells were predominantly composed of TEM and TEff. This observation might be 
explained by the circumstance that CD19+ cells had been already eliminated by the 
CAR T cells. It is well known that TEM as well as TEM vanish after antigen clearance, which 
is part of the negative feedback-loop of the immune systems to shut off an immune 
reaction upon antigen clearance and prevent over-activation. This might be the reason for 
the lower frequency of these cells within the CD8-LV(CAR)-treated PBMC engrafted mice. 
In mice engrafted with CD19-depleted PBMC, in contrast, CAR T cells did not yet 
encounter their antigen. They therefore circulate to increase the likelihood of antigen 
encounter. However, this analysis only refers to floating cells, which had been isolated by 
peritoneal lavage. Dependent on the surface receptor expression of T cells and the ligand 
expression on the associated tissue T cells traffic and home to respective tissues. 
Especially effector T cells express receptors specific for homing to peripheral tissue such 
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as gut- or skin-associated tissue (Mora and Andrian, 2006). Therefore, for detailed 
analysis of the distribution of the different T cell subtypes other tissues would need to be 
analyzed.  
However, the presence of CAR T cells of different phenotypes clearly suggests that 
CD8-LV(CAR) is in principle able to transduce different T cell phenotypes in vivo, which 
is highly preferred in terms of generating a pool of CAR T cells with various effector and 
proliferative functions. Each phenotype contributes to successful therapeutic effects as 
seen in clinical studies (Golubovskaya and Wu, 2016). Effector CAR T cells provide 
immediate anti-tumoral activity, critical to stop fast growing tumors in the first place. 
However, their limited proliferative capability provides only short-term activities. Less 
differentiated CAR T cells ensure long-term persistence of CAR T cells and memory 
CAR T cells, ideally, provide long-term protection against relapsing tumors. 
4.3 Properties influencing anti-tumoral functions of CAR T cells 
Anti-tumoral activity of CAR T cells is studied in murine models, mainly in xenograft 
models in order to facilitate transferring outcomes to human physiology. To evaluate 
anti-tumoral efficiency of in vivo generated human CAR T cells, pre-established tumors in 
NSG mice were monitored for tumor growth after PBMC and vector administration. 
Although successful in vivo generation of CAR T cells was demonstrated by the presence 
of CAR T cells in the blood ten days post vector administration, tumor growth was not 
impaired. Even more astounding, the control group showed less tumor signals than the 
CD8-LV(CAR) group (Figure 36). Clearly, this outcome was unexpected and anti-tumoral 
effects of CAR T cells were missing here. Which criteria determine the success of 
CAR T cell therapy, and which properties must CAR T cells meet to confer anti-tumoral 
functions?  
Anti-tumoral efficiency is dependent on various factors. A critical determinant, among 
others is the status of differentiation of a CAR T cell. While effector CAR T cells rather 
confer immediate killing activities towards the tumor cells, less differentiated CAR T cells 
give rise to further daughter cells, ensuring long-term persistence of CAR T cells.  
Detailed analysis of CD8-LV(CAR)-treated mice revealed the presence of CAR T cells in 
various organs such as peritoneum, spleen, blood and even bone marrow. Remarkably, 
all different phenotypes were detected, whereby a particular subset distribution was 
observed for each organ (Figure 42).  
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Figure 42: Schematic overview and proposed model of in vivo CAR T cell generation, their functions 
and migration into other tissues 
Tumor cells were i.v. injected into NSG mice, followed by i.p. injection of PBMC and CD8-LV(CAR). 
(1) CD8-LV(CAR) transduces CD8+ T cells delivering the CAR transgene. (2) A pool of diversely differentiated 
CAR T cells is generated: stem cell memory/naïve (SCM/Naïve), central memory (CM), effector memory (EM) 
and effector CAR T cells. (3) CAR T cells recognize and kill CD19+ B cells, which are completely eliminated 
from the peritoneal cavity. (4) CAR T cells selectively expand due to the provided antigen stimulus by the 
CD19+ B cells and (5) emigrate from the peritoneal cavity to other organs, which results in organ-specific 
distribution of diversely differentiated CAR T cells. At the time point of analysis, (6) predominantly CM and EM 
CAR T cells are observed in the peritoneal cavity, (7) CM, EM and SCM/Naïve CAR T cells in the spleen and 
(8) blood. (9) The bone marrow mainly consists of EM and Eff CAR T cells. Anti-tumoral functions are exerted 
by (10) EM and Eff CAR T cells and (11) HLA-mismatched T cells, which exert more efficient anti-tumoral 
activity than CAR T cells. (12) The development of an exhausted phenotype in CAR T cells might contribute 
to the absence of anti-tumoral functions of CAR T cells. 
This suggests that the initial transduction event must have generated all kinds of 
phenotypes. Most likely, the B cells contributed to proliferation of CAR T cells, which 
subsequently emigrated to other organs. In particular, CAR T cells in the peritoneal cavity 
were mainly composed of TCM and TEM subtypes at the time point of analysis. These cell 
types were also found in blood and in spleen, additionally accompanied by few TSCM/Naïve. 
The presence of less differentiated TSCM/Naïve and TCM CAR T cells is favourable since 
these cells are currently investigated to be of advantage for CAR T cell therapy due to 
their increased expansion and long-term persistence profile (Wang et al., 2012; Xu et al., 
2014). However, for immediate anti-tumoral activities TEff and TEM CAR T cells are critical. 
Indeed, these have been detected in higher frequencies in the bone marrow, the region 
from which strong tumor signals were coming up (Figure 40). However, although these 
data demonstrated successful migration of CAR T cells to various organs and even 
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homing of CAR T cells to tumor bearing tissues the presence of TEff and TEM somehow 
was not sufficient to prevent tumor outgrowth. Therapy failure can in principle be caused 
by downregulation of the targeted CD19 antigen, however, antigen loss was excluded 
(Figure 39).  
Several previous studies demonstrated successful tumor cell eradication by 
CD19 CAR T cells in the very same xenograft model when administering in vitro 
generated CAR T cells (Hudecek et al., 2015; Liu et al., 2016). However, administration 
of high amounts of CAR T cells immediately conferring anti-tumoral functions is a major 
difference to the present study. Upon vector administration, the generation of CAR T cells 
requires some time from transduction event to CAR surface expression. Even though 
CAR T cell proliferation had been demonstrated (3.3.4), it might well be that CAR T cell 
numbers were not sufficient to mediate a strong anti-tumoral response. Most likely, the 
kinetics of CAR T cell generation, expansion and emigration to tumor sites were delayed 
in the present study contributing to the missing anti-tumoral effects. Several clinical 
studies demonstrated that the magnitude of CAR T cell expansion is becoming a key 
predictor for therapeutic success and that the amount of CAR T cells correlates with 
therapeutic response (Turtle et al., 2016; Roberts et al., 2017). Even clinical studies 
underlined this aspect correlating therapy failure to a low level of CAR T cells in the blood 
of the patients within the first two weeks (Maude et al., 2014; Lee et al., 2015). However, 
total CAR T cell numbers were not determined in the present study, which does not allow 
comparison to other pre-clinical studies with successful anti-tumoral functions. Further 
investigations are required to evaluate whether low numbers of CAR T cells contributed 
to therapy failure.  
Nevertheless, complete elimination of CD19+ B cells demonstrated in vivo generated 
CAR T cells to be functional. As explained above, the amount of CAR T cells might have 
been sufficient to eliminate B cells but not tumor cells. However, some observations 
suggest that CAR T cells were active at earlier time-points. Higher frequencies of 
CAR T cells were observed in CD8-LV(CAR)-treated mice sacrificed at early time points 
compared to CD8-LV(CAR)-treated mice sacrificed for endpoint analysis (Figure 37). 
Further, higher frequencies of tumor cells were detected in PBS-treated mice than in 
CD8-LV(CAR)-treated mice when comparing mice, which had been sacrificed at early 
time points. This might indicate CAR T cell activity at early time points.  
 
A state of unresponsiveness called T cell exhaustion is known to render T cells 
non-functional over time. Although initially functional, prolonged antigen exposure can 
trigger T cell exhaustion characterized by poor effector functions (Wherry, 2011). This 
might explain initial killing activities against B cells, which were present at the initial 
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location of CAR T cell generation. However, CAR T cell exhaustion at later time points 
might have contributed to therapy failure. Further, previous studies demonstrated that 
additionally introduced intracellular signalling domains by CAR expression might favour 
T cell exhaustion. Clustering of sticky scFvs on the surface of CAR T cells contributes to 
a permanent signalling activity, so-called tonic signalling, which induces slight and 
permanent activation of the CAR T cell resulting in early exhaustion and less functional 
T cells. Although the FMC63-derived scFV, which was used in the present study, was 
shown to be less prone to exhaustion by scFv clustering (Long et al., 2015), CAR T cell 
exhaustion cannot be excluded but requires further investigation such as the analysis of 
exhaustion markers PD-1, TIM-3 and LAG-3.  
4.4 Limitations of the PBMC-humanized NSG mouse model for the study of 
CAR T cell functions 
Several factors might have contributed to the therapy failure in CD8-LV(CAR)-treated 
mice, however, this does not explain tumor shrinkage in control mice. Xenograft models 
represent models, in which the functions of CAR T cells towards human tumor cells can 
be studied within an organism. However, the murine-human chimerism comes along with 
several downsides and limitations (Figure 41). GvHD, caused by the xenogeneic reaction 
of the engrafted T cells towards the murine host, is one side effect. Transplanted adult 
T cells exert a comprehensive immune reaction against murine cells, causing the death 
of transplanted mice within 4-6 weeks independently from tumor growth (Ito et al., 2009; 
Schroeder and DiPersio, 2011). However, the reaction against foreign antigens is not only 
restricted to murine antigens but can also be mounted against the engrafted human tumor 
cells when MHC-type of engrafted PBMC and tumor cells are not matched. In fact, this 
phenomenon was observed in clinics when allogeneic transplantation of HSC induced a 
graft-versus-leukemia effect in the recipient (Kolb, 2008). In the present study, allogeneic 
reactivity of the T cells most likely caused the strong rejection of the tumor cells in control 
mice. The strong alloreactive effect in control mice impedes evaluating anti-tumoral 
function of CAR T cells. Why this effect is much more pronounced in control mice having 
no CAR T cells is unknown. As discussed above, CAR T cells might have exerted less 
potent anti-tumoral functions compared to allogeneic untransduced T cells due to an 
exhaustion status characterized by poor effector functions. Higher amounts of 
untransduced functional allogeneic T cells might have contributed to tumor shrinkage in 
the control mice. Clearly, this model is limited by xenogeneic and alloreactive reactions. 
Overlaying alloreactive reactions impede the evaluation of anti-tumoral functions of in vivo 
generated CAR T cells, and xenogeneic reactions limit observation periods to 4-6 weeks 
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due to the development of GvHD. It will be necessary to test anti-tumoral effects of in vivo 
generated CAR T cell in better suited models.  
To overcome these limitations, efforts had been made to generate a murine model, which 
even better reflects the human immune system. The engraftment of CD34+ hematopoietic 
stem cells into immune-incompetent mice leads to the development of a human immune 
system, consisting of innate and adaptive components (Ishikawa et al., 2005) (Figure 42). 
Here, T cells go through thymic development, not reacting to murine environment, which 
makes GvHD less likely (Pearson et al., 2008). Further, T cells are in a resting status, 
more reflecting the clinical situation of unstimulated T cells. First studies already 
demonstrated successful CAR T cell generation upon intravenous administration of 
CD8-LV in CD34+ engrafted NSG mice (Pfeiffer et al., submitted). To enhance 
transduction rates, mice were pre-treated with IL-7, which was administered systemically 
prior to vector administration. Importantly, B cell elimination correlated with the presence 
of CAR T cells. The presence of other immune cells in this model allows the observation 
of interaction between CAR T cells and other components of the adaptive and innate 
immune system. Indeed, some mice showed signs of CRS with elevated cytokine levels 
– a side-effect, which is not occurring in PBMC-humanized NSG mice, however, a 
well-known adverse reaction in patients treated with CAR T cells (Pfeiffer et al., 
submitted). This underlines even more the potential of CAR T cell studies in 
CD34+-engrafted NSG mice better reflecting the patients situation than PBMC-humanized 
NSG mice. Detecting CAR T cells in the blood seven weeks post vector administration 
rather indicated delayed kinetics of CAR T cell generation. However, further investigations 
will reveal whether in vivo generated CAR T cells confer anti-tumoral functions and also 
allow further kinetic studies, particularly since this model allows long-term studies due to 
the low probability of GvHD development. Yet, the successful in vivo generation of 
CAR T cells in this model further underlines the potential of CD8-LV for in vivo 
CAR delivery. 
4.5 Clinical potential of CD8-LV for in vivo CAR delivery 
In vivo generation of CAR T cells using receptor-targeted LVs represent a promising tool 
to circumvent ex vivo manufacturing of CAR T cells. Although nanoparticles might be a 
further option, lentiviral vectors represent a tool already well known in the clinics. Several 
years of practice resulted in a documented safety profile of LVs. Risk of insertional 
oncogenesis and mobilization of replication competent particles have remained 
theoretical since recent follow-up clinical trials did not indicate such events with the latest 
generation of vectors (Kaufmann et al., 2013; Naldini et al., 2016).  
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Although intravenous administration is performed in preclinical models, direct 
administration of vector particle into lymph nodes appears to be a reasonable application 
for patients, providing close contact between vector particles and target cells. Major 
concerns, however, are the risk of off-target transduction and toxicity of the vector upon 
administration. As the CD8 receptor is expressed on other cell entities, transduction might 
occur in CD8+CD4+ double positive immature T cells, CD8+ NK cells and CD8+ DCs. 
Transduction of immature T cells can be hardly seen as a concern. Even if differentiation 
into a CD4 T cell occurs, transduction of CD4 T cells is current standard in ex vivo 
manufacturing of CAR T cells. Further, CD4 CAR T cells have been shown to be 
supportive for CAR T cell proliferation increasing anti-tumoral effects. However, if a 
transduced immature double positive cell differentiates into a regulatory T cell (Treg), 
CAR T cell-directed immune response might be dampened. In contrast, CAR expression 
in NK cells might be actually beneficial since CAR NK cells also have been shown to be 
of therapeutic relevance (Glienke et al., 2015). Transduction of DCs, however, might be 
harmful due to the professional presentation of vector and transgene components, which 
could trigger an unintended immune response. To address this issue and to prevent 
antigen presentation, Brown and colleagues demonstrated successful suppression of 
transgene expression in DCs by incorporating an APC-specific micro RNA (miRNA) target 
sequence (Brown et al., 2006). Toxicity-induced adverse events triggered by innate and 
adaptive immune responses upon vector administration are another concern. Stimulation 
of toll-like receptors and subsequent cytokine secretion, complement activation, and 
pre-existing neutralizing antibodies might contribute to an immune reaction against the 
vector particles (Nayak and Herzog, 2010). Neutralizing antibodies would even impair 
transduction efficiency, which is a downside of MV-pseudotyped LVs, and makes these 
vectors rather unsuitable for in vivo applications due to the broad immunization against 
MV. This issue, however, is expected to be of a minor concern for CD8-LV. Bender et al. 
have demonstrated the absence of neutralizing antibodies against NiV-pseudotpyed LVs 
when NiV-based LVs pre-incubated with pooled human sera still mediated transduction 
while MV-based LVs did not (Bender et al., 2016). However, toxicity studies and safety 
concerns need to be addressed prior to clinical studies. Since the OKT8-derived scFV 
incorporated into CD8-LV is cross-reactive to macaca mulatta, non-human primate 
studies can be performed without the need for adjustments in the targeting domain.  
 
The current CAR T cell therapy procedure consists of administering high amounts of 
CAR T cells at a time. In contrast, vector administration is assumed to mediate a slow 
increase in CAR T cell numbers. Upon transduction, CAR surface expression and 
CAR T cell proliferation probably requires some time until high numbers of CAR T cells 
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are expanded. This might avoid CRS, which is currently a matter of concern, induced by 
high amounts of highly activated CAR T cells. Although it is also possible that kinetics and 
CRS development occur delayed. However, when side effects become severe, current 
emergency protocols for CRS treatment are available. Incorporation of off-switches or 
suicide genes, which control or eliminate CAR T cells, is another tool currently 
investigated to increase safety (Jones et al., 2014; Wu et al., 2015). 
Not only that complex ex vivo manufacturing of CAR T cells including logistic and financial 
hurdles could be circumvented, patients in need would not need to wait until their 
personalized product is manufactured, but rather get the vector immediately administered.  
Furthermore, ex vivo manipulation might impair functional properties of cells influencing 
the functionality of the CAR T cell product. Dependent on the culture conditions, it has 
been shown to drive them into differentiation. However, since preclinical trials suggested 
less differentiated CAR T cells to mediate superior anti-tumoral activities, efforts are being 
made to keep cells as undifferentiated as possible by the usage of homeostatic cytokines 
such as IL-7 and IL-15 (Xu et al., 2014; Sabatino et al., 2016). Although still a long way to 
go, it will be interesting to investigate whether in vivo generated CAR T cells are as good 
as their ex vivo generated counterparts or even outperform them due to the absence of 
ex vivo manipulation, which might influence their functionality.  
In conclusion, CD8-LV represents a highly promising tool for the in vivo generation of 
CAR T cells. The potential of tremendously simplifying CAR T cell therapy by 
circumventing the ex vivo manufacturing process represents a highly attractive approach 
for future CAR T cell therapy enabling broad and flexible applicability to patients. 
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6 Abbreviations 
∆  .............................................................................................................................. delta 
°C .............................................................................................................. degree celcius 
µg .................................................................................................................... microgram 
µl  ....................................................................................................................... microliter 
µm .................................................................................................................. micrometer 
µM .................................................................................................................. micromolar 
ALL ..................................................................................... acute lymphoblastic leukemia 
APC .............................................................................................. antigen presenting cell 
ASCO ...................................................................... american society of clinical oncology 
BaEV ....................................................................................... baboon endogenous virus 
BFP ............................................................................................. blue fluorescent protein 
bp .................................................................................................................... base pairs 
CAR .......................................................................................... chimeric antigen receptor 
CCR7 ....................................................................................... C-C chemokine receptor 7 
CD ............................................................................................... cluster of differentiation 
CD8-LV ............................................................................... CD8-targeted lentiviral vector 
CFSE ..................................................................... carboxyfluorescein succinimidyl ester 
CLL ..................................................................................... chronic lymphocytic leukemia 
CRS ........................................................................................ cytokine release syndrome 
DARPins ........................................................................ designed ankyrin repeat proteins 
DC ................................................................................................................ dendritic cell 
DLBL ................................................................................. diffuse large B-cell lymphoma 
DMEM ........................................................................ dulbecco’s modified eagle medium 
DMSO ................................................................................................... dimethyl sulfoxide 
DNA ................................................................................................ deoxyribonucleic acid 
dNTP ........................................................................... deoxyribonucleoside triphosphate 
E.coli ........................................................................................................ Escherichia coli 
e.g. ........................................................................................ exempli gratia, for example 
EDTA .............................................................................. ethylenediaminetetraacetic acid 
EF1α .......................................................................................... elongation factor 1 alpha 
et al. ................................................................................................................. and others 
F  ................................................................................................................. fusion protein 
FCS .......................................................................................................... fetal calf serum 
FDA ..................................................................................... food and drug administration 
FoxP3 ..................................................................................................... forkhead box P3 
Abbreviations 
103 
 
g  ...................................................................................................................gravity force 
G  ................................................................................................................... glycoprotein 
ɤ  .......................................................................................................................... gamma 
gag ................................................................................................ group-specific antigen 
gDNA .......................................................................................................... genomic DNA 
GFP ........................................................................................... green fluorescent protein 
GMP .................................................................................... good manufacturing practice 
GvHD ........................................................................................ graft-versus-host disease 
Gy .............................................................................................................................. gray 
h  ............................................................................................................................... hour 
H  ................................................................................................................ hemagglutinin 
HEK-293T .........................................................................human embryonic kidney 293T 
HEPES .............................................. 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV-1 ............................................................................ human immunodeficiency virus-1 
HLA ...........................................................................................human leukocyte antigen 
HSC ............................................................................................. hematopoietic stem cell 
i.v. ................................................................................................................ intravenously 
IFN-ɤ .................................................................................................... interferon gamma 
Ig  ............................................................................................................. Immunoglobulin 
IL-2 ................................................................................................................interleukin-2 
IRES ...................................................................................... internal ribosomal entry site 
ITAM ....................................................... immunoreceptor tyrosine-based activation motif 
IVC ......................................................................................... individually ventilated cage 
kb......................................................................................................................... kilobase 
LB .............................................................................................................. lysogeny broth 
LDL ................................................................................................ low density lipoprotein 
LED .................................................................................................... light-emitting diode 
LM-PCR ........................................................................................ ligation-mediated PCR 
LTR .................................................................................................... long terminal repeat 
luc ...................................................................................................................... luciferase 
LV ............................................................................................................. lentiviral vector 
MFI ....................................................................................... mean fluorescence intensity 
MHC .............................................................................. major histocompatibility complex 
min ....................................................................................................................... minutes 
miRNA ............................................................................................................. micro RNA 
ml........................................................................................................................... mililiter 
mM ..................................................................................................................... milimolar 
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MOI ................................................................................................ multiplicity of infection 
MV .............................................................................................................. measles virus 
ng ..................................................................................................................... nanogram 
NiV .................................................................................................................. Nipah virus 
NK cell .................................................................................................... natural killer cell 
ns................................................................................................................ not significant 
NSG ............................................................................ NOD.Cg.PrkdcscidIL2rgtmWjl/SzJ 
p/sec/cm²/sr .............................................. photons/seconds/square centimeter/steradian 
PBMC ........................................................................ peripheral blood mononuclear cells 
PBS ......................................................................................... phosphate-buffered saline 
PCR ......................................................................................... polymerase chain reaction 
PE ................................................................................................................ phycoerythrin 
PEI ......................................................................................................... polyethylenimine 
pol .......................................................................................................... DNA-polymerase 
qPCR ....................................................................................... quantitative real-time PCR 
r/r ........................................................................................................ relapsed/refractory 
rpm ...................................................................................................... rounds per minute 
RT ......................................................................................................... room temperature 
s  ......................................................................................................................... seconds 
scFv ................................................................................... single chain variable fragment 
SD ....................................................................................................... standard deviation 
SEM ........................................................................................ standard error of the mean 
SFFV ....................................................................................... spleen focus forming virus 
SIN-LV ............................................................................. self-inactivating lentiviral vector 
t.u./ml .......................................................................................... transducing units per ml 
TCM .................................................................................................. central memory T cell 
TCR ........................................................................................................... T cell receptor 
TEff ............................................................................................................... effector T cell 
TEM ................................................................................................. effector memory T cell 
TIL ........................................................................................ tumor infiltrating lymphocyte 
TM .............................................................................................. transmembrane domain 
TN ................................................................................................................... naïve T cell 
TNF-α .................................................................................... tumor necrosis factor alpha 
Treg ........................................................................................................... regulatory T cell 
TSCM ...................................................................................... stem cell-like memory T cell 
U  .............................................................................................................................. units 
U.S. .............................................................................................................. united states 
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V  ................................................................................................................................ volt 
VCN ................................................................................................... vector copy number 
VSV ............................................................................................vesicular stomatitis virus 
w/o ......................................................................................................................... without 
w/v ....................................................................................................... weight per volume 
WPRE ........................... woodchuck hepatitis virus posttranscriptional regulatory element 
α  .................................................................................................................. alpha or anti 
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